## Palbociclib and Letrozole in Advanced Breast Cancer

New England Journal of Medicine 375, 1925-1936 DOI: 10.1056/nejmoa1607303

**Citation Report** 

#	Article	IF	CITATIONS
1	Interview for Breast Cancer Management with Dr David Montgomery: marketing authorization for Pfizer's metastatic breast cancer treatment, palbociclib (Ibrance®) in combination with endocrine therapy. Breast Cancer Management, 2016, 5, 145-150.	0.2	0
2	Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet, The, 2016, 388, 2997-3005.	13.7	435
3	CDK4 and CDK6 Inhibition in Breast Cancer — A New Standard. New England Journal of Medicine, 2016, 375, 1993-1994.	27.0	25
4	NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor–Positive Breast Cancer. Clinical Cancer Research, 2017, 23, 4055-4065.	7.0	243
5	Opportunities and challenges of long term anti-estrogenic adjuvant therapy: treatment forever or intermittently?. Expert Review of Anticancer Therapy, 2017, 17, 297-310.	2.4	3
6	Increased life expectancy as a result of non-hormonal targeted therapies for HER2 or hormone receptor positive metastatic breast cancer: A systematic review and meta-analysis. Cancer Treatment Reviews, 2017, 55, 16-25.	7.7	18
7	CDK4/6 Inhibition in Breast Cancer: Mechanisms of Response and Treatment Failure. Current Breast Cancer Reports, 2017, 9, 26-33.	1.0	55
8	The Growing Role of CDK4/6 Inhibitors in Treating Hormone Receptor-Positive Advanced Breast Cancer. Current Treatment Options in Oncology, 2017, 18, 6.	3.0	44
9	Molecular targeted therapies in adrenal, pituitary and parathyroid malignancies. Endocrine-Related Cancer, 2017, 24, R239-R259.	3.1	16
10	Tackling endocrine resistance in ER-positive HER2-negative advanced breast cancer: A tale of imprecision medicine. Critical Reviews in Oncology/Hematology, 2017, 114, 91-101.	4.4	15
11	Pharmacokinetic drug evaluation of ribociclib for the treatment of metastatic, hormone-positive breast cancer. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 575-581.	3.3	17
12	Characterization of Neutropenia in Advanced Cancer Patients Following Palbociclib Treatment Using a Population Pharmacokinetic-Pharmacodynamic Modeling and Simulation Approach. Journal of Clinical Pharmacology, 2017, 57, 1159-1173.	2.0	30
13	Neoadjuvant Trials in ER+ Breast Cancer: A Tool for Acceleration of Drug Development and Discovery. Cancer Discovery, 2017, 7, 561-574.	9.4	33
14	Palbociclib: A Review in HR-Positive, HER2-Negative, Advanced or Metastatic Breast Cancer. Targeted Oncology, 2017, 12, 373-383.	3.6	38
15	Emerging therapies for breast cancer. Journal of Hematology and Oncology, 2017, 10, 98.	17.0	60
16	Phase 2 trial of everolimus and letrozole in relapsed estrogen receptor-positive high-grade ovarian cancers. Gynecologic Oncology, 2017, 146, 64-68.	1.4	35
17	Recent advances of highly selective CDK4/6 inhibitors in breast cancer. Journal of Hematology and Oncology, 2017, 10, 97.	17.0	126
18	New agents for endocrine resistance in breast cancer. Breast, 2017, 34, 1-11.	2.2	22

#	Article	IF	CITATIONS
19	Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies. Drugs, 2017, 77, 1313-1336.	10.9	39
20	The use of systemic therapies to prevent progression of inflammatory breast cancer: which targeted therapies to add on cytotoxic combinations?. Expert Review of Anticancer Therapy, 2017, 17, 593-606.	2.4	3
21	An overall review of targeted therapy in solid cancers. Current Medicine Research and Practice, 2017, 7, 99-105.	0.1	9
22	Hormonoresistance in advanced breast cancer: a new revolution in endocrine therapy. Therapeutic Advances in Medical Oncology, 2017, 9, 335-346.	3.2	39
23	<scp>CDK</scp> 4 phosphorylation status and a linked gene expression profile predict sensitivity to palbociclib. EMBO Molecular Medicine, 2017, 9, 1052-1066.	6.9	65
24	Meta-analysis of selected toxicity endpoints of CDK4/6 inhibitors: Palbociclib and ribociclib. Breast, 2017, 35, 1-7.	2.2	23
25	Single-Cell Dynamics Determines Response to CDK4/6 Inhibition in Triple-Negative Breast Cancer. Clinical Cancer Research, 2017, 23, 5561-5572.	7.0	198
26	Ribociclib (LEE011): Mechanism of Action and Clinical Impact of This Selective Cyclin-Dependent Kinase 4/6 Inhibitor in Various Solid Tumors. Clinical Cancer Research, 2017, 23, 3251-3262.	7.0	175
27	Entinostat: a promising treatment option for patients with advanced breast cancer. Future Oncology, 2017, 13, 1137-1148.	2.4	94
28	PALOMA-2 — hope beyond the threshold. Nature Reviews Clinical Oncology, 2017, 14, 1-1.	27.6	11
30	Palbociclib-induced autophagy and senescence in gastric cancer cells. Experimental Cell Research, 2017, 360, 390-396.	2.6	50
31	Ribociclib: a valuable addition to treatment options in breast cancer?. ESMO Open, 2017, 2, e000246.	4.5	3
32	Selective Androgen Receptor Modulator RAD140 Inhibits the Growth of Androgen/Estrogen Receptor–Positive Breast Cancer Models with a Distinct Mechanism of Action. Clinical Cancer Research, 2017, 23, 7608-7620.	7.0	26
33	Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer. Clinical Cancer Research, 2017, 23, 7288-7300.	7.0	29
34	Combined CDK4/6 and PI3Kα Inhibition Is Synergistic and Immunogenic in Triple-Negative Breast Cancer. Cancer Research, 2017, 77, 6340-6352.	0.9	163
35	CDK4/6 inhibition in early and metastatic breast cancer: A review. Cancer Treatment Reviews, 2017, 60, 130-138.	7.7	49
36	Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial. Lancet Oncology, The, 2017, 18, 1502-1511.	10.7	119
37	CDK4/6 blockade in breast cancer: current experience and future perspectives. Expert Opinion on Investigational Drugs, 2017, 26, 1357-1372.	4.1	21

#	Article	IF	CITATIONS
38	PI3K/mTOR Inhibitors in the Treatment of Luminal Breast Cancer. Why, When and to Whom. Breast Care, 2017, 12, 290-294.	1.4	21
39	Risks and benefits from CDK inhibitors for advanced HR+ Her 2â^ breast cancer. Annals of Oncology, 2017, 28, 3099-3100.	1.2	6
40	miR-6883 Family miRNAs Target CDK4/6 to Induce G1 Phase Cell-Cycle Arrest in Colon Cancer Cells. Cancer Research, 2017, 77, 6902-6913.	0.9	43
41	The next era of treatment for hormone receptor-positive, HER2-negative advanced breast cancer: Triplet combination-based endocrine therapies. Cancer Treatment Reviews, 2017, 61, 53-60.	7.7	39
43	Palbociclib in hormone receptor positive advanced breast cancer: A cost-utility analysis. European Journal of Cancer, 2017, 85, 146-154.	2.8	29
44	Extending indication of cyclin-dependent kinase 4/6 inhibitors in the adjuvant and neoadjuvant setting. Current Opinion in Oncology, 2017, 29, 428-433.	2.4	2
45	Preoperative predicting malignancy in breast mass-like lesions: value of adding histogram analysis of apparent diffusion coefficient maps to dynamic contrast-enhanced magnetic resonance imaging for improving confidence level. British Journal of Radiology, 2017, 90, 20170394.	2.2	8
46	Targeting androgen-independent pathways: new chances for patients with prostate cancer?. Critical Reviews in Oncology/Hematology, 2017, 118, 42-53.	4.4	25
47	Fulvestrant in advanced breast cancer: evidence to date and place in therapy. Therapeutic Advances in Medical Oncology, 2017, 9, 465-479.	3.2	46
48	Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations. Oncologist, 2017, 22, 1039-1048.	3.7	115
49	The Evolving Role of Companion Diagnostics for Breast Cancer in an Era of Next-Generation Omics. American Journal of Pathology, 2017, 187, 2185-2198.	3.8	17
50	Influence of non-measurable disease on progression-free survival in patients with metastatic breast cancer. Cancer Treatment Reviews, 2017, 59, 46-53.	7.7	2
51	Oesophageal cancer. Nature Reviews Disease Primers, 2017, 3, 17048.	30.5	671
52	Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancer. Breast Cancer Research and Treatment, 2017, 166, 167-177.	2.5	40
53	Inhibition of nuclear Wnt signalling: challenges of an elusive target for cancer therapy. British Journal of Pharmacology, 2017, 174, 4589-4599.	5.4	48
54	CDK4/6 Inhibition on Glucose and Pancreatic Beta Cell Homeostasis in Young and Aged Rats. Molecular Cancer Research, 2017, 15, 1531-1541.	3.4	15
56	Ribociclib for the treatment of advanced hormone receptor-positive, HER2-negative breast cancer. Future Oncology, 2017, 13, 2137-2149.	2.4	7
57	Are Cyclin-dependent Kinase 4/6 Inhibitors Needed for all Oestrogen Receptor-positive Metastatic Breast Cancers?. Clinical Oncology, 2017, 29, 703-706.	1.4	0

#	Article	IF	Citations
58	CDK4/6 inhibition triggers anti-tumour immunity. Nature, 2017, 548, 471-475.	27.8	998
60	H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma. Cancer Research, 2017, 77, 6999-7013.	0.9	100
61	Incorporating CDK4/6 Inhibitors in the Treatment of Advanced Luminal Breast Cancer. Breast Care, 2017, 12, 296-302.	1.4	8
62	Overall survival and progression-free survival with endocrine therapy for hormone receptor-positive, HER2-negative advanced breast cancer: review. Therapeutic Advances in Medical Oncology, 2017, 9, 693-709.	3.2	32
63	Androgen Receptor-Targeted Therapy for Breast Cancer. Current Breast Cancer Reports, 2017, 9, 242-250.	1.0	1
64	Mechanisms of Resistance to CDK4/6 Inhibitors in Breast Cancer and Potential Biomarkers of Response. Breast Care, 2017, 12, 304-308.	1.4	53
65	Identification of cell cycle-targeting microRNAs through genome-wide screens. Cell Cycle, 2017, 16, 2241-2248.	2.6	7
66	Should endocrine therapy still be used as an initial treatment for postmenopausal women with metastatic breast cancer?. Future Oncology, 2017, 13, 1361-1364.	2.4	0
67	Is hormonal therapy effective in advanced endometrial cancer? A systematic review and meta-analysis. Gynecologic Oncology, 2017, 147, 158-166.	1.4	71
68	Combination of palbociclib and radiotherapy for glioblastoma. Cell Death Discovery, 2017, 3, 17033.	4.7	62
69	Breast cancer treatment-induced cardiotoxicity. Expert Opinion on Drug Safety, 2017, 16, 1021-1038.	2.4	58
70	Real-world palbociclib dosing patterns and implications for drug costs in the treatment of HR+/HER2- metastatic breast cancer. Expert Opinion on Pharmacotherapy, 2017, 18, 1167-1178.	1.8	21
71	Long-term management of patients with hormone receptor-positive metastatic breast cancer: Concepts for sequential and combination endocrine-based therapies. Cancer Treatment Reviews, 2017, 59, 22-32.	7.7	38
72	Treatment for the endocrine resistant breast cancer: Current options and future perspectives. Journal of Steroid Biochemistry and Molecular Biology, 2017, 172, 166-175.	2.5	41
73	Detection of Activating Estrogen Receptor Gene ( <i>ESR1</i> ) Mutations in Single Circulating Tumor Cells. Clinical Cancer Research, 2017, 23, 6086-6093.	7.0	68
75	A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer. Current Medical Research and Opinion, 2017, 33, 1559-1569.	1.9	36
76	The safety and efficacy of palbociclib in the treatment of metastatic breast cancer. Expert Review of Anticancer Therapy, 2017, 17, 661-668.	2.4	9
77	Optimizing Quality of Life in Patients with Hormone Receptor-Positive Metastatic Breast Cancer: Treatment Options and Considerations. Oncology, 2017, 93, 143-156.	1.9	7

		CITATION REPORT		
#	Article		IF	CITATIONS
78	Precision medicine in breast cancer: reality or utopia?. Journal of Translational Medicine, 2017	7, 15, 139.	4.4	56
79	Cell Cycle Regulation in Treatment of Breast Cancer. Advances in Experimental Medicine and 2017, 1026, 251-270.	Biology,	1.6	20
80	Strategies and Progress of Endocrine Therapy for Patients with Metastatic Breast Cancer. Ad Experimental Medicine and Biology, 2017, 1026, 403-418.	vances in	1.6	4
81	Update Breast Cancer 2017 – Implementation of Novel Therapies. Geburtshilfe Und Frauer 2017, 77, 1281-1290.	heilkunde,	1.8	19
82	Is There Still a Role for First-Line Single Agent Endocrine Therapy in HR+ and HER2- Advanced Cancer. Breast Care, 2017, 12, 288-289.	Breast	1.4	1
83	CDK4/6 Inhibitors in Cancer Therapy: AÂNovel Treatement Strategy for Bladder Cancer. Bladc 2017, 3, 79-88.	ler Cancer,	0.4	21
84	CDK4/6 Inhibition as a therapeutic strategy in breast cancer: palbociclib, ribociclib, and abem Seminars in Oncology, 2017, 44, 395-403.	aciclib.	2.2	58
85	New agents for the management of resistant metastatic breast cancer. Expert Opinion on Pharmacotherapy, 2017, 18, 1815-1831.		1.8	5
86	Major clinical research advances in gynecologic cancer in 2016: 10-year special edition. Journ Gynecologic Oncology, 2017, 28, e45.	al of	2.2	24
87	HR+, HER2– Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of Action, Clinical Activi Safety Profiles. Current Cancer Drug Targets, 2017, 17, 637-649.	ty, and	1.6	65
88	Molecular Biomarkers for Prediction of Targeted Therapy Response in Metastatic Breast Canc or Treat?. International Journal of Molecular Sciences, 2017, 18, 85.	er: Trick	4.1	25
89	Appendix 2: Advanced breast cancer: MCBS eUpdate published online 25 April 2017 (www.esmo.org/Guidelines/Breast-Cancer). Annals of Oncology, 2017, 28, iv145-iv146.		1.2	0
90	Clinical Implications of ESR1 Mutations in Hormone Receptor-Positive Advanced Breast Canc Frontiers in Oncology, 2017, 7, 26.	er.	2.8	79
91	Recent advances of cyclin-dependent kinases as potential therapeutic targets in HR+/HER2& metastatic breast cancer: a focus on ribociclib. Breast Cancer: Targets and Therapy, 2017, Vo 567-579.	amp;minus; lume 9,	1.8	10
92	Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib. Breast Research, 2017, 19, 123.	4/6 Cancer	5.0	53
93	Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemacicli Cancer Research and Treatment, 2017, 166, 41-54.	b. Breast	2.5	153
94	Pre-operative Endocrine Therapy. Current Breast Cancer Reports, 2017, 9, 202-209.		1.0	17
95	Increasing the Potential Targets and Molecularly Targeted Agent Combinations Against Canc Proliferation. Journal of Cell Signaling, 2017, 02, .	er Cell	0.3	1

#	Article	IF	CITATIONS
96	De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Annals of Oncology, 2017, 28, 1700-1712.	1.2	844
97	Cell-Cycle Therapeutics Come of Age. Journal of Clinical Oncology, 2017, 35, 2949-2959.	1.6	269
98	MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. Journal of Clinical Oncology, 2017, 35, 3638-3646.	1.6	1,099
99	Blocking the Cycle: Cyclin-Dependent Kinase 4/6 Inhibitors in Metastatic, Hormone Receptor–Positive Breast Cancer. Journal of Clinical Oncology, 2017, 35, 2866-2870.	1.6	12
100	Breast Cancer in the Central Nervous System: Multidisciplinary Considerations and Management. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 45-56.	3.8	24
101	Genomic Resistance Patterns to Second-Generation Androgen Blockade in Paired Tumor Biopsies of Metastatic Castration-Resistant Prostate Cancer. JCO Precision Oncology, 2017, 1, 1-11.	3.0	13
102	Cyclin-Dependent Kinase 4/6 Inhibitors in the Treatment of Breast Cancer: More Breakthroughs and an Embarrassment of Riches. Journal of Clinical Oncology, 2017, 35, 2857-2859.	1.6	6
103	Differences Are Important: Breast Cancer Therapy in Different Ethnic Groups. Journal of Global Oncology, 2017, 3, 281-284.	0.5	9
104	Ribociclib for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. Expert Review of Anticancer Therapy, 2018, 18, 201-213.	2.4	13
105	Cyclin-dependent kinase 4/6 inhibitors as first-line treatment for post-menopausal metastatic hormone receptor-positive breast cancer patients: a systematic review and meta-analysis of phase III randomized clinical trials. Breast Cancer, 2018, 25, 479-488.	2.9	40
106	Endocrine therapy and palbociclib within a compassionate use program in heavily pretreated hormone receptor-positive, HER2-negative metastatic breast cancer. Breast, 2018, 39, 14-18.	2.2	14
107	Palbociclib in combination with letrozole as firstâ€line treatment for advanced breast cancer: A Japanese phase <scp>II</scp> study. Cancer Science, 2018, 109, 803-813.	3.9	29
108	Preclinical Activity of Abemaciclib Alone or in Combination with Antimitotic and Targeted Therapies in Breast Cancer. Molecular Cancer Therapeutics, 2018, 17, 897-907.	4.1	77
109	ABC4 Consensus: Assessment by a German Group of Experts. Breast Care, 2018, 13, 48-58.	1.4	7
110	Randomized phase II study of anastrozole plus tegafur-uracil as neoadjuvant therapy for ER-positive breast cancer in postmenopausal Japanese women (Neo-ACET BC). Cancer Chemotherapy and Pharmacology, 2018, 81, 755-762.	2.3	8
111	Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer. Nature Communications, 2018, 9, 896.	12.8	305
112	<i>In Vivo</i> E2F Reporting Reveals Efficacious Schedules of MEK1/2–CDK4/6 Targeting and mTOR–S6 Resistance Mechanisms. Cancer Discovery, 2018, 8, 568-581.	9.4	62
113	CCRK is a novel signalling hub exploitable in cancer immunotherapy. , 2018, 186, 138-151.		35

#	Article	IF	CITATIONS
114	Inhibition of cyclin-dependent kinase 4 as a potential therapeutic strategy for treatment of synovial sarcoma. Cell Death and Disease, 2018, 9, 446.	6.3	26
117	Optimising endocrine therapy in postmenopausal women with advanced breast cancer. Endocrine-Related Cancer, 2018, 25, 705-721.	3.1	1
118	Representation of obese participants in obesity-related cancer randomized trials. Annals of Oncology, 2018, 29, 1582-1587.	1.2	20
119	SULFATION PATHWAYS: Steroid sulphatase inhibition via aryl sulphamates: clinical progress, mechanism and future prospects. Journal of Molecular Endocrinology, 2018, 61, T233-T252.	2.5	55
120	Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2. Breast Cancer Research and Treatment, 2018, 170, 535-545.	2.5	68
121	Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort. European Journal of Cancer, 2018, 96, 17-24.	2.8	211
122	Mechanisms of Resistance to PI3K and AKT Inhibitors. Resistance To Targeted Anti-cancer Therapeutics, 2018, , 117-146.	0.1	3
123	Progression-free Survival With First-line Endocrine-based Therapies Among Postmenopausal Women With HR+/HER2– Metastatic Breast Cancer:. Clinical Therapeutics, 2018, 40, 628-639.e3.	2.5	9
124	Use of dual mTOR inhibitor MLN0128 against everolimus-resistant breast cancer. Breast Cancer Research and Treatment, 2018, 170, 499-506.	2.5	14
125	Nucleoside diphosphate kinase B promotes osteosarcoma proliferation through c-Myc. Cancer Biology and Therapy, 2018, 19, 565-572.	3.4	10
127	Clinical development of CDK4/6 inhibitor for breast cancer. Breast Cancer, 2018, 25, 402-406.	2.9	29
128	Pharmacotherapeutic Management of Breast Cancer in Elderly Patients: The Promise of Novel Agents. Drugs and Aging, 2018, 35, 93-115.	2.7	6
129	First-line ribociclib plus letrozole in postmenopausal women with HR+Â, HER2â^'Âadvanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trial. Breast Cancer Research and Treatment, 2018, 169, 469-479.	2.5	39
130	Oral etoposide in heavily pre-treated metastatic breast cancer: A retrospective series. Breast, 2018, 38, 160-164.	2.2	16
131	Targeting Cyclin D-CDK4/6 Sensitizes Immune-Refractory Cancer by Blocking the SCP3–NANOG Axis. Cancer Research, 2018, 78, 2638-2653.	0.9	30
132	Cyclin-dependent kinase (CDK) inhibitors for hormone receptor-positive advanced breast cancer. The Cochrane Library, 2018, , .	2.8	2
133	An update on first line therapies for metastatic breast cancer. Expert Opinion on Pharmacotherapy, 2018, 19, 243-252.	1.8	8
134	Circulating tumour DNA analyses reveal novel resistance mechanisms to CDK inhibition in metastatic breast cancer. Annals of Oncology, 2018, 29, 535-537.	1.2	8

#	Article	IF	CITATIONS
135	Optimizing Breast Cancer Management. Cancer Treatment and Research, 2018, , .	0.5	2
136	The safety of palbociclib for the treatment of advanced breast cancer. Expert Opinion on Drug Safety, 2018, 17, 325-330.	2.4	2
137	Therapeutically targeting tumor microenvironment–mediated drug resistance in estrogen receptor–positive breast cancer. Journal of Experimental Medicine, 2018, 215, 895-910.	8.5	63
138	FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor–Positive, HER2-Negative Advanced or Metastatic Breast Cancer. Clinical Cancer Research, 2018, 24, 2999-3004.	7.0	79
139	Advances in Endocrine Therapy for Postmenopausal Metastatic Breast Cancer. Cancer Treatment and Research, 2018, 173, 141-154.	0.5	13
140	First-line vs second-line fulvestrant for hormone receptor-positive advanced breast cancer: A post-hoc analysis of the CONFIRM study. Breast, 2018, 38, 144-149.	2.2	10
141	Estrogen Receptor-Positive Breast Cancer: Exploiting Signaling Pathways Implicated in Endocrine Resistance. Oncologist, 2018, 23, 528-539.	3.7	102
142	E2112: randomized phase iii trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer. Npj Breast Cancer, 2018, 4, 1.	5.2	84
143	Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial. Annals of Oncology, 2018, 29, 888-894.	1.2	104
144	Palbociclib has no clinically relevant effect on the QTc interval in patients with advanced breast cancer. Anti-Cancer Drugs, 2018, 29, 271-280.	1.4	33
145	Fulvestrant: A Review in Advanced Breast Cancer Not Previously Treated with Endocrine Therapy. Drugs, 2018, 78, 131-137.	10.9	16
146	Complete Response to Single-agent Palbociclib in Metastatic Breast Cancer: A Case Report. Clinical Breast Cancer, 2018, 18, e277-e280.	2.4	2
147	Ongoing unmet needs in treating estrogen receptor-positive/HER2-negative metastatic breast cancer. Cancer Treatment Reviews, 2018, 63, 144-155.	7.7	26
148	A European, Observational Study of Endocrine Therapy Administration in Patients With an Initial Diagnosis of Hormone Receptor-Positive Advanced Breast Cancer. Clinical Breast Cancer, 2018, 18, e613-e619.	2.4	9
149	Management of QT prolongation induced by anti-cancer drugs: Target therapy and old agents. Different algorithms for different drugs. Cancer Treatment Reviews, 2018, 63, 135-143.	7.7	56
150	Metabolomics Reveals that Dietary Xenoestrogens Alter Cellular Metabolism Induced by Palbociclib/Letrozole Combination Cancer Therapy. Cell Chemical Biology, 2018, 25, 291-300.e3.	5.2	52
151	Metastatic Breast Cancer: Prognosis, Diagnosis and Oncological Management. , 2018, , 579-594.		1
152	Efficacy of palbociclib plus fulvestrant after everolimus in hormone receptor-positive metastatic breast cancer. Breast Cancer Research and Treatment, 2018, 168, 559-566.	2.5	26

#	Article	IF	CITATIONS
153	Hormone receptor positive breast cancer: state of the art. Current Opinion in Obstetrics and Gynecology, 2018, 30, 51-54.	2.0	12
154	A single institution experience with palbociclib toxicity requiring dose modifications. Breast Cancer Research and Treatment, 2018, 168, 381-387.	2.5	29
155	Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases. Annals of Oncology, 2018, 29, 669-680.	1.2	74
156	Dual Inhibition of CDK4 and CDK2 via Targeting p27 Tyrosine Phosphorylation Induces a Potent and Durable Response in Breast Cancer Cells. Molecular Cancer Research, 2018, 16, 361-377.	3.4	48
157	Phosphoinositide 3-kinase inhibitors in advanced breast cancer: A systematic review and meta-analysis. European Journal of Cancer, 2018, 91, 38-46.	2.8	17
158	Using gene expression data to direct breast cancer therapy: evidence from a preclinical trial. Journal of Molecular Medicine, 2018, 96, 111-117.	3.9	6
159	A new era for treatment development in HER2-positive breast cancer. Lancet Oncology, The, 2018, 19, 160-162.	10.7	9
160	Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer. Annals of Oncology, 2018, 29, 640-645.	1.2	245
161	CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought. Cancer Cell, 2018, 34, 9-20.	16.8	300
162	Mechanisms of resistance in estrogen receptor positive breast cancer: overcoming resistance to tamoxifen/aromatase inhibitors. Current Opinion in Pharmacology, 2018, 41, 59-65.	3.5	105
163	The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells. Journal of Experimental and Clinical Cancer Research, 2018, 37, 72.	8.6	68
164	Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG). Breast Cancer Research and Treatment, 2018, 171, 11-20.	2.5	32
165	Cyclin-dependent kinase 4/6 inhibitors in hormone receptor-positive early breast cancer: preliminary results and ongoing studies. Breast Cancer, 2018, 25, 506-516.	2.9	15
166	Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Annals of Oncology, 2018, 29, 1541-1547.	1.2	526
166 168	Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Annals of Oncology, 2018, 29, 1541-1547. An update on treatment for post-menopausal metastatic breast cancer in elderly patients. Expert Opinion on Pharmacotherapy, 2018, 19, 597-609.	1.2 1.8	526 1
166 168 169	Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Annals of Oncology, 2018, 29, 1541-1547. An update on treatment for post-menopausal metastatic breast cancer in elderly patients. Expert Opinion on Pharmacotherapy, 2018, 19, 597-609. The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade. Cell Reports, 2018, 22, 2978-2994.	1.2 1.8 6.4	526 1 315
166 168 169 170	Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Annals of Oncology, 2018, 29, 1541-1547.   An update on treatment for post-menopausal metastatic breast cancer in elderly patients. Expert Opinion on Pharmacotherapy, 2018, 19, 597-609.   The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade. Cell Reports, 2018, 22, 2978-2994.   Current Treatment Patterns Among Postmenopausal Women with HR+/HER2â <sup>-2</sup> Metastatic Breast Cancer in US Community Oncology Practices: An Observational Study. Advances in Therapy, 2018, 35, 482-493.	1.2 1.8 6.4 2.9	526 1 315 9

#	Article	IF	CITATIONS
172	Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer. Clinical Cancer Research, 2018, 24, 2804-2811.	7.0	249
173	Everolimus Plus Endocrine Therapy for Postmenopausal Women With Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer. JAMA Oncology, 2018, 4, 977.	7.1	48
174	Preclinical and clinical development of palbociclib and future perspectives. Clinical and Translational Oncology, 2018, 20, 1136-1144.	2.4	20
175	Different inhibitors for the same target in metastatic luminal breast cancer: is there any difference?. Future Oncology, 2018, 14, 891-895.	2.4	5
176	Abemaciclib for the treatment of breast cancer. Expert Opinion on Pharmacotherapy, 2018, 19, 517-524.	1.8	17
177	Emerging combination endocrine therapies for advanced breast cancer. Breast Journal, 2018, 24, 214-215.	1.0	0
178	Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial. Breast Cancer Research and Treatment, 2018, 167, 659-669.	2.5	64
179	Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer. Breast Cancer, 2018, 25, 392-401.	2.9	134
180	Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors – Data from the German PRAEGNANT breast cancer registry. Breast, 2018, 37, 42-51.	2.2	54
182	Palbociclib-Induced Thrombotic Microangiopathy in Metastatic Breast Cancer Patient Surviving for 18 Years: Case Report and Review of the Literature. Clinical Breast Cancer, 2018, 18, e263-e266.	2.4	8
183	Radical radiation therapy for oligometastatic breast cancer: Results of a prospective phase II trial. Radiotherapy and Oncology, 2018, 126, 177-180.	0.6	116
184	Everolimus Plus Letrozole for Treatment of Patients With HR+, HER2– Advanced Breast Cancer Progressing on Endocrine Therapy: An Open-label, Phase II Trial. Clinical Breast Cancer, 2018, 18, e197-e203.	2.4	10
185	Dual or multi-targeting inhibitors: The next generation anticancer agents. European Journal of Medicinal Chemistry, 2018, 143, 1277-1300.	5.5	182
186	Efficacy and safety in older patient subsets in studies of endocrine monotherapy versus combination therapy in patients with HR+/HER2â^Âadvanced breast cancer: a review. Breast Cancer Research and Treatment, 2018, 167, 607-614.	2.5	18
187	Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2â^' advanced breast cancer in the randomized MONALEESA-2 trial. Breast Cancer Research and Treatment, 2018, 168, 127-134.	2.5	90
188	Efficacy and safety of palbociclib in heavily pretreated patients with HR+/HER2-Âmetastatic breast cancer. Future Oncology, 2018, 14, 537-544.	2.4	14
189	Trends in progression-free survival (PFS) and time to progression (TTP) over time within first-line aromatase inhibitors trials in hormone receptor-positive advanced breast cancer. Breast Cancer Research and Treatment, 2018, 168, 457-465.	2.5	5
190	Emerging Innovative Therapeutic Approaches Leveraging Cyclinâ€Dependent Kinase Inhibitors to Treat Advanced Breast Cancer. Clinical Pharmacology and Therapeutics, 2018, 103, 1009-1019.	4.7	5

#	Article	IF	CITATIONS
191	Spurring science, marking progress, and influencing history. Nature Reviews Clinical Oncology, 2018, 15, 79-80.	27.6	3
192	Potential biomarkers of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer. Breast Cancer Research and Treatment, 2018, 168, 287-297.	2.5	30
193	Impact of disease progression on health-related quality of life in patients with metastatic breast cancer registry. Breast, 2018, 37, 154-160.	2.2	56
194	Emerging data on improving response to hormone therapy: the role of novel targeted agents. Expert Review of Anticancer Therapy, 2018, 18, 3-18.	2.4	2
195	Macrocytosis and dysplastic anemia is associated with the cyclin-dependent kinase 4/6 inhibitor palbociclib in metastatic breast cancer. Haematologica, 2018, 103, e98-e102.	3.5	8
196	Inhibiting CDK in Cancer Therapy: Current Evidence and Future Directions. Targeted Oncology, 2018, 13, 21-38.	3.6	78
197	Risk of adverse events with the addition of targeted agents to endocrine therapy in patients with hormone receptor-positive metastatic breast cancer: A systematic review and meta-analysis. Cancer Treatment Reviews, 2018, 62, 123-132.	7.7	16
198	Targeting FGFR pathway in breast cancer. Breast, 2018, 37, 126-133.	2.2	89
199	Precision Oncology beyond Targeted Therapy: Combining Omics Data with Machine Learning Matches the Majority of Cancer Cells to Effective Therapeutics. Molecular Cancer Research, 2018, 16, 269-278.	3.4	127
200	Extranuclear signaling by sex steroid receptors and clinical implications in breast cancer. Molecular and Cellular Endocrinology, 2018, 466, 51-72.	3.2	38
201	Cáncer de mama avanzado receptor de estrógeno positivo: Manejo sistémico actual. Revista Chilena De Cirugia, 2018, 70, 464-473.	0.1	2
204	National Cancer Institute Breast Cancer Steering Committee Working Group Report on Meaningful and Appropriate End Points for Clinical Trials in Metastatic Breast Cancer. Journal of Clinical Oncology, 2018, 36, 3259-3268.	1.6	19
205	A case report of primary cardiac sarcoma: a diagnostic and therapeutic challenge. European Heart Journal - Case Reports, 2018, 2, yty143.	0.6	4
206	Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102. Journal of Clinical Oncology, 2018, 36, 1556-1563.	1.6	134
207	Innovative Strategies: Targeting Subtypes in Metastatic Breast Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 65-77.	3.8	11
208	Evolution of Targeted Therapy in Breast Cancer: Where Precision Medicine Began. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 78-86.	3.8	36
209	The role of palbociclib in thyroid carcinoma with BRAF mutation. Gland Surgery, 2018, 7, S82-S85.	1.1	2
210	Immunotherapy in pancreatic adenocarcinoma—overcoming barriers to response. Journal of Castrointestinal Oncology, 2018, 9, 143-159	1.4	42

#	Article	IF	CITATIONS
211	Highlights from the 10th Breast, Gynaecological and Immunotherapy International Cancer Conference (BGICC), 18–19 January 2018, Cairo, Egypt. Ecancermedicalscience, 2018, 12, 820.	1.1	0
213	Management of Hormone Receptor-Positive Metastatic Breast Cancer. , 0, , .		0
214	Inhibitors targeting CDK4/6, PARP and PI3K in breast cancer: a review. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591880850.	3.2	30
215	Novel Agents for the Management of Endocrine Resistant Breast Cancer. Current Breast Cancer Reports, 2018, 10, 274-281.	1.0	0
216	Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer – the SONIA study: study protocol for a randomized controlled trial. BMC Cancer, 2018, 18, 1146.	2.6	36
217	Blocking Cyclin-Dependent Kinase 4/6 During Single Dose Versus Fractionated Radiation Therapy Leads to Opposite Effects on Acute Gastrointestinal Toxicity in Mice. International Journal of Radiation Oncology Biology Physics, 2018, 102, 1569-1576.	0.8	29
218	Case 35-2018: A 68-Year-Old Woman with Back Pain and a Remote History of Breast Cancer. New England Journal of Medicine, 2018, 379, 1946-1953.	27.0	4
219	Cyclin-Dependent Kinase 4/6 Inhibitor (Palbociclib) Induced Aplastic Anemia in a Patient with Metastatic Breast Cancer. Case Reports in Hematology, 2018, 2018, 1-4.	0.4	1
220	Cost-effectiveness analysis of ribociclib versus palbociclib in the first-line treatment of HR+/HER2– advanced or metastatic breast cancer in Spain. ClinicoEconomics and Outcomes Research, 2018, Volume 10, 773-790.	1.9	24
221	Use of Novel Combination Therapies in the Treatment of Advanced HR+/HER2â^' Breast Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, S5-S17.	4.9	0
222	Managing advanced HR-positive, HER2-negative breast cancer with CDK4/6 inhibitors in post-menopausal patients: is there a best sequence?. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591881559.	3.2	5
223	CDK4/6 inhibitors in breast cancer: beyond hormone receptor-positive HER2-negative disease. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591881834.	3.2	33
224	CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors. Frontiers in Oncology, 2018, 8, 608.	2.8	160
225	Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacy. Npj Breast Cancer, 2018, 4, 41.	5.2	41
226	Non-Coding RNAs in Breast Cancer: Intracellular and Intercellular Communication. Non-coding RNA, 2018, 4, 40.	2.6	110
227	Use of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in older patients with ER-positive HER2-negative breast cancer: Young International Society of Geriatric Oncology review paper. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591880961.	3.2	44
228	Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer. Npj Breast Cancer, 2018, 4, 38.	5.2	78
229	Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway. Cancer Cell, 2018, 34, 893-905.e8.	16.8	307

#	Article	IF	CITATIONS
230	Endocrine Therapy for Breast Cancer: A Model of Hormonal Manipulation. Oncology and Therapy, 2018, 6, 141-156.	2.6	30
231	Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigm. Asia-Pacific Journal of Clinical Oncology, 2018, 14, 3-11.	1.1	4
232	Matching-adjusted indirect treatment comparison of ribociclib and palbociclib in HR+, HER2− advanced breast cancer. Cancer Management and Research, 2018, Volume 10, 1319-1327.	1.9	17
233	Emerging data and future directions for CDK4/6 inhibitor treatment of patients with hormone receptor positive HER2â€nonâ€amplified metastatic breast cancer. Asia-Pacific Journal of Clinical Oncology, 2018, 14, 12-21.	1.1	1
234	A comprehensive review of protein kinase inhibitors for cancer therapy. Expert Review of Anticancer Therapy, 2018, 18, 1249-1270.	2.4	164
235	Integrated genomic analyses in PDX model reveal a cyclin-dependent kinase inhibitor Palbociclib as a novel candidate drug for nasopharyngeal carcinoma. Journal of Experimental and Clinical Cancer Research, 2018, 37, 233.	8.6	23
236	Butein suppresses hepatocellular carcinoma growth via modulating Aurora B kinase activity. International Journal of Biological Sciences, 2018, 14, 1521-1534.	6.4	23
237	Value Assessment in Oncology Drugs: Funding of Drugs for Metastatic Breast Cancer in Canada. Current Oncology, 2018, 25, 161-170.	2.2	9
238	Systematic bias between blinded independent central review and local assessment: literature review and analyses of 76 phase III randomised controlled trials in 45 688 patients with advanced solid tumour. BMJ Open, 2018, 8, e017240.	1.9	20
240	Acquired palbociclib resistance in KRAS-mutant lung cancer. Oncotarget, 2018, 9, 32734-32735.	1.8	3
241	LEM4 confers tamoxifen resistance to breast cancer cells by activating cyclin D-CDK4/6-Rb and ERα pathway. Nature Communications, 2018, 9, 4180.	12.8	47
242	Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer. Annals of Oncology, 2018, 29, 2334-2340.	1.2	97
243	CDK4-6 inhibitors in breast cancer: current status and future development. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 1-16.	3.3	23
244	Single-cell barcode analysis provides a rapid readout of cellular signaling pathways in clinical specimens. Nature Communications, 2018, 9, 4550.	12.8	47
245	CDK4/6 inhibitors as neoadjuvant treatment in breast cancer—what can we learn?. Annals of Oncology, 2018, 29, 2274-2278.	1.2	4
246	A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR-β. Investigational New Drugs, 2018, 36, 1103-1109.	2.6	13
247	Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer. New England Journal of Medicine, 2018, 379, 1926-1936.	27.0	805
248	Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial. Breast Cancer Research, 2018, 20, 123.	5.0	41

#	Article	IF	CITATIONS
249	The Emerging Role of Cyclin-Dependent Kinases (CDKs) in Pancreatic Ductal Adenocarcinoma. International Journal of Molecular Sciences, 2018, 19, 3219.	4.1	60
250	Profile of abemaciclib and its potential in the treatment of breast cancer. OncoTargets and Therapy, 2018, Volume 11, 5253-5259.	2.0	28
251	A contemporary review of male breast cancer: current evidence and unanswered questions. Cancer and Metastasis Reviews, 2018, 37, 599-614.	5.9	63
252	The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial. Cancer Discovery, 2018, 8, 1390-1403.	9.4	397
253	Management of adverse events during cyclin-dependent kinase 4/6 (CDK4/6) inhibitor-based treatment in breast cancer. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591879332.	3.2	104
254	Updates on managing advanced breast cancer with palbociclib combination therapy. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591879384.	3.2	16
255	C-3- and C-4-Substituted Bicyclic Coumarin Sulfamates as Potent Steroid Sulfatase Inhibitors. ACS Omega, 2018, 3, 10748-10772.	3.5	21
256	Identification of Chemotherapy-Induced Leukemic-Regenerating Cells Reveals a Transient Vulnerability of Human AML Recurrence. Cancer Cell, 2018, 34, 483-498.e5.	16.8	125
257	Cure in metastatic breast cancer. Memo - Magazine of European Medical Oncology, 2018, 11, 172-179.	0.5	23
258	An insight into the emerging role of cyclin-dependent kinase inhibitors as potential therapeutic agents for the treatment of advanced cancers. Biomedicine and Pharmacotherapy, 2018, 107, 1326-1341.	5.6	74
259	CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion. ESMO Open, 2018, 3, e000368.	4.5	35
260	The CDK4/6 inhibitor in HR-positive advanced breast cancer. Medicine (United States), 2018, 97, e10746.	1.0	14
261	Palbociclib in highly pretreated metastatic ER-positive HER2-negative breast cancer. Breast Cancer Research and Treatment, 2018, 171, 131-141.	2.5	12
262	Progression-free survival with endocrine-based therapies following progression on non-steroidal aromatase inhibitor among postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative metastatic breast cancer: a network meta-analysis. Current	1.9	10
263	Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncology, The, 2018, 19, 904-915.	10.7	648
264	PDLIM7 and CDH18 regulate the turnover of MDM2 during CDK4/6 inhibitor therapy-induced senescence. Oncogene, 2018, 37, 5066-5078.	5.9	38
265	Ribociclib in premenopausal women with advanced breast cancer. Lancet Oncology, The, 2018, 19, 850-852.	10.7	2
266	<i>TMPRSS2-ERG</i> Controls Luminal Epithelial Lineage and Antiandrogen Sensitivity in <i>PTEN</i> and <i>TP53</i> -Mutated Prostate Cancer. Clinical Cancer Research, 2018, 24, 4551-4565.	7.0	51

#	Article	IF	CITATIONS
267	Updates in the Evaluation and Management of Breast Cancer. Mayo Clinic Proceedings, 2018, 93, 794-807.	3.0	39
269	Repeated in-field radiosurgery for locally recurrent brain metastases: Feasibility, results and survival in a heavily treated patient cohort. PLoS ONE, 2018, 13, e0198692.	2.5	47
270	Cdk4/6 inhibitors and overall survival: power of first-line trials in metastatic breast cancer. Npj Breast Cancer, 2018, 4, 14.	5.2	10
272	Advances in geriatric oncology: a multidisciplinary perspective. Tumori, 2018, 104, 252-257.	1.1	6
273	Beyond the Cell Cycle: Enhancing the Immune Surveillance of Tumors Via CDK4/6 Inhibition. Molecular Cancer Research, 2018, 16, 1454-1457.	3.4	35
274	New developments in brain metastases. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628641878550.	3.5	25
275	The Cell Cycle. , 2018, , 197-219.		10
276	Clinical and molecular aspects of breast cancer: Targets and therapies. Biomedicine and Pharmacotherapy, 2018, 106, 14-34.	5.6	49
277	Valproic acid as an adjunctive therapeutic agent for the treatment of breast cancer. European Journal of Pharmacology, 2018, 835, 61-74.	3.5	70
278	Small Molecules in Oncology. Recent Results in Cancer Research, 2018, , .	1.8	5
279	Overcoming Endocrine Resistance in Hormone Receptor–Positive Breast Cancer. Current Oncology, 2018, 25, 18-27.	2.2	96
280	Budget impact of including ribociclib in combination with letrozole on US payer formulary: first-line treatment of post-menopausal women with HR+/HER2â^ advanced or metastatic breast cancer. Current Medical Research and Opinion, 2018, 34, 2143-2150.	1.9	7
281	Molecular Regulation of Cell Cycle and Cell Cycle-Targeted Therapies in Head and Neck Squamous Cell Carcinoma (HNSCC). Current Cancer Research, 2018, , 185-227.	0.2	0
282	CDK4/6 inhibitors in advanced hormone receptor-positive/HER2-negative breast cancer: a systematic review and meta-analysis of randomized trials. Breast Cancer Research and Treatment, 2018, 172, 9-21.	2.5	52
283	Palbociclib plus endocrine therapy in older women with HR+/HER2– advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies. European Journal of Cancer, 2018, 101, 123-133.	2.8	59
284	Expanded-Access Study of Palbociclib in Combination With Letrozole for Treatment of Postmenopausal Women With Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer. Clinical Breast Cancer, 2018, 18, e1239-e1245.	2.4	17
285	Personalizing aromatase inhibitor therapy in patients with breast cancer. Cancer Treatment Reviews, 2018, 70, 47-55.	7.7	27
286	CDK4/6 inhibition in breast cancer: current practice and future directions. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591878645.	3.2	218

#	Article	IF	CITATIONS
287	Association of Circulating Tumor Cells With Late Recurrence of Estrogen Receptor–Positive Breast Cancer. JAMA Oncology, 2018, 4, 1700.	7.1	151
288	Everolimus-based combination therapies for HR+, HER2â^' metastatic breast cancer. Cancer Treatment Reviews, 2018, 69, 204-214.	7.7	48
289	DUB3 Promotes BET Inhibitor Resistance and Cancer Progression by Deubiquitinating BRD4. Molecular Cell, 2018, 71, 592-605.e4.	9.7	114
290	Effect of first-line endocrine therapy in patients with hormone-sensitive advanced breast cancer: a network meta-analysis. OncoTargets and Therapy, 2018, Volume 11, 2647-2656.	2.0	8
291	CDK4/6 Inhibition in Cancer: Beyond Cell Cycle Arrest. Trends in Cell Biology, 2018, 28, 911-925.	7.9	273
292	Palbociclib—The First of a New Class of Cell Cycle Inhibitors. Recent Results in Cancer Research, 2018, 211, 153-175.	1.8	9
293	Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer. Journal of Hematology and Oncology, 2018, 11, 80.	17.0	36
294	Novel Therapeutic Targets in Cutaneous Squamous Cell Carcinoma. Frontiers in Oncology, 2018, 8, 79.	2.8	24
295	Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients. Frontiers in Oncology, 2018, 8, 89.	2.8	64
296	Precision Medicine in Hormone Receptor-Positive Breast Cancer. Frontiers in Oncology, 2018, 8, 144.	2.8	32
297	Recent Advances in the Treatment of Breast Cancer. Frontiers in Oncology, 2018, 8, 227.	2.8	263
298	Progress in targeted therapy for breast cancer. Chronic Diseases and Translational Medicine, 2018, 4, 164-175.	1.2	31
299	4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4). Annals of Oncology, 2018, 29, 1634-1657.	1.2	891
300	Cardiovascular sequelae of breast cancer treatments: A review. Current Problems in Cancer, 2018, 42, 409-421.	2.0	4
301	Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer: Redrawing the Lines. Current Oncology, 2018, 25, 131-141.	2.2	31
302	Cyclin E overexpression confers resistance to the CDK4/6 specific inhibitor palbociclib in gastric cancer cells. Cancer Letters, 2018, 430, 123-132.	7.2	52
303	Abemaciclib for the treatment of HR+/HER2- breast cancer. Expert Review of Precision Medicine and Drug Development, 2018, 3, 151-161.	0.7	2
304	Real-world evidence analysis of palbociclib prescribing patterns for patients withÂadvanced/metastatic breast cancer treated in community oncology practice in the USA one year post approval. Breast Cancer Research, 2018, 20, 37.	5.0	51

#	Article	IF	CITATIONS
305	Clinical implications of the non-luminal intrinsic subtypes in hormone receptor-positive breast cancer. Cancer Treatment Reviews, 2018, 67, 63-70.	7.7	79
306	CDK4/6 Inhibitors in Combination With Hormone Therapy for HR+/HER2â^' Advanced Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Clinical Breast Cancer, 2018, 18, e943-e953.	2.4	29
307	Fulvestrant for the treatment of advanced breast cancer. Expert Review of Anticancer Therapy, 2018, 18, 619-628.	2.4	27
309	Genetic and Epigenetic Features of Rapidly Progressing IDH-Mutant Astrocytomas. Journal of Neuropathology and Experimental Neurology, 2018, 77, 542-548.	1.7	34
310	Patterns of Distant Failure by Intrinsic Breast Cancer Subtype in Premenopausal Women Treated With Neoadjuvant Chemotherapy. Clinical Breast Cancer, 2018, 18, e1077-e1085.	2.4	4
311	Plasma thymidine kinase-1 activity predicts outcome in patients with hormone receptor positive and HER2 negative metastatic breast cancer treated with endocrine therapy. Oncotarget, 2018, 9, 16389-16399.	1.8	37
312	Cutaneous and Gastrointestinal Leukocytoclastic Vasculitis Induced by Palbociclib in a Metastatic Breast Cancer Patient: A Case Report. Clinical Breast Cancer, 2018, 18, e755-e758.	2.4	9
313	Aggressive Systemic Therapy with Response-Based Radiation. International Journal of Radiation Oncology Biology Physics, 2018, 102, 14-15.	0.8	1
314	Pharmacokinetic drug evaluation of palbociclib for the treatment of breast cancer. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 891-900.	3.3	16
315	An Update on the Clinical Use of CDK4/6 Inhibitors in Breast Cancer. Drugs, 2018, 78, 1353-1362.	10.9	6
316	Current Landscape of Targeted Therapies for Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer. Frontiers in Oncology, 2018, 8, 308.	2.8	62
317	Phase-2 trial of palbociclib in adult patients with recurrent RB1-positive glioblastoma. Journal of Neuro-Oncology, 2018, 140, 477-483.	2.9	82
318	Understanding patterns of brain metastasis in breast cancer and designing rational therapeutic strategies. Annals of Translational Medicine, 2018, 6, 163-163.	1.7	86
319	Recent advances in CDK inhibitors for cancer therapy. Future Medicinal Chemistry, 2018, 10, 1369-1388.	2.3	35
320	Targeting forkhead box M1 transcription factor in breast cancer. Biochemical Pharmacology, 2018, 154, 407-413.	4.4	28
321	Dosing Patterns and Economic Burden of Palbociclib Drug Wastage in HR+/HER2â^' Metastatic Breast Cancer. Advances in Therapy, 2018, 35, 768-778.	2.9	9
322	Effect of aromatase inhibitor letrozole on the proliferation of spermatogonia by regulating the MAPK pathway. Experimental and Therapeutic Medicine, 2018, 15, 5269-5274.	1.8	2
323	The role of abemaciclib in treatment of advanced breast cancer. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591877692.	3.2	14

#	Article	IF	CITATIONS
324	Cell-Cycle Regulation. , 2018, , 257-269.		3
325	Targeted Therapy for Premenopausal Women with HR+, HER2â^ Advanced Breast Cancer: Focus on Special Considerations and Latest Advances. Clinical Cancer Research, 2018, 24, 5206-5218.	7.0	40
326	4th International Consensus Conference on Advanced Breast Cancer (ABC4), Lisbon, November 4, 2017. Geburtshilfe Und Frauenheilkunde, 2018, 78, 469-480.	1.8	3
327	Modulation of Rb phosphorylation and antiproliferative response to palbociclib: the preoperative-palbociclib (POP) randomized clinical trial. Annals of Oncology, 2018, 29, 1755-1762.	1.2	42
328	Reporting of HRQoL results from the PALOMA-2 trial: Relevant data are still missing. Annals of Oncology, 2018, 29, 1877.	1.2	3
329	Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial. Annals of Oncology, 2018, 29, 1748-1754.	1.2	76
330	Update on cardio-oncology: Novel cancer therapeutics and associated cardiotoxicities. Trends in Cardiovascular Medicine, 2019, 29, 29-39.	4.9	43
331	Hair Changes due to Drugs. , 2019, , 245-258.		Ο
332	Review of Cyclin-Dependent Kinase 4/6 Inhibitors for the Treatment of Hormone Receptor–Positive Advanced Breast Cancer. Annals of Pharmacotherapy, 2019, 53, 195-203.	1.9	5
333	Current frontline endocrine treatment options for women with hormone receptor-positive, Human Epidermal Growth Factor Receptor 2 (HER2)-negative advanced-stage breast cancer. Hematology/ Oncology and Stem Cell Therapy, 2019, 12, 1-9.	0.9	3
334	Hormone-Responsive Cancers. , 2019, , 717-741.e8.		2
335	Fulvestrant-Based Combination Therapy for Second-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer. Targeted Oncology, 2019, 14, 1-12.	3.6	12
336	Time to treatment failure of palbociclib and letrozole as second-line therapy or beyond in hormone receptor-positive advanced breast cancer. Journal of Oncology Pharmacy Practice, 2019, 25, 1374-1380.	0.9	3
337	Abemaciclib: The Newest CDK4/6 Inhibitor for the Treatment of Breast Cancer. Annals of Pharmacotherapy, 2019, 53, 178-185.	1.9	27
338	Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer. Journal of the National Cancer Institute, 2019, 111, 419-430.	6.3	55
339	Role of cyclin-dependent kinase 4/6 inhibitors in the current and future eras of cancer treatment. Journal of Oncology Pharmacy Practice, 2019, 25, 110-129.	0.9	30
340	The Effects of Eribulin on Breast Cancer Microenvironment Identified Using Eribulin-resistant Breast Cancer Cell Lines. Anticancer Research, 2019, 39, 4031-4041.	1.1	10
341	Palbociclib in metastatic breast cancer: current evidence and real-life data. Drugs in Context, 2019, 8, 1-16.	2.2	58

#	Article	IF	CITATIONS
342	Mechanisms of Resistance to CDK4/6 Inhibitors: Potential Implications and Biomarkers for Clinical Practice. Frontiers in Oncology, 2019, 9, 666.	2.8	113
343	CDK 4/6 inhibitors and stereotactic radiation in the management of hormone receptor positive breast cancer brain metastases. Journal of Neuro-Oncology, 2019, 144, 583-589.	2.9	48
344	Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions. JNCI Cancer Spectrum, 2019, 3, pkz049.	2.9	11
345	Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women. American Journal of Health-System Pharmacy, 2019, 76, 1183-1202.	1.0	21
346	Metastatic breast cancer patients with lung or liver metastases should be distinguished before being treated with fulvestrant. Cancer Medicine, 2019, 8, 6212-6220.	2.8	15
347	First-Line Treatment for Endocrine-Sensitive Bone-Only Metastatic Breast Cancer: Systematic Review and Meta-analysis. Clinical Breast Cancer, 2019, 19, e701-e716.	2.4	10
348	Unique presentation of occult breast cancer with uterine cervix metastasis. Clinical Case Reports (discontinued), 2019, 7, 1573-1576.	0.5	2
349	CDK4/6 inhibitor palbociclib suppresses IgE-mediated mast cell activation. Journal of Translational Medicine, 2019, 17, 276.	4.4	11
350	EMERALD: Phase III trial of elacestrant (RAD1901) vs endocrine therapy for previously treated ER+ advanced breast cancer. Future Oncology, 2019, 15, 3209-3218.	2.4	43
351	<i>ESR1</i> mutations in breast cancer. Cancer, 2019, 125, 3714-3728.	4.1	154
352	A Review of Local and Systemic Therapy in Breast Cancer. , 2019, , 637-690.		0
353	Blood-based monitoring identifies acquired and targetable driver HER2 mutations in endocrine-resistant metastatic breast cancer. Npj Precision Oncology, 2019, 3, 18.	5.4	25
354	Assessment of the efficacy of successive endocrine therapies in hormone receptor–positive and HER2-negative metastatic breast cancer: a real-life multicentre national study. European Journal of Cancer, 2019, 118, 131-141.	2.8	11
355	Endocrine Therapy in Breast Cancer: a Snapshot of Current Practice. Clinical Oncology, 2019, 31, e112.	1.4	0
356	Impact of Routine Use of CDK4/6 Inhibitor Therapy on Breast Cancer Outpatient Clinic Workload and Patient Experience. Clinical Oncology, 2019, 31, e112.	1.4	0
357	Screening Colonoscopy Unmasking Colonic Metastasis from an Occult Breast Ductal Carcinoma: A Case Report and Review of the Literature. Case Reports in Oncological Medicine, 2019, 2019, 1-6.	0.3	3
358	Endocrine and Targeted Therapy for Hormone-Receptor-Positive, HER2-Negative Advanced Breast Cancer: Insights to Sequencing Treatment and Overcoming Resistance Based on Clinical Trials. Frontiers in Oncology, 2019, 9, 510.	2.8	49

#	Article	IF	CITATIONS
360	Functional genomics identifies predictive markers and clinically actionable resistance mechanisms to CDK4/6 inhibition in bladder cancer. Journal of Experimental and Clinical Cancer Research, 2019, 38, 322.	8.6	23
361	Palbociclib Promotes Dephosphorylation of NPM/B23 at Threonine 199 and Inhibits Endometrial Cancer Cell Growth. Cancers, 2019, 11, 1025.	3.7	8
362	Achieving Improved Survival Outcomes in Advanced Breast Cancer. New England Journal of Medicine, 2019, 381, 371-372.	27.0	15
363	PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences Are Emerging. A Literature Review. Cancers, 2019, 11, 1033.	3.7	160
364	Quantification of Economic Impact of Drug Wastage in Oral Oncology Medications: Comparison of 3 Methods Using Palbociclib and Ribociclib in Advanced or Metastatic Breast Cancer. Journal of Managed Care & Specialty Pharmacy, 2019, 25, 859-866.	0.9	7
365	Predictors of ribociclib-mediated antitumour effects in native and sorafenib-resistant human hepatocellular carcinoma cells. Cellular Oncology (Dordrecht), 2019, 42, 705-715.	4.4	18
366	Advances in Targeted Therapies for Triple-Negative Breast Cancer. Drugs, 2019, 79, 1217-1230.	10.9	71
367	A phase II feasibility study of palbociclib in combination with adjuvant endocrine therapy for hormone receptor-positive invasive breast carcinoma. Annals of Oncology, 2019, 30, 1514-1520.	1.2	13
368	Outcomes of Neoadjuvant Chemotherapy in Breast Cancer Subtypes Guide Rationalising its Use in High-risk Patients by Tumour Genomic Profile. Clinical Oncology, 2019, 31, e111-e112.	1.4	0
369	Identifying and Monitoring Steroid-induced Hyperglycaemia in Breast Cancer Patients Receiving Steroids as Part of their Systemic Anticancer Therapy. Clinical Oncology, 2019, 31, e112.	1.4	0
370	Treating HR+/HER2â^' breast cancer in premenopausal Asian women: Asian Breast Cancer Cooperative Group 2019 Consensus and position on ovarian suppression. Breast Cancer Research and Treatment, 2019, 177, 549-559.	2.5	29
371	Diagnostic Leukapheresis Enables Reliable Transcriptomic Profiling of Single Circulating Tumor Cells to Characterize Inter-Cellular Heterogeneity in Terms of Endocrine Resistance. Cancers, 2019, 11, 903.	3.7	24
372	Advances in Endocrine-Based Therapies for Estrogen Receptor-Positive Metastatic Breast Cancer. Drugs, 2019, 79, 1849-1866.	10.9	36
373	Combining CDK4/6 inhibitors ribociclib and palbociclib with cytotoxic agents does not enhance cytotoxicity. PLoS ONE, 2019, 14, e0223555.	2.5	18
374	Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncology, The, 2019, 20, 1750-1759.	10.7	86
375	Antitumor Activity of Vanicoside B Isolated from <i>Persicaria dissitiflora</i> by Targeting CDK8 in Triple-Negative Breast Cancer Cells. Journal of Natural Products, 2019, 82, 3140-3149.	3.0	22
376	Randomized phase-II evaluation of letrozole plus dasatinib in hormone receptor positive metastatic breast cancer patients. Npj Breast Cancer, 2019, 5, 36.	5.2	9
377	Efficacy and Safety of Palbociclib and Fulvestrant in Japanese Patients With ER+/HER2â^' Advanced/Metastatic Breast Cancer. In Vivo, 2019, 33, 2037-2044.	1.3	2

	CHANOR	LPORT	
#	Article	IF	CITATIONS
378	Strategies for Early Prediction and Timely Recognition of Drug-Induced Liver Injury: The Case of Cyclin-Dependent Kinase 4/6 Inhibitors. Frontiers in Pharmacology, 2019, 10, 1235.	3.5	24
379	Association between ribociclib and changes in creatinine in patients with hormone receptor positive metastatic breast cancer. Internal Medicine Journal, 2019, 49, 1438-1442.	0.8	10
380	Homeopathic supportive care protocol for oral inhibitors of cyclin dependent kinases 4 and 6 (CDK) Tj ETQq0 0 10, e69-e73.	0 rgBT /Ov 0.1	verlock 10 Tf
381	Differences of cyclin-dependent kinase 4/6 inhibitor, palbociclib and abemaciclib, in breast cancer. Japanese Journal of Clinical Oncology, 2019, 49, 993-998.	1.3	23
382	Update Breast Cancer 2019 Part 5 – Diagnostic and Therapeutic Challenges of New, Personalised Therapies in Patients with Advanced Breast Cancer. Geburtshilfe Und Frauenheilkunde, 2019, 79, 1090-1099.	1.8	16
383	CDK4/6 inhibition mitigates stem cell damage in a novel model for taxaneâ€induced alopecia. EMBO Molecular Medicine, 2019, 11, e11031.	6.9	45
384	The Targeted Therapies Era Beyond the Surgical Point of View: What Spine Surgeons Should Know Before Approaching Spinal Metastases. Cancer Control, 2019, 26, 107327481987054.	1.8	16
385	The PI3K/AKT/mTOR and CDK4/6 Pathways in Endocrine Resistant HR+/HER2â^' Metastatic Breast Cancer: Biological Mechanisms and New Treatments. Cancers, 2019, 11, 1242.	3.7	68
386	CDK4/6 inhibitors in advanced breast cancer, what is beyond?. Oncology Reviews, 2019, 13, 416.	1.8	6
387	Prognostic relevance of DNA damage and repair biomarkers in elderly patients with hormone-receptor-positive breast cancer treated with neoadjuvant hormone therapy: evidence from the real-world setting. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591985319.	3.2	2
388	Short- and Long-Term Effects of CDK4/6 Inhibition on Early-Stage Breast Cancer. Molecular Cancer Therapeutics, 2019, 18, 2220-2232.	4.1	7
389	Are all cyclin-dependent kinases 4/6 inhibitors created equal?. Npj Breast Cancer, 2019, 5, 27.	5.2	85
390	CDK4/6 inhibitors: taking the place of chemotherapy?. Lancet Oncology, The, 2019, 20, 1329-1330.	10.7	4
391	An evaluation of fulvestrant for the treatment of metastatic breast cancer. Expert Opinion on Pharmacotherapy, 2019, 20, 1819-1829.	1.8	18
392	Abemaciclib, a potent cyclin-dependent kinase 4 and 6 inhibitor, for treatment of ER-positive metastatic breast cancer. Future Oncology, 2019, 15, 3309-3326.	2.4	6
393	Cyclin-Dependent Kinases 4/6 Inhibitors in Breast Cancer: Current Status, Resistance, and Combination Strategies. Journal of Cancer, 2019, 10, 5504-5517.	2.5	60
394	Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis. Lancet Oncology, The, 2019, 20, 1360-1369.	10.7	131
398	Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial. Breast Cancer Research, 2019, 21, 108.	5.0	21

#	Article	IF	CITATIONS
399	AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2019. Breast Care, 2019, 14, 247-255.	1.4	32
400	Impact of systemic therapy on circulating leukocyte populations in patients with metastatic breast cancer. Scientific Reports, 2019, 9, 13451.	3.3	21
401	CDK4/6 inhibitors in breast cancer: a role in triple-negative disease?. Lancet Oncology, The, 2019, 20, 1479-1481.	10.7	7
402	Breast cancer. Nature Reviews Disease Primers, 2019, 5, 66.	30.5	1,620
403	Breast Cancer Treatment. JAMA - Journal of the American Medical Association, 2019, 321, 288.	7.4	2,785
404	Comparative efficacy of palbociclib, ribociclib and abemaciclib for ER+ metastatic breast cancer: an adjusted indirect analysis of randomized controlled trials. Breast Cancer Research and Treatment, 2019, 174, 597-604.	2.5	55
405	Does guideline non-adherence result in worse clinical outcomes for hormone receptor-positive and HER2-negative metastatic breast cancer in premenopausal women?: result of an institution database from South Korea. BMC Cancer, 2019, 19, 84.	2.6	8
406	Cardiac arrhythmia considerations of hormone cancer therapies. Cardiovascular Research, 2019, 115, 878-894.	3.8	42
407	Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Annals of Oncology, 2019, 30, 365-373.	1.2	106
408	Addressing physician barriers to administering cyclin-dependent kinases 4 and 6 inhibitors in first-line treatment of hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer. Cancer Management and Research, 2019, Volume 11, 513-524.	1.9	5
410	Cyclin-dependent kinase 4/6 inhibitors: what have we learnt across studies, therapy situations and substances. Current Opinion in Obstetrics and Gynecology, 2019, 31, 56-66.	2.0	9
411	RN181 is a tumour suppressor in gastric cancer by regulation of the ERK/MAPK–cyclin D1/CDK4 pathway. Journal of Pathology, 2019, 248, 204-216.	4.5	16
412	A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB). Clinical Cancer Research, 2019, 25, 2975-2987.	7.0	76
413	Clinical Predictive Factors for the Efficacy of Everolimus in Patients With Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer: A Multicenter Retrospective Cohort Study in Japan. Breast Cancer: Basic and Clinical Research, 2019, 13, 117822341882513.	1.1	1
414	Palbociclib and endocrine therapy in heavily pretreated hormone receptor-positive HER2-negative advanced breast cancer: the UK Compassionate Access Programme experience. Breast Cancer Research and Treatment, 2019, 174, 731-740.	2.5	18
415	Prevention and Treatment of Skeletal Complications. , 2019, , 193-218.		0
416	Palbociclib Plus Letrozole as First-Line Therapy in Postmenopausal Asian Women With Metastatic Breast Cancer: Results From the Phase III, Randomized PALOMA-2 Study. Journal of Global Oncology, 2019, 5, 1-19.	0.5	34
417	Cardiotoxicities of Modern Treatments in Breast Cancer. Current Treatment Options in Cardiovascular Medicine, 2019, 21, 34.	0.9	2

		CITATION R	EPORT	
#	Article		IF	Citations
418	Update on Precision Medicine in Breast Cancer. Cancer Treatment and Research, 2019, 178, 4	15-80.	0.5	27
419	Recent advances with cyclin-dependent kinase inhibitors: therapeutic agents for breast cance their role in immuno-oncology. Expert Review of Anticancer Therapy, 2019, 19, 569-587.	r and	2.4	21
420	Palbociclib with Letrozole in Postmenopausal Women with ER+/HER2â^' Advanced Breast Car Hematologic Safety Analysis of the Randomized PALOMA-2 Trial. Oncologist, 2019, 24, 1514	ıcer: ·1525.	3.7	49
421	Cyclin D1 differential activation and its prognostic impact in patients with advanced breast ca treated with trastuzumab. ESMO Open, 2019, 4, e000441.	ancer	4.5	3
422	Influence of patient and tumor characteristics on therapy persistence with letrozole in postmenopausal women with advanced breast cancer: results of the prospective observations EvAluate-TM study. BMC Cancer, 2019, 19, 611.	al	2.6	5
423	Safety and Efficacy of Palbociclib and Radiation Therapy in Patients With Metastatic Breast Ca Initial Results of a Novel Combination. Advances in Radiation Oncology, 2019, 4, 453-457.	ancer:	1.2	52
424	Cyclin-Dependent Kinase 4/6 Inhibitors in Neoadjuvant Endocrine Therapy of Hormone Receptor-Positive Breast Cancer. Clinical Breast Cancer, 2019, 19, 392-398.		2.4	12
425	Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval. JAMA Inte Medicine, 2019, 179, 906.	rnal	5.1	189
426	Palbociclib Effectively Halts Proliferation but Fails to Induce Senescence in Patient-Derived Gli Stem Cells. Molecular Neurobiology, 2019, 56, 7810-7821.	oma	4.0	15
427	Neutropenia management with palbociclib in Japanese patients with advanced breast cancer. Cancer, 2019, 26, 637-650.	Breast	2.9	8
428	Therapeutic innovations in breast cancer. Presse Medicale, 2019, 48, 1131-1137.		1.9	5
429	Endocrine Resistance in Hormone Receptor Positive Breast Cancer–From Mechanism to The Frontiers in Endocrinology, 2019, 10, 245.	erapy.	3.5	150
430	CDK4/6 inhibitors for hormone receptor-positive HER2-negative metastatic breast cancer: doe fit all?. Future Medicinal Chemistry, 2019, 11, 1237-1239.	es one size	2.3	1
431	Adjuvant Systemic Therapy in Breast Cancer. , 2019, , 179-194.			0
432	Contemporary management of metastatic soft tissue sarcoma. Current Problems in Cancer, 2 289-299.	.019, 43,	2.0	14
433	Utility of Ki67 labeling index, cyclin D1 expression, and ER-activity level in postmenopausal ER and HER2-negative breast cancer with neoadjuvant chemo-endocrine therapy. PLoS ONE, 201 e0217279.	-positive 9, 14,	2.5	5
434	Management of Breast Cancer in Older Women. , 2019, , .			0
435	Management of toxicities associated with targeted therapies for HR-positive metastatic breas a multidisciplinary approach is the key to success. Breast Cancer Research and Treatment, 20 483-494.	t cancer: 19, 176,	2.5	28

~		<u> </u>	
		IV F D(	<b>DDT</b>
$\sim$	IIAI	IVE F	

#	Article	IF	CITATIONS
436	Healthâ€related quality of life associated with different cancer treatments in Chinese breast cancer survivors in Taiwan. European Journal of Cancer Care, 2019, 28, e13069.	1.5	11
437	PALOMA-3 clinical trial: is there a significant benefit in overall survival for breast cancer? Is it worth it?. Future Oncology, 2019, 15, 1407-1410.	2.4	4
438	The Role of CDK4/6 Inhibitors in Breast Cancer. Current Treatment Options in Oncology, 2019, 20, 52.	3.0	39
439	Targeting cyclin-dependent kinases for the treatment of pulmonary arterial hypertension. Nature Communications, 2019, 10, 2204.	12.8	69
440	Real-World Treatment Patterns and Clinical Outcomes in Patients Receiving Palbociclib for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced or Metastatic Breast Cancer in Argentina: The IRIS Study. Journal of Global Oncology, 2019, 5, JGO1800239.	0.5	34
441	Clinical benefit, toxicity and cost of metastatic breast cancer therapies: systematic review and meta-analysis. Breast Cancer Research and Treatment, 2019, 176, 535-543.	2.5	12
442	Concurrent radiotherapy with palbociclib or ribociclib for metastatic breast cancer patients: Preliminary assessment of toxicity. Breast, 2019, 46, 70-74.	2.2	49
443	An analysis of available biomarker data for targeting cyclin-dependent kinases 4 and 6 (CDK4/6) in breast cancer. Expert Review of Precision Medicine and Drug Development, 2019, 4, 129-138.	0.7	1
444	Role of Cyclin-Dependent Kinase Inhibitors in Endometrial Cancer. International Journal of Molecular Sciences, 2019, 20, 2353.	4.1	24
445	Dependency of Cholangiocarcinoma on Cyclin D–Dependent Kinase Activity. Hepatology, 2019, 70, 1614-1630.	7.3	22
446	Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591983386.	3.2	39
447	Letrozole supplementation during controlled ovarian stimulation in expected high responders: a pilot randomized controlled study. Reproductive Biology and Endocrinology, 2019, 17, 43.	3.3	17
448	Treatment Patterns and Outcomes Associated With Palbociclib Plus Letrozole for Postmenopausal Women With HR+/HER2â^' Advanced Breast Cancer Enrolled in an Expanded Access Program. Clinical Breast Cancer, 2019, 19, 317-325.e4.	2.4	13
449	Multi-Omic Data Interpretation to Repurpose Subtype Specific Drug Candidates for Breast Cancer. Frontiers in Genetics, 2019, 10, 420.	2.3	36
450	Fulvestrant in the treatment of hormone receptorâ€positive/human epidermal growth factor receptor 2â€negative advanced breast cancer: A review. Cancer Medicine, 2019, 8, 1943-1957.	2.8	26
451	Management of Adverse Events Due to Cyclin-Dependent Kinase 4/6 Inhibitors. Breast Care, 2019, 14, 86-92.	1.4	28
452	Highlights from the 11th Breast-Gynecological and Immunooncology International Cancer Conference (BGICC), 17–18 January 2019, Egypt. Ecancermedicalscience, 2019, 13, 926.	1.1	0
453	Maintenance Therapy in HER2-Negative Metastatic Breast Cancer: A New Approach for an Old Concept. Clinical Drug Investigation, 2019, 39, 595-606.	2.2	6

#	Article	IF	CITATIONS
454	A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer. Frontiers in Oncology, 2019, 9, 303.	2.8	8
455	Expanding Therapeutic Options for Older Adults: Caseâ€Based Updates in Breast and Lung Cancer. Journal of the American Geriatrics Society, 2019, 67, 1012-1019.	2.6	2
456	Body Composition, Serum Biomarkers of Inflammation and Quality of Life in Clinically Stable Women with Estrogen Receptor Positive Metastatic Breast Cancer. Nutrition and Cancer, 2019, 71, 981-991.	2.0	16
457	Cost-Effectiveness Analysis of Fulvestrant 500Âmg in Endocrine Therapy-NaÃ <sup>-</sup> ve Postmenopausal Women with Hormone Receptor-Positive Advanced Breast Cancer in the UK. PharmacoEconomics - Open, 2019, 3, 559-570.	1.8	7
458	Genomics in non-adenoid cystic group of salivary gland cancers: one or more druggable entities?. Expert Opinion on Investigational Drugs, 2019, 28, 435-443.	4.1	8
459	Safety and efficacy profile of cyclinâ€dependent kinases 4/6 inhibitor palbociclib in cancer therapy: A metaâ€analysis of clinical trials. Cancer Medicine, 2019, 8, 1389-1400.	2.8	12
460	Real-world clinical outcomes and toxicity in metastatic breast cancer patients treated with palbociclib and endocrine therapy. Breast Cancer Research and Treatment, 2019, 176, 429-434.	2.5	51
461	MicroRNA-Mediated Suppression of the TGF-β Pathway Confers Transmissible and Reversible CDK4/6 Inhibitor Resistance. Cell Reports, 2019, 26, 2667-2680.e7.	6.4	101
462	Post-neoadjuvant treatment and the management of residual disease in breast cancer: state of the art and perspectives. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591982771.	3.2	38
463	CDK4/6 Inhibitors Expand the Therapeutic Options in Breast Cancer: Palbociclib, Ribociclib and Abemaciclib. BioDrugs, 2019, 33, 125-135.	4.6	75
465	Targeting Apoptosis: A New Paradigm for the Treatment of Estrogen Receptor–Positive Breast Cancer. Cancer Discovery, 2019, 9, 323-325.	9.4	16
466	Risk Factors of QTc Prolongation in Women With Hormone Receptor‒positive/Human Epidermal Growth Factor Receptor 2‒negative Metastatic Breast Cancer: A Retrospective Analysis of Health Care Claims Data. Clinical Therapeutics, 2019, 41, 494-504.e1.	2.5	2
467	Progression-free survival (PFS) and toxicities of palbociclib in a geriatric population. Breast Cancer Research and Treatment, 2019, 175, 667-674.	2.5	18
468	Enhanced dermatologic toxicity following concurrent treatment with palbociclib and radiation therapy: A case report. Reports of Practical Oncology and Radiotherapy, 2019, 24, 276-280.	0.6	33
469	Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer. Nature Communications, 2019, 10, 1373.	12.8	252
470	Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer. New England Journal of Medicine, 2019, 380, 1226-1234.	27.0	95
471	Properties of FDA-approved small molecule protein kinase inhibitors. Pharmacological Research, 2019, 144, 19-50.	7.1	377
472	Prognostic effect of Ki-67 in common clinical subgroups of patients with HER2-negative, hormone receptor-positive early breast cancer. Breast Cancer Research and Treatment, 2019, <u>175, 617-625</u> .	2.5	35

#	Article	IF	CITATIONS
474	Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor–Positive Early Breast Cancer: PALLET Trial. Journal of Clinical Oncology, 2019, 37, 178-189.	1.6	136
475	Cyclin D-Cdk4,6 Drives Cell-Cycle Progression via the Retinoblastoma Protein's C-Terminal Helix. Molecular Cell, 2019, 74, 758-770.e4.	9.7	162
476	Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer. Cells, 2019, 8, 321.	4.1	100
477	Efficacy and Safety of Ribociclib With Letrozole in US Patients Enrolled in the MONALEESA-2 Study. Clinical Breast Cancer, 2019, 19, 268-277.e1.	2.4	13
478	Progression-free survival: Starting point or endpoint in advanced HCC trial design?. Journal of Hepatology, 2019, 70, 1062-1064.	3.7	7
479	Rethinking Our Approach of Combining Novel Agents With Standard Chemotherapy in Small Cell Lung Cancer. Journal of Thoracic Oncology, 2019, 14, 580-582.	1.1	1
480	Next-Generation Sequencing of Tissue and Circulating Tumor DNA: The UC San Diego Moores Center for Personalized Cancer Therapy Experience with Breast Malignancies. Molecular Cancer Therapeutics, 2019, 18, 1001-1011.	4.1	34
481	Comparative Efficacy of CDK4/6 Inhibitors Plus Aromatase Inhibitors Versus Fulvestrant for the First-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer: A Network Meta-Analysis. Targeted Oncology, 2019, 14, 139-148.	3.6	15
482	Cyclin E mRNA: Assessing Cyclin-Dependent Kinase (CDK) Activation State to Elucidate Breast Cancer Resistance to CDK4/6 Inhibitors. Journal of Clinical Oncology, 2019, 37, 1148-1150.	1.6	17
483	Therapeutic advances in hormone-dependent cancers: focus on prostate, breast and ovarian cancers. Endocrine Connections, 2019, 8, R10-R26.	1.9	33
484	Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor–Positive Metastatic Breast Cancer. Journal of Clinical Oncology, 2019, 37, 1169-1178.	1.6	266
485	CDK4/6 Inhibitors for Advanced Hormone Receptor–Positive Breast Cancer, 2019 and Beyond. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 190-192.	4.9	3
486	Translational highlights in breast cancer research and treatment: recent developments with clinical impact. Current Opinion in Obstetrics and Gynecology, 2019, 31, 67-75.	2.0	16
487	CDK 4/6 Inhibitors in Breast Cancer: Current Controversies and Future Directions. Current Oncology Reports, 2019, 21, 25.	4.0	122
488	Palbociclib or Ribociclib in First-Line Treatment in Patients With Hormone Receptor–Positive/Human Epidermal Receptor 2–Negative Advanced or Metastatic Breast Cancer? A Perspective Based on Pharmacologic Costs. Clinical Breast Cancer, 2019, 19, e519-e521.	2.4	5
489	Central Nervous System Metastases in HER2-Positive Breast Cancer. , 2019, , 75-93.		0
490	CDK11p110 plays a critical role in the tumorigenicity of esophageal squamous cell carcinoma cells and is a potential drug target. Cell Cycle, 2019, 18, 452-466.	2.6	10
491	Pharmacotherapeutic options for patients with refractory breast cancer. Expert Opinion on Pharmacotherapy, 2019, 20, 851-861.	1.8	3

#	ARTICLE	IF	CITATIONS
493	Preclinical characterization of SHR6390, a novel CDK 4/6 inhibitor, inÂvitro and in human tumor xenograft models. Cancer Science, 2019, 110, 1420-1430.	3.9	48
494	Immunotherapy and targeted therapy combinations in metastatic breast cancer. Lancet Oncology, The, 2019, 20, e175-e186.	10.7	329
495	Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer. New England Journal of Medicine, 2019, 380, 741-751.	27.0	542
496	Retrospective Analysis of Treatment Patterns and Effectiveness of Palbociclib and Subsequent Regimens in Metastatic Breast Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 141-147.	4.9	58
501	Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?. Oncologist, 2019, 24, 1469-1478.	3.7	25
502	Prevention, Monitoring, and Management of Cardiac Dysfunction in Patients with Metastatic Breast Cancer. Oncologist, 2019, 24, e1034-e1043.	3.7	13
503	Should All Patients With HR-Positive HER2-Negative Metastatic Breast Cancer Receive CDK 4/6 Inhibitor As First-Line Based Therapy? A Network Meta-Analysis of Data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT Trials. Cancers, 2019, 11, 1661.	3.7	48
504	Cisplatin exposure causes c-Myc-dependent resistance to CDK4/6 inhibition in HPV-negative head and neck squamous cell carcinoma. Cell Death and Disease, 2019, 10, 867.	6.3	29
505	Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors. Breast Cancer Research, 2019, 21, 146.	5.0	52
506	Implementing Patient-Derived Xenografts to Assess the Effectiveness of Cyclin-Dependent Kinase Inhibitors in Glioblastoma. Cancers, 2019, 11, 2005.	3.7	10
507	Efficacy of PI3K inhibitors in advanced breast cancer. Annals of Oncology, 2019, 30, x12-x20.	1.2	145
508	Targeting PI3KCA pathway to improve patient outcomes in hormone receptor-positive breast cancer: a worthy 20-year wager?. Annals of Oncology, 2019, 30, x1-x2.	1.2	2
509	A view on drug resistance in cancer. Nature, 2019, 575, 299-309.	27.8	1,391
510	Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer. Breast Cancer Research, 2019, 21, 135.	5.0	12
512	The emerging role of CDK4/6i in HER2-positive breast cancer. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591988766.	3.2	25
514	Selective oestrogen receptor degraders in breast cancer. Current Opinion in Oncology, 2019, 31, 424-429.	2.4	24
515	p27 allosterically activates cyclin-dependent kinase 4 and antagonizes palbociclib inhibition. Science, 2019, 366, .	12.6	132
516	Surprising regulation of cell cycle entry. Science, 2019, 366, 1315-1316.	12.6	8

#	Article	IF	CITATIONS
517	Elevated Radiation Therapy Toxicity in the Setting of Germline PTEN Mutation. Practical Radiation Oncology, 2019, 9, 492-495.	2.1	4
518	Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer. Geburtshilfe Und Frauenheilkunde, 2019, 79, 1328-1335.	1.8	3
519	Transcriptional Silencing of MCL-1 Through Cyclin-Dependent Kinase Inhibition in Acute Myeloid Leukemia. Frontiers in Oncology, 2019, 9, 1205.	2.8	29
520	Identification of Distinct Prognostic Groups: Implications for Patient Selection to Targeted Therapies Among Anti-Endocrine Therapy–Resistant Early Breast Cancers. JCO Precision Oncology, 2019, 3, 1-13.	3.0	0
521	Hormonal treatment combined with targeted therapies in endocrine-responsive and HER2-positive metastatic breast cancer. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591989410.	3.2	17
522	Palbociclib for the Treatment of Metastatic Nasopharyngeal Carcinoma With CDK4 Amplification: A Case Report. JCO Precision Oncology, 2019, 3, 1-4.	3.0	2
523	Palbociclib in Patients With Pancreatic and Biliary Cancer With <i>CDKN2A</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precision Oncology, 2019, 3, 1-8.	3.0	46
524	<p>CDK4/6 Inhibitor Palbociclib Amplifies the Radiosensitivity to Nasopharyngeal Carcinoma Cells via Mediating Apoptosis and Suppressing DNA Damage Repair</p> . OncoTargets and Therapy, 2019, Volume 12, 11107-11117.	2.0	12
525	Cytokine sensitivity screening highlights BMP4 pathway signaling as a therapeutic opportunity in ER + breast cancer. FASEB Journal, 2019, 33, 1644-1657.	0.5	13
526	To Cycle or Fight—CDK4/6 Inhibitors at the Crossroads of Anticancer Immunity. Clinical Cancer Research, 2019, 25, 21-28.	7.0	46
527	Treatment satisfaction in women receiving palbociclib combination therapies for advanced/metastatic breast cancer. Future Oncology, 2019, 15, 141-150.	2.4	11
528	The efficacy of HRAS and CDK4/6 inhibitors in anaplastic thyroid cancer cell lines. Journal of Endocrinological Investigation, 2019, 42, 527-540.	3.3	17
529	Genomic Alterations Associated with Recurrence and TNBC Subtype in High-Risk Early Breast Cancers. Molecular Cancer Research, 2019, 17, 97-108.	3.4	17
530	Real-World Experience of Palbociclib-Induced Adverse Events and Compliance With Complete Blood Count Monitoring in Women With Hormone Receptor–Positive/HER2-Negative Metastatic Breast Cancer. Clinical Breast Cancer, 2019, 19, e186-e194.	2.4	27
531	Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics, 2019, 37, 141-153.	3.3	8
532	Examination of a paradox: recurrent metastatic breast cancer incidence decline without improved distant disease survival: 1990–2011. Breast Cancer Research and Treatment, 2019, 174, 505-514.	2.5	20
533	A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2–Positive Metastatic Breast Cancer. Cancer Discovery, 2019, 9, 354-369.	9.4	104
534	Ribociclib in HR+/HER2â^ Advanced or Metastatic Breast Cancer Patients. Annals of Pharmacotherapy, 2019, 53, 501-509.	1.9	15

#	ARTICLE	IF	CITATIONS
535	Pharmacokinetic drug evaluation of abemaciclib for advanced breast cancer. Expert Opinion on Drug Metabolism and Toxicology, 2019, 15, 85-91.	3.3	5
536	The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper. Critical Reviews in Oncology/Hematology, 2019, 134, 39-45.	4.4	200
537	Palbociclib in combination with fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-3 subgroup analysis of Japanese patients. International Journal of Clinical Oncology, 2019, 24, 262-273.	2.2	39
538	Intestinal Toxicity in Rats Following Administration of CDK4/6 Inhibitors Is Independent of Primary Pharmacology. Molecular Cancer Therapeutics, 2019, 18, 257-266.	4.1	12
539	Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review. International Journal of Cancer, 2019, 145, 1179-1188.	5.1	199
540	Why upfront use of CDK inhibitors for the treatment of advanced breast cancer may be wasteful, and how we can increase their value. Breast, 2019, 43, 81-84.	2.2	3
541	Overcoming Endocrine Resistance in Breast Cancer. , 2019, , 393-422.		2
542	Efficacy of a CDK4/6 Inhibitor in a Patient with Breast Cancer and Liposarcoma: A Case Report and Review of the Literature. Breast Care, 2019, 14, 325-328.	1.4	4
543	Exaggeration of PFS by blinded, independent, central review (BICR). Annals of Oncology, 2019, 30, 332-338.	1.2	17
544	Palbociclib enhances activinâ€< scp>SMADâ€induced cytostasis in estrogen receptorâ€positive breast cancer. Cancer Science, 2019, 110, 209-220.	3.9	17
545	Metastatic or locally advanced breast cancer patients: towards an expert consensus on nab-paclitaxel treatment in HER2-negative tumours—the MACBETH project. Cancer Chemotherapy and Pharmacology, 2019, 83, 301-318.	2.3	1
546	Combination Paclitaxel and Palbociclib: Results of a Phase I Trial in Advanced Breast Cancer. Clinical Cancer Research, 2019, 25, 2072-2079.	7.0	29
547	Phase II, Multicenter, Single-arm Trial of Eribulin as First-line Therapy for Patients With Aggressive Taxane-pretreated HER2-Negative Metastatic Breast Cancer: The MERIBEL Study. Clinical Breast Cancer, 2019, 19, 105-112.	2.4	12
548	Response to First-line Recurrence Treatment Influences Survival in Hormone Receptor-positive, HER2-negative Breast Cancer: A Multicenter Study. In Vivo, 2019, 33, 281-287.	1.3	9
549	Novel Non–HER2-targeted Therapies in HER2+ Breast Cancer. , 2019, , 179-212.		0
550	SEOM clinical guidelines in advanced and recurrent breast cancer (2018). Clinical and Translational Oncology, 2019, 21, 31-45.	2.4	14
551	Dosage adjustments in pivotal clinical trials with oral targeted therapies in solid tumors conducted in Europe. European Journal of Clinical Pharmacology, 2019, 75, 697-706.	1.9	3
552	Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. Breast Cancer Research and Treatment, 2019, 174, 719-729.	2.5	265

	Сітат	CITATION REPORT	
#	Article	IF	Citations
553	Immunotherapy in pancreatic cancer: New hope or mission impossible?. Cancer Letters, 2019, 445, 57-64	. 7.2	26
554	Optimal regimen for treatment-naive hormone receptor-positive HER-2 negative metastatic breast cancer. Future Oncology, 2019, 15, 105-107.	2.4	0
555	Treatment patterns and clinical outcomes among patients receiving palbociclib in combination with an aromatase inhibitor or fulvestrant for HR+/HER2-negative advanced/metastatic breast cancer in real-world settings in the US: Results from the IRIS study. Breast, 2019, 43, 22-27.	2.2	57
556	Ribociclib in hormone-receptor-positive advanced breast cancer: Establishing a value-based cost in China. Breast, 2019, 43, 1-6.	2.2	12
557	Frequent ESR1 and CDK Pathway Copy-Number Alterations in Metastatic Breast Cancer. Molecular Cancer Research, 2019, 17, 457-468.	3.4	29
558	Treatment of advanced HR+/HER2â^' breast cancer with new targeted agents in combination with endocrine therapy: a review of efficacy and tolerability based on available randomized trials on everolimus, ribociclib, palbociclib and abemaciclib. Acta Oncológica, 2019, 58, 147-153.	1.8	7
559	Compensatory role of insulin-like growth factor 1 receptor in estrogen receptor signaling pathway and possible therapeutic target for hormone therapy-resistant breast cancer. Breast Cancer, 2019, 26, 272-281.	2.9	22
560	Systemic Treatment of HER2-Negative Metastatic Breast Cancer. , 2019, , 483-508.		0
561	Palbociclib plus endocrine therapy in HER2 negative, hormonal receptorâ€positive, advanced breast cancer: A realâ€world experience. Journal of Cellular Physiology, 2019, 234, 7708-7717.	4.1	21
562	Survival Impact of Locoregional Treatment of the Primary Tumor in De Novo Metastatic Breast Cancers in a Large Multicentric Cohort Study: A Propensity Score-Matched Analysis. Annals of Surgical Oncology, 2019, 26, 356-365.	1.5	47
563	Cyclin-Dependent Kinase Inhibitor–Associated Thromboembolism. JAMA Oncology, 2019, 5, 141.	7.1	13
564	Palbociclib in combination with letrozole in patients with estrogen receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients. International Journal of Clinical Oncology, 2019, 24, 274-287.	2.2	43
565	Targeting regulation of cyclin dependent kinase 9 as a novel therapeutic strategy in synovial sarcoma. Journal of Orthopaedic Research, 2019, 37, 510-521.	2.3	14
566	Decision Pathways in Breast Cancer Management. , 2019, , 3-97.		0
567	Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs. Pharmacological Research, 2019, 139, 471-488.	7.1	270
568	Targeting CDK4/6 pathways and beyond in breast cancer. Breast, 2019, 43, 8-17.	2.2	22
569	N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma. Neuro-Oncology, 2019, 21, 95-105.	1.2	100
570	Arrested Developments: CDK4/6 Inhibitor Resistance and Alterations in the Tumor Immune Microenvironment. Clinical Cancer Research, 2019, 25, 921-927.	7.0	85

		Report	
#	Article	IF	CITATIONS
571	In case of anastrozole-related hallucinations, can switching to letrozole be a treatment option? A case report and literature review. Journal of Oncology Pharmacy Practice, 2019, 25, 754-757.	0.9	5
572	Targeted therapy for breast cancer in older patients. Journal of Geriatric Oncology, 2020, 11, 380-388.	1.0	9
573	The impact of new cancer drug therapies on site specialised cancer treatment activity in a UK cancer network 2014–2018. Journal of Oncology Pharmacy Practice, 2020, 26, 93-98.	0.9	5
574	Control of the Cell Cycle. , 2020, , 56-73.e5.		1
576	Fulvestrant and palbociclib combination in heavily pretreated hormone receptor-positive, HER2-negative metastatic breast cancer patients. Breast Cancer Research and Treatment, 2020, 179, 371-376.	2.5	8
577	PTEN Loss Mediates Clinical Cross-Resistance to CDK4/6 and PI3Kα Inhibitors in Breast Cancer. Cancer Discovery, 2020, 10, 72-85.	9.4	154
578	Breast reconstruction in the patient with stable, metastatic breast cancer. Breast Journal, 2020, 26, 335-336.	1.0	0
579	Cutaneous toxicities of new targeted cancer therapies: must know for diagnosis, management, and patient-proxy empowerment. Annals of Palliative Medicine, 2020, 9, 1296-1306.	1.2	5
581	Progression-Free Survival for Real-World Use of Palbociclib in Hormone Receptor-Positive Metastatic Breast Cancer. Clinical Breast Cancer, 2020, 20, 33-40.	2.4	30
582	Progression-free Survival Outcome Is Independent of Objective Response in Patients With Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer Treated With Palbociclib Plus Letrozole Compared With Letrozole: Analysis From PALOMA-2. Clinical Breast Cancer 2020, 20, e173-e180	2.4	21
583	Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptorâ€positive/human epidermal growth factor receptor 2â€negative metastatic breast cancer. Breast Journal, 2020, 26, 368-375.	1.0	8
584	Mechanisms of resistance to estrogen receptor modulators in ER+/HER2â^ advanced breast cancer. Cellular and Molecular Life Sciences, 2020, 77, 559-572.	5.4	19
585	Practical Treatment Strategies and Future Directions After Progression While Receiving CDK4/6 Inhibition and Endocrine Therapy in Advanced HR+/HER2â^' Breast Cancer. Clinical Breast Cancer, 2020, 20, 1-11.	2.4	20
586	Understanding the benefits and challenges of firstâ€line cyclinâ€dependent kinases 4 and 6 inhibitors in advanced breast cancer among postmenopausal women. Breast Journal, 2020, 26, 630-642.	1.0	3
587	CDK4/6 inhibitors in breast cancer – from <i>inÂvitro</i> models to clinical trials. Acta Oncológica, 2020, 59, 219-232.	1.8	8
588	Durable response to palbociclib and letrozole in ovarian cancer with <i>CDKN2A</i> loss. Cancer Biology and Therapy, 2020, 21, 197-202.	3.4	18
589	FDA Approval Summary: Palbociclib for Male Patients with Metastatic Breast Cancer. Clinical Cancer Research, 2020, 26, 1208-1212.	7.0	95
590	Venous thromboembolism in breast cancer patients receiving cyclinâ€dependent kinase inhibitors. Journal of Thrombosis and Haemostasis, 2020, 18, 162-168.	3.8	55

#	Article	IF	CITATIONS
591	A role for fulvestrant monotherapy in the firstâ€line treatment of ER+Âmetastatic breast cancer?. Breast Journal, 2020, 26, 109-111.	1.0	2
592	Research priorities in metastatic breast cancer: A James Lind Alliance Priority Setting Partnership. Breast Journal, 2020, 26, 488-493.	1.0	8
593	Evaluation of the pharmacokinetics of the simultaneous quantification of letrozole and palbociclib in rat plasma by a developed and validated HPLC–PDA. Acta Chromatographica, 2020, 32, 170-178.	1.3	4
594	Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-Na¬ve Metastatic Breast Cancer. Clinical Cancer Research, 2020, 26, 110-121.	7.0	120
595	New Drugs, Old Toxicities: Pneumonitis Related to Palbociclib – A Case Report. Breast Care, 2020, 15, 548-552.	1.4	5
596	Molecular imaging to identify patients with metastatic breast cancer who benefit from endocrine treatment combined with cyclin-dependent kinase inhibition. European Journal of Cancer, 2020, 126, 11-20.	2.8	39
597	Bone Metastasis: Current State of Play. Translational Oncology, 2020, 13, 308-320.	3.7	30
598	Poor efficacy of palbociclib in secondâ€ine treatment of metastatic lobular breast cancer in a case series: Use before or never more?. Breast Journal, 2020, 26, 1458-1460.	1.0	3
599	Endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: extending endocrine sensitivity. Future Oncology, 2020, 16, 129-145.	2.4	5
600	Local Treatment in Addition to Endocrine Therapy in Hormone Receptor-Positive and HER2-Negative Oligometastatic Breast Cancer Patients: A Retrospective Multicenter Analysis. Breast Care, 2020, 15, 408-414.	1.4	13
601	The Ongoing Search for Biomarkers of CDK4/6 Inhibitor Responsiveness in Breast Cancer. Molecular Cancer Therapeutics, 2020, 19, 3-12.	4.1	63
602	CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis. Lancet Oncology, The, 2020, 21, 250-260.	10.7	186
603	CDK4/6 inhibitors in breast cancer: one more step towards reduced mortality. Lancet Oncology, The, 2020, 21, 191-192.	10.7	7
604	Causes of death after breast cancer diagnosis: A US populationâ€based analysis. Cancer, 2020, 126, 1559-1567.	4.1	101
605	Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. New England Journal of Medicine, 2020, 382, 514-524.	27.0	482
607	The impact of new systemic therapies on survival and time on hormonal treatment in hormone receptor–positive, human epidermal growth factor receptor 2–negative metastatic breast cancer: A populationâ€based study in British Columbia from 2003 to 2013. Cancer, 2020, 126, 971-977.	4.1	3
608	Window of opportunity treatment in breast cancer. ANZ Journal of Surgery, 2020, 90, 34-40.	0.7	2
609	Holistic cost-effectiveness analysis of anticancer drug regimens in Japan. Drug Discovery Today, 2020, 25, 269-273.	6.4	4

#	Article	IF	CITATIONS
610	Stereotactic ablative body radiotherapy (SABR) for bone only oligometastatic breast cancer: A prospective clinical trial. Breast, 2020, 49, 55-62.	2.2	49
611	Palbociclib safety and efficacy beyond Ribociclib-induced liver toxicity in metastatic hormone-receptors positive breast cancer patient. Anti-Cancer Drugs, 2020, 31, 85-89.	1.4	11
612	Association of Cyclin-Dependent Kinases 4 and 6 Inhibitors With Survival in Patients With Hormone Receptor–Positive Metastatic Breast Cancer. JAMA Network Open, 2020, 3, e2020312.	5.9	48
613	Real-world Outcomes of Cyclin-dependent Kinase Inhibitors Continued Beyond First Disease Progression in Hormone Receptor-positive Metastatic Breast Cancer. Clinical Breast Cancer, 2021, 21, 205-209.	2.4	10
614	Developing themes in targeted therapies for hormone receptor–positive breast cancer. Current Opinion in Endocrine and Metabolic Research, 2020, 15, 15-23.	1.4	0
615	Efficacy and safety of selective cyclin-dependent kinases 4/6 inhibitors in hormone-receptor-positive, HER2-negative advanced breast cancer – results from a real-world setting. Cancer Treatment and Research Communications, 2020, 25, 100201.	1.7	4
616	Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer: A network meta-analysis. Cancer Treatment Reviews, 2020, 90, 102086.	7.7	29
617	CSCO BC guideline: updates for hormone receptor-positive breast cancer in 2020. Translational Breast Cancer Research, 0, 1, 3-3.	0.4	2
618	5th ESO-ESMO international consensus guidelines for advanced breastÂcancer (ABC 5). Annals of Oncology, 2020, 31, 1623-1649.	1.2	761
619	Clinical Pharmacokinetics and Pharmacodynamics of the Cyclin-Dependent Kinase 4 and 6 Inhibitors Palbociclib, Ribociclib, and Abemaciclib. Clinical Pharmacokinetics, 2020, 59, 1501-1520.	3.5	43
621	Emerging and investigational targeted chemotherapy and immunotherapy agents for metastatic brain tumors. Expert Opinion on Investigational Drugs, 2020, 29, 1389-1406.	4.1	4
622	Optimal duration of prior endocrine therapy predicts the efficacy of Fulvestrant in a realâ€world study for patients with hormone receptorâ€positive and HER2â€negative advanced breast cancer. Cancer Medicine, 2020, 9, 8821-8831.	2.8	4
623	ABC4 Consensus: First Latin American Meeting—Assessment, Comments, and Application of Its Recommendations. JCO Global Oncology, 2020, 6, 819-827.	1.8	2
624	Survival in patients with HR+/HER2â <sup>~°</sup> metastatic breast cancer treated with initial endocrine therapy versus initial chemotherapy. A French population-based study. British Journal of Cancer, 2020, 123, 1071-1077.	6.4	5
625	Impact of early dose intensity reduction of Palbociclib on clinical outcomes in patients with hormone-receptor-positive metastatic breast cancer. Breast Cancer Research and Treatment, 2020, 183, 411-418.	2.5	6
626	<scp>CDK4/6</scp> inhibitor palbociclib overcomes acquired resistance to thirdâ€generation <scp>EGFR</scp> inhibitor osimertinib in <scp>nonâ€small</scp> cell lung cancer ( <scp>NSCLC</scp> ). Thoracic Cancer, 2020, 11, 2389-2397.	1.9	36
627	Activation of CD8+ T Cells Contributes to Antitumor Effects of CDK4/6 Inhibitors plus MEK Inhibitors. Cancer Immunology Research, 2020, 8, 1114-1121.	3.4	9
628	Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2â° advanced breast cancer (PALOMA-1, TRIO-18), Breast Cancer Research and Treatment, 2020, 183, 419-428.	2.5	73

#	Article	IF	CITATIONS
629	Willingness of Women with Early Estrogen Receptor–Positive Breast Cancer to Take Adjuvant CDK4/6 Inhibitors. Current Oncology, 2020, 27, 127-134.	2.2	2
631	Real-world experience of palbociclib and ribociclib: novel oral therapy in metastatic breast cancer. International Journal of Clinical Pharmacy, 2021, 43, 893-899.	2.1	12
632	CDK4/6 inhibition in HR-positive early breast cancer: are we putting all eggs in one basket?. ESMO Open, 2020, 5, e001132.	4.5	5
633	CDK4/6 and MAPK—Crosstalk as Opportunity for Cancer Treatment. Pharmaceuticals, 2020, 13, 418.	3.8	28
634	Therapeutic evaluation of palbociclib and its compatibility with other chemotherapies for primary and recurrent nasopharyngeal carcinoma. Journal of Experimental and Clinical Cancer Research, 2020, 39, 262.	8.6	13
635	Palbociclib combined with endocrine therapy in heavily pretreated HR+/HER2- advanced breast cancer patients: Results from the compassionate use program in Spain (PALBOCOMP). Breast, 2020, 54, 286-292.	2.2	4
636	Real life efficacy of palbociclib and endocrine therapy in HR positive, HER2 negative advanced breast cancer. Breast, 2020, 54, 303-310.	2.2	9
637	Mechanisms of CDK4/6 Inhibitor Resistance in Luminal Breast Cancer. Frontiers in Pharmacology, 2020, 11, 580251.	3.5	38
638	Combined CDK2 and CDK4/6 Inhibition Overcomes Palbociclib Resistance in Breast Cancer by Enhancing Senescence. Cancers, 2020, 12, 3566.	3.7	66
639	Overview of New Treatments with Immunotherapy for Breast Cancer and a Proposal of a Combination Therapy. Molecules, 2020, 25, 5686.	3.8	19
640	Update Breast Cancer 2020 Part 4 – Advanced Breast Cancer. Geburtshilfe Und Frauenheilkunde, 2020, 80, 1115-1122.	1.8	11
641	Treatment patterns and clinical outcomes ofÂpalbociclib-based therapy received in US community oncology practices. Future Oncology, 2021, 17, 1001-1011.	2.4	12
642	Comparative Overall Survival of CDK4/6 Inhibitors Plus Endocrine Therapy vs. Endocrine Therapy Alone for Hormone receptor-positive, HER2-negative metastatic breast cancer. Journal of Cancer, 2020, 11, 7127-7136.	2.5	11
643	Activating transcription factor-2 (ATF2) is a key determinant of resistance to endocrine treatment in an in vitro model of breast cancer. Breast Cancer Research, 2020, 22, 126.	5.0	14
644	Pseudoprogression After Palbociclib with Aromatase Inhibitors Treatment in Metastatic Breast Cancer. OncoTargets and Therapy, 2020, Volume 13, 7785-7792.	2.0	2
645	Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical trials. Breast Cancer Research and Treatment, 2020, 184, 23-35.	2.5	21
646	Combinatorial drug therapy in cancer - New insights. Life Sciences, 2020, 258, 118134.	4.3	31
647	Chinese expert consensus on the clinical diagnosis and treatment of advanced breast cancer (2018). Cancer, 2020, 126, 3867-3882.	4.1	15

#	Article	IF	CITATIONS	
648	Current trends and opportunities in targeting p21 activated kinase-1(PAK1) for therapeutic management of breast cancers. Gene, 2020, 760, 144991.	2.2	13	
649	MEK blockade overcomes the limited activity of palbociclib in head and neck cancer. Translational Oncology, 2020, 13, 100833.	3.7	6	
650	Current and emerging biologic therapies for triple negative breast cancer. Expert Opinion on Biological Therapy, 2022, 22, 591-602.	3.1	11	
651	Abemaciclib, a CDK4 and CDK6 inhibitor for the treatment of metastatic breast cancer. Future Oncology, 2020, 16, 2763-2778.	2.4	8	
652	Endocrine-Resistant Breast Cancer: Mechanisms and Treatment. Breast Care, 2020, 15, 347-354.	1.4	46	
653	Novel targeted therapies for metastatic breast cancer. Annals of Translational Medicine, 2020, 8, 907-907.	1.7	10	
654	Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer. Breast Cancer Research, 2020, 22, 89.	5.0	74	
655	<p>Novel Therapeutic Strategies for CDK4/6 Inhibitors in Metastatic Castrate-Resistant Prostate Cancer</p> . OncoTargets and Therapy, 2020, Volume 13, 10499-10513.	2.0	16	
656	Safety and efficacy of cyclin-dependent kinase inhibitor rechallenge following ribociclib-induced limiting hypertransaminasemia. Breast, 2020, 54, 160-163.	2.2	12	
657	Endocrine therapy combined with targeted therapy in hormone receptor-positive metastatic breast cancer. Chinese Medical Journal, 2020, 133, 2338-2345.	2.3	8	
658	MONARCH plus: abemaciclib plus endocrine therapy in women with HR+/HER2– advanced breast cancer: the multinational randomized phase III study. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592096392.	3.2	42	
659	Whole exome sequencing and transcriptome-wide profiling identify potentially subtype-relevant genes of nasopharyngeal carcinoma. Pathology Research and Practice, 2020, 216, 153244.	2.3	2	
660	Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers. ESMO Open, 2020, 5, e000926.	4.5	35	
661	CDK4/6 Dependence of Cyclin D1–Driven Parathyroid Neoplasia in Transgenic Mice. Endocrinology, 2020, 161, .	2.8	1	
662	The Future of ER+/HER2â^' Metastatic Breast Cancer Therapy: Beyond PI3K Inhibitors. Anticancer Research, 2020, 40, 4829-4841.	1.1	21	
663	Future perspectives and challenges with CDK4/6 inhibitors in hormone receptor–positive metastatic breast cancer. Future Oncology, 2020, 16, 2661-2672.	2.4	6	
664	CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions. International Journal of Molecular Sciences, 2020, 21, 6350.	4.1	34	
665	The economic impact of disease progression and death in hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer patients: using Korean nationwide health insurance claims data. Current Medical Research and Opinion, 2020, 36, 1825-1833.	1.9	1	
		CITATION REPORT		
-----	---	---	------	-----------
#	Article		IF	CITATIONS
666	Integrating Old and New Paradigms of G1/S Control. Molecular Cell, 2020, 80, 183-192.		9.7	140
667	Management of ER positive metastatic breast cancer. Seminars in Oncology, 2020, 47, 2	70-277.	2.2	25
668	Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave Roussy. Npj Oncology, 2020, 4, 27.	Precision	5.4	16
669	Beyond Chemotherapies: Recent Strategies in Breast Cancer Treatment. Cancers, 2020,	12, 2634.	3.7	7
670	Mantle cell lymphoma: insights into therapeutic targets at the preclinical level. Expert Op Therapeutic Targets, 2020, 24, 1029-1045.	vinion on	3.4	4
671	Real-world clinical outcome and toxicity data and economic aspects in patients with adva cancer treated with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endo the experience of the Hellenic Cooperative Oncology Group. ESMO Open, 2020, 5, e000	anced breast ocrine therapy: 774.	4.5	20
672	Diagnosis and Treatment of Bone Metastases in Breast Cancer: Radiotherapy, Local Appr Systemic Therapy in a Guide for Clinicians. Cancers, 2020, 12, 2390.	oach and	3.7	21
673	Endocrine therapy-based treatments in hormone receptor-positive/HER2-negative advance cancer: systematic review and network meta-analysis. ESMO Open, 2020, 5, e000842.	ed breast	4.5	16
674	Plasma thymidine kinase 1 activity and outcome of ER+ HER2â <sup>~?</sup> metastatic breast cance with palbociclib and endocrine therapy. Breast Cancer Research, 2020, 22, 98.	r patients treated	5.0	16
675	Managing therapeutic resistance in breast cancer: from the lncRNAs perspective. Therand 10, 10360-10377.	ostics, 2020,	10.0	30
676	c-myc regulates the sensitivity of breast cancer cells to palbociclib via c-myc/miR-29b-3p/ Death and Disease, 2020, 11, 760.	CDK6 axis. Cell	6.3	39
677	CDK4/6 inhibitors: a novel strategy for tumor radiosensitization. Journal of Experimental Cancer Research, 2020, 39, 188.	and Clinical	8.6	35
678	Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the SOLTI-1303 PATRICIA Trial. Clinical Cancer Research, 2020, 26, 5820-5829.	Phase II	7.0	68
679	Outcome of Everolimus-Based Therapy in Hormone-Receptor-Positive Metastatic Breast ( After Progression on Palbociclib. Breast Cancer: Basic and Clinical Research, 2020, 14, 117822342094486.	Cancer Patients	1.1	20
680	CDK4/6 Inhibitors in Hormone Receptor-Positive Metastatic Breast Cancer: Current Pract Knowledge. Cancers, 2020, 12, 2480.	ice and	3.7	15
681	Targeting the PI3K/AKT/mTOR Pathway in Hormone-Positive Breast Cancer. Drugs, 2020,	80, 1685-1697.	10.9	72
682	Targeting Cell Cycle in Breast Cancer: CDK4/6 Inhibitors. International Journal of Molecul 2020, 21, 6479.	ar Sciences,	4.1	71
683	Progression-Free Survival and Overall Survival of CDK 4/6 Inhibitors Plus Endocrine Thera Metastatic Breast Cancer: A Systematic Review and Meta-Analysis. International Journal Sciences, 2020, 21, 6400.	by in of Molecular	4.1	50

#	Article	IF	CITATIONS
684	Association of Sperm-Associated Antigen 5 and Treatment Response in Patients With Estrogen Receptor–Positive Breast Cancer. JAMA Network Open, 2020, 3, e209486.	5.9	2
685	Ki67 and PR in Patients Treated with CDK4/6 Inhibitors: A Real-World Experience. Diagnostics, 2020, 10, 573.	2.6	13
686	The use of CDK 4/6 inhibitors in the adjuvant treatment of breast cancer: Timing matters. Breast Journal, 2020, 26, 2435-2436.	1.0	1
687	Past, present and future use of cytotoxic agents in oncology practice: A systematic review of Pubmed and ClinicalTrials.gov databases. Journal of Oncology Pharmacy Practice, 2020, 26, 2069-2072.	0.9	1
688	A single-center retrospective safety analysis of cyclin-dependent kinase 4/6 inhibitors concurrent with radiation therapy in metastatic breast cancer patients. Scientific Reports, 2020, 10, 13589.	3.3	27
689	Efficacy and safety of cyclin dependent kinases 4/6 inhibitors in the treatment of metastatic breast cancer: a real-world experience. Acta Oncológica, 2020, 59, 1382-1387.	1.8	11
690	Therapy Algorithms for the Diagnosis and Treatment of Patients with Early and Advanced Breast Cancer. Breast Care, 2020, 15, 608-618.	1.4	8
691	Phase II randomized trial of a non-steroidal mouth wash for prevention and treatment of stomatitis in women with hormone receptor positive breast cancer treated with everolimus. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592096725.	3.2	0
692	<p>Cost-Effectiveness of Ribociclib for Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer</p> . Cancer Management and Research, 2020, Volume 12, 12905-12913.	1.9	10
693	Combinatorial Epigenetic and Immunotherapy in Breast Cancer Management: A Literature Review. Epigenomes, 2020, 4, 27.	1.8	6
694	Medication-Related Osteonecrosis of the Jaws and CDK4/6 Inhibitors: A Recent Association. International Journal of Environmental Research and Public Health, 2020, 17, 9509.	2.6	7
695	Palbociclib in the treatment of recurrent ovarian cancer. Gynecologic Oncology Reports, 2020, 34, 100626.	0.6	6
696	Alpelisib in the Treatment of Breast Cancer: A Short Review on the Emerging Clinical Data. Breast Cancer: Targets and Therapy, 2020, Volume 12, 251-258.	1.8	10
697	Living with Metastatic Cancer: A Roadmap for Future Research. Cancers, 2020, 12, 3684.	3.7	26
698	Everolimus in Advanced Breast Cancer: A Systematic Review and Meta-analysis. Targeted Oncology, 2020, 15, 723-732.	3.6	6
699	Targeted Molecular Therapy in Palliative Cancer Management. , 2020, 5, .		1
700	National comprehensive cancer network recommendations for drugs without US food and drug administration approval in metastatic breast cancer: A cross-sectional study. Cancer Treatment Reviews, 2020, 91, 102113.	7.7	4
701	Optimizing care for younger women with hormone receptorâ€positive, HER2â€negative metastatic breast cancer. Asia-Pacific Journal of Clinical Oncology, 2020, 16, 3-14.	1.1	3

#	Article	IF	CITATIONS
702	The application and prospect of CDK4/6 inhibitors in malignant solid tumors. Journal of Hematology and Oncology, 2020, 13, 41.	17.0	91
703	Cyclin-dependent kinase inhibitors plus aromatase inhibitor in first-line treatment hormone-receptor–positive/HER2-negative advanced breast cancer women with or without visceral disease: time to turn page?. Anti-Cancer Drugs, 2020, 31, 528-532.	1.4	2
704	Sequencing Endocrine Therapy for Metastatic Breast Cancer: What Do We Do After Disease Progression on a CDK4/6 Inhibitor?. Current Oncology Reports, 2020, 22, 57.	4.0	26
705	Palbociclibâ€letrozole as firstâ€line treatment for advanced breast cancer: Updated results from a Japanese phase 2 study. Cancer Medicine, 2020, 9, 4929-4940.	2.8	10
706	Therapy after cyclinâ€dependent kinase inhibition in metastatic hormone receptorâ€positive breast cancer: Resistance mechanisms and novel treatment strategies. Cancer, 2020, 126, 3400-3416.	4.1	19
707	What's the Price? Toxicities of Targeted Therapies in Breast Cancer Care. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, 55-70.	3.8	13
708	Metabolic Adaptations to MEK and CDK4/6 Cotargeting in Uveal Melanoma. Molecular Cancer Therapeutics, 2020, 19, 1719-1726.	4.1	22
709	Baicalin suppresses the cell cycle progression and proliferation of prostate cancer cells through the CDK6/FOXM1 axis. Molecular and Cellular Biochemistry, 2020, 469, 169-178.	3.1	24
710	Advances in endocrine and targeted therapy for hormone-receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. Chinese Medical Journal, 2020, 133, 1099-1108.	2.3	17
711	LncRNA TROJAN promotes proliferation and resistance to CDK4/6 inhibitor via CDK2 transcriptional activation in ER+ breast cancer. Molecular Cancer, 2020, 19, 87.	19.2	53
712	The efficacy of sequential second-line endocrine therapies (ETs) in postmenopausal estrogen receptor-positive and HER2-negative metastatic breast cancer patients with lower sensitivity to initial ETs. Breast Cancer, 2020, 27, 973-981.	2.9	4
713	The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor–Positive Metastatic Breast Cancer. Cancer Discovery, 2020, 10, 1174-1193.	9.4	176
714	Quality of adverse event reporting in phase III randomized controlled trials of breast and colorectal cancer: A systematic review. Cancer Medicine, 2020, 9, 5035-5050.	2.8	8
715	Ribociclib plus Fulvestrant in Advanced Breast Cancer. New England Journal of Medicine, 2020, 382, e85.	27.0	1
716	Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: to prescribe for the patient or the physician? A meta-analysis of phase II and III randomized clinical trials. BMC Cancer, 2020, 20, 418.	2.6	6
717	The role of <scp>CDK6</scp> in cancer. International Journal of Cancer, 2020, 147, 2988-2995.	5.1	93
718	Overall Survival of CDK4/6-Inhibitor–Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-Analysis. Journal of the National Cancer Institute, 2020, 112, 1089-1097.	6.3	59
719	Naturally-Occurring Canine Mammary Tumors as a Translational Model for Human Breast Cancer. Frontiers in Oncology, 2020, 10, 617.	2.8	78

#	Article	IF	CITATIONS
720	Risk of early progression according to circulating ESR1 mutation, CA-15.3 and cfDNA increases under first-line anti-aromatase treatment in metastatic breast cancer. Breast Cancer Research, 2020, 22, 56.	5.0	25
721	Cyclin-Dependent Kinase 4/6 Inhibitors Combined With Radiotherapy for Patients With Metastatic Breast Cancer. Clinical Breast Cancer, 2020, 20, 495-502.	2.4	23
722	The role of chemotherapy in treatment of advanced breast cancer: an overview for clinical practice. Critical Reviews in Oncology/Hematology, 2020, 153, 102988.	4.4	25
723	<p>Current Therapeutic Progress of CDK4/6 Inhibitors in Breast Cancer</p> . Cancer Management and Research, 2020, Volume 12, 3477-3487.	1.9	40
724	Enhancer-Driven IncRNA BDNF-AS Induces Endocrine Resistance and Malignant Progression of Breast Cancer through the RNH1/TRIM21/mTOR Cascade. Cell Reports, 2020, 31, 107753.	6.4	52
725	Retinoblastoma protein expression and its predictors in triple-negative breast cancer. Npj Breast Cancer, 2020, 6, 19.	5.2	23
726	Regulation of breast cancer metastasis signaling by miRNAs. Cancer and Metastasis Reviews, 2020, 39, 837-886.	5.9	87
727	Efficacy and Safety of Cyclin-Dependent Kinases 4 and 6 Inhibitors in HR+/HER2â^ Advanced Breast Cancer. Cancer Management and Research, 2020, Volume 12, 4241-4250.	1.9	7
728	Combination cyclin-dependent kinase 4/6 inhibitors and endocrine therapy versus endocrine monotherapy for hormonal receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: A systematic review and meta-analysis. PLoS ONE, 2020, 15, e0233571.	2.5	16
729	Palbociclib and beyond for the treatment of HR + HER2- metastatic breast cancer: an Asian-Pacific perspective and practical management guide on the use of CDK4/6 inhibitors. Current Medical Research and Opinion, 2020, 36, 1363-1373.	1.9	5
730	Impressive long-term response with chemo-endocrine therapy in a premenopausal patient with metastatic breast cancer. Medicine (United States), 2020, 99, e20396.	1.0	1
732	<p>Fulvestrant in Combination with CDK4/6 Inhibitors for HER2- Metastatic Breast Cancers: Current Perspectives</p> . Breast Cancer: Targets and Therapy, 2020, Volume 12, 45-56.	1.8	15
733	Systematic exploration of different E3 ubiquitin ligases: an approach towards potent and selective CDK6 degraders. Chemical Science, 2020, 11, 3474-3486.	7.4	77
734	Transcription and Translation Inhibitors in Cancer Treatment. Frontiers in Chemistry, 2020, 8, 276.	3.6	54
735	Challenges in the treatment of breast cancer brain metastases: evidence, unresolved questions, and a practical algorithm. Clinical and Translational Oncology, 2020, 22, 1698-1709.	2.4	9
736	Breast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific Treatments. Medical Sciences (Basel, Switzerland), 2020, 8, 18.	2.9	72
737	Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies. Breast Cancer Research, 2020, 22, 27.	5.0	24
738	Oral Capecitabine-Vinorelbine Is Associated with Longer Overall Survival When Compared to Single-Agent Capecitabine in Patients with Hormone Receptor-Positive Advanced Breast Cancer.	3.7	4

#	Article	IF	CITATIONS
739	The impact of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) on the incidence of alopecia in patients with metastatic breast cancer (BC). Acta Oncológica, 2020, 59, 723-725.	1.8	7
740	Cyclin-dependent kinase inhibitors for the treatment of lung cancer. Expert Opinion on Pharmacotherapy, 2020, 21, 941-952.	1.8	19
741	Subacute cutaneous lupus erythematosus with positive antiâ€Ro antibodies following palbociclib and letrozole treatment: A case report and literature review. Journal of Cutaneous Pathology, 2020, 47, 654-658.	1.3	14
742	Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future. Lancet, The, 2020, 395, 817-827.	13.7	260
743	2. Therapie des metastasierten Mammakarzinoms. , 2020, , 71-120.		0
744	4. Supportivtherapie. , 2020, , 127-216.		Ο
745	Concurrent use of palbociclib and radiation therapy: single-centre experience and review of the literature. British Journal of Cancer, 2020, 123, 905-908.	6.4	30
746	Therapy options after CDK4/6 inhibitors for HR+, HER2- postmenopausal metastatic/recurrent breast cancer in Japan: a role for mammalian target of rapamycin inhibitors?. Future Oncology, 2020, 16, 1851-1862.	2.4	4
747	Venous thromboembolism risk in patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with combined CDK 4/6 inhibitors plus endocrine therapy versus endocrine therapy alone: a systematic review and meta-analysis of randomized controlled trials. Breast Cancer Research and Treatment, 2020, 183, 479-487.	2.5	30
748	Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancer. Breast Cancer Research and Treatment, 2020, 183, 107-116.	2.5	2
749	Targeting CDK4 (cyclin-dependent kinase) amplification in liposarcoma: A comprehensive review. Critical Reviews in Oncology/Hematology, 2020, 153, 103029.	4.4	35
750	The introduction of a third CDK4/6 inhibitor does not change the cost-effectiveness profile in first and subsequent-lines after progression or relapse during previous endocrine therapy in patients with hormone receptor positive (HR+)/human epidermal receptor-2 negative (HER-2) advanced or metastatic breast cancer, Journal of Oncology Pharmacy Practice, 2020, 26, 1486-1491.	0.9	12
751	Real-World Clinical and Economic Outcomes Associated with Palbociclib for HR-Positive/HER2 Negative Metastatic Breast Cancer: A Commentary. Journal of Managed Care & Specialty Pharmacy, 2020, 26, 826-831.	0.9	8
752	Early treatment-related neutropenia predicts response to palbociclib. British Journal of Cancer, 2020, 123, 912-918.	6.4	14
753	Immunohistological expression of oestrogen receptor, progesterone receptor, mammaglobin, human epidermal growth factor receptor 2 and GATAâ€binding protein 3 in nonâ€smallâ€cell lung cancer. Histopathology, 2020, 77, 900-914.	2.9	6
754	Does minimum follow-up time post-diagnosis matter? An assessment of changing loss of life expectancy for people with cancer in Western Australia from 1982 to 2016. Cancer Epidemiology, 2020, 66, 101705.	1.9	0
755	Clinico-radiological monitoring strategies in patients with metastatic breast cancer: a real-world study. Future Oncology, 2020, 16, 2059-2073.	2.4	2
756	Management of brain metastases in breast cancer: a review of current practices and emerging treatments. Breast Cancer Research and Treatment, 2020, 180, 279-300.	2.5	52

			0
#		IF	CITATIONS
757	LC-MS/MS method for clinical application. PLoS ONE, 2020, 15, e0228822.	2.5	26
758	Prognostic study for isolated local recurrence operated with salvage excision in hormone-receptor-positive patients with invasive breast cancer after primary breast surgery. Biomedical Journal, 2020, 43, 83-93.	3.1	4
759	High-Dose Toremifene as a Promising Candidate Therapy for Hormone Receptor-Positive Metastatic Breast Cancer with Secondary Resistance to Aromatase Inhibitors. International Journal of Breast Cancer, 2020, 2020, 1-7.	1.2	2
760	Transcription-Associated Cyclin-Dependent Kinases as Targets and Biomarkers for Cancer Therapy. Cancer Discovery, 2020, 10, 351-370.	9.4	162
761	Severe Cellular Immunodeficiency Triggered by the CDK4/6 Inhibitor Palbociclib. Clinical Breast Cancer, 2020, 20, e192-e195.	2.4	3
762	The PALBONET Trial: A Phase II Study of Palbociclib in Metastatic Grade 1 and 2 Pancreatic Neuroendocrine Tumors (GETNE-1407). Oncologist, 2020, 25, 745-e1265.	3.7	25
763	Review of concepts in therapeutic decision-making in HER2-negative luminal metastatic breast cancer. Clinical and Translational Oncology, 2020, 22, 1364-1377.	2.4	1
764	<p>Strategies for Increasing the Effectiveness of Aromatase Inhibitors in Locally Advanced Breast Cancer: An Evidence-Based Review on Current Options</p> . Cancer Management and Research, 2020, Volume 12, 675-686.	1.9	27
765	The underreporting of phase III chemo-therapeutic clinical trial data of older patients with cancer: A systematic review. Journal of Geriatric Oncology, 2020, 11, 369-379.	1.0	20
766	Cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer: a meta-analysis of randomized clinical trials. Breast Cancer Research and Treatment, 2020, 180, 21-32.	2.5	20
767	Plasma Thymidine Kinase Activity as a Biomarker in Patients with Luminal Metastatic Breast Cancer Treated with Palbociclib within the TREnd Trial. Clinical Cancer Research, 2020, 26, 2131-2139.	7.0	40
768	Cyclin-dependent kinase 4/6 inhibitor in combination with endocrine therapy versus endocrine therapy only for advanced breast cancer: a systematic review and meta-analysis. Translational Cancer Research, 2020, 9, 657-668.	1.0	3
769	Pharmacological cancer treatment and venous thromboembolism risk. European Heart Journal Supplements, 2020, 22, C2-C14.	0.1	11
770	CDKs in Sarcoma: Mediators of Disease and Emerging Therapeutic Targets. International Journal of Molecular Sciences, 2020, 21, 3018.	4.1	30
771	CDK6 Inhibition: A Novel Approach in AML Management. International Journal of Molecular Sciences, 2020, 21, 2528.	4.1	25
772	The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2018 edition. Breast Cancer, 2020, 27, 322-331.	2.9	47
773	The Evolving Complexity of Treating Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer: Special Considerations in Older Breast Cancer Patients—Part II: Metastatic Disease. Drugs and Aging, 2020, 37, 349-358.	2.7	3
774	Mechanisms of Sensitivity and Resistance to CDK4/6 Inhibition. Cancer Cell, 2020, 37, 514-529.	16.8	201

#	Article	IF	CITATIONS
775	Biologic therapy for advanced breast cancer: recent advances and future directions. Expert Opinion on Biological Therapy, 2020, 20, 1009-1024.	3.1	23
776	Endocrine therapies in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative, pretreated, advanced breast cancer. Medicine (United States), 2020, 99, e19618.	1.0	2
777	Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with <i>AKT1</i> E17K-Mutant, ER-Positive Metastatic Breast Cancer. Clinical Cancer Research, 2020, 26, 3947-3957.	7.0	54
778	Combination Strategies for Immune-Checkpoint Blockade and Response Prediction by Artificial Intelligence. International Journal of Molecular Sciences, 2020, 21, 2856.	4.1	31
779	Breast cancer immunology and immunotherapy: targeting the programmed cell death protein-1/programmed cell death protein ligand-1. Chinese Medical Journal, 2020, 133, 853-862.	2.3	21
780	Cyclin-dependent kinase inhibition: an opportunity to target protein-protein interactions. Advances in Protein Chemistry and Structural Biology, 2020, 121, 115-141.	2.3	5
781	Tumour kinome re-wiring governs resistance to palbociclib in oestrogen receptor positive breast cancers, highlighting new therapeutic modalities. Oncogene, 2020, 39, 4781-4797.	5.9	52
782	Concordance of real-world versus conventional progression-free survival from a phase 3 trial of endocrine therapy as first-line treatment for metastatic breast cancer. PLoS ONE, 2020, 15, e0227256.	2.5	42
783	<p>Combination Strategies of Checkpoint Immunotherapy in Metastatic Breast Cancer</p> . OncoTargets and Therapy, 2020, Volume 13, 2657-2666.	2.0	9
784	Dual Targeting of CDK4/6 and BCL2 Pathways Augments Tumor Response in Estrogen Receptor–Positive Breast Cancer. Clinical Cancer Research, 2020, 26, 4120-4134.	7.0	65
785	Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications. Breast Cancer Research, 2020, 22, 33.	5.0	26
786	Breast Cancer: 45 Years of Research and Progress. Journal of Clinical Oncology, 2020, 38, 2454-2462.	1.6	15
787	Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells. Cancers, 2020, 12, 927.	3.7	6
788	Effectiveness and Tolerability of Nab-paclitaxel in Younger versus Elderly Patients With Metastatic HR-positive/HER2-negative Breast Cancer: Results From the Noninterventional, Prospective Study NABUCCO. Clinical Breast Cancer, 2020, 20, e315-e326.	2.4	2
789	Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference. Hepatology, 2021, 73, 158-191.	7.3	235
790	Circulating Tumor DNA Markers for Early Progression on Fulvestrant With or Without Palbociclib in ER+ Advanced Breast Cancer. Journal of the National Cancer Institute, 2021, 113, 309-317.	6.3	60
791	Palbociclibâ€induced histiocytoid Sweet syndrome. Clinical and Experimental Dermatology, 2021, 46, 348-350.	1.3	5
792	Efficacy of Circulating Tumor Cell Count–Driven vs Clinician-Driven First-line Therapy Choice in Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer. JAMA Oncology, 2021, 7, 34.	7.1	92

#	Article	IF	CITATIONS
793	Evaluating the Clinical Utility of Circulating Tumor Cells in Metastatic Breast Cancer—Is Not Worse Good Enough?. JAMA Oncology, 2021, 7, 30.	7.1	1
794	Safety of palbociclib concurrent with palliative pelvic radiotherapy: discussion of a case of increased toxicity and brief review of literature. Journal of Medical Radiation Sciences, 2021, 68, 96-102.	1.5	10
795	Severe rhabdomyolysis induced by possible drug–drug interaction between Ribociclib and Simvastatin. Journal of Oncology Pharmacy Practice, 2021, 27, 722-726.	0.9	8
796	A Phase Ib Study of Alpelisib or Buparlisib Combined with Tamoxifen Plus Goserelin in Premenopausal Women with HR-Positive HER2-Negative Advanced Breast Cancer. Clinical Cancer Research, 2021, 27, 408-417.	7.0	21
797	PI3K mutations detected in liquid biopsy are associated to reduced sensitivity to CDK4/6 inhibitors in metastatic breast cancer patients. Pharmacological Research, 2021, 163, 105241.	7.1	23
798	A Phase II Study of Fulvestrant 500 mg as Maintenance Therapy in Hormone Receptorâ€Positive, Human Epidermal Growth Factor Receptor 2â€Negative Patients with Advanced Breast Cancer After Firstâ€Line Chemotherapy. Oncologist, 2021, 26, e742-e748.	3.7	2
799	RON signalling promotes therapeutic resistance in ESR1 mutant breast cancer. British Journal of Cancer, 2021, 124, 191-206.	6.4	16
800	CDK4/6 inhibitors for HR+HER2â^' early stage breast cancer — when to escalate treatment?. Nature Reviews Clinical Oncology, 2021, 18, 67-68.	27.6	4
801	CDK4/6 inhibitors in breast cancer: differences in toxicity profiles and impact on agent choice. A systematic review and meta-analysis. Expert Review of Anticancer Therapy, 2021, 21, 283-298.	2.4	39
802	A Novel CDK2/9 Inhibitor CYC065 Causes Anaphase Catastrophe and Represses Proliferation, Tumorigenesis, and Metastasis in Aneuploid Cancers. Molecular Cancer Therapeutics, 2021, 20, 477-489.	4.1	9
803	Everolimus Plus Exemestane Treatment in Patients with Metastatic Hormone Receptor-Positive Breast Cancer Previously Treated with CDK4/6 Inhibitor Therapy. Oncologist, 2021, 26, 101-106.	3.7	28
804	A review of the use of next generation sequencing methodologies to identify biomarkers of resistance to CDK4/6 inhibitors in ER+/HER2- breast cancer. Critical Reviews in Oncology/Hematology, 2021, 157, 103191.	4.4	9
805	CDK4/6 inhibitors: A focus on biomarkers of response and post-treatment therapeutic strategies in hormone receptor-positive HER2-negative breast cancer. Cancer Treatment Reviews, 2021, 93, 102136.	7.7	25
806	Brain metastases in metastatic cancer: a review of recent advances in systemic therapies. Expert Review of Anticancer Therapy, 2021, 21, 325-339.	2.4	10
807	Clinical Challenges in the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: A Literature Review. Advances in Therapy, 2021, 38, 109-136.	2.9	23
808	Impact of Dose Reduction on Efficacy: Implications of Exposure-Response Analysis of Palbociclib. Targeted Oncology, 2021, 16, 69-76.	3.6	19
809	An evaluation of palbociclib as a breast cancer treatment option: a current update. Expert Opinion on Pharmacotherapy, 2021, 22, 281-290.	1.8	3
810	The cyclin-dependent kinases pathway as a target for prostate cancer treatment: rationale and future perspectives. Critical Reviews in Oncology/Hematology, 2021, 157, 103199.	4.4	16

#	Article	IF	CITATIONS
811	Alpelisib in the treatment of metastatic HR+ breast cancer with <i>PIK3CA</i> mutations. Future Oncology, 2021, 17, 13-36.	2.4	9
812	How selective are clinical CDK4/6 inhibitors?. Medicinal Research Reviews, 2021, 41, 1578-1598.	10.5	15
813	Enhanced toxicity with CDK 4/6 inhibitors and palliative radiotherapy: Non-consecutive case series and review of the literature. Translational Oncology, 2021, 14, 100939.	3.7	18
814	Analysis of subsequent therapy in Japanese patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer who received palbociclib plus endocrine therapy in PALOMA-2 and -3. Breast Cancer, 2021, 28, 335-345.	2.9	5
815	Ribociclib plus fulvestrant in the treatment of breast cancer. Expert Review of Anticancer Therapy, 2021, 21, 93-106.	2.4	9
816	Triple-negative breast cancer: new treatment strategies in the era of precision medicine. Science China Life Sciences, 2021, 64, 372-388.	4.9	26
817	Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3. Oncologist, 2021, 26, e53-e65.	3.7	64
818	Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in <i>PIK3CA</i> -Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid Cancers. Cancer Discovery, 2021, 11, 92-107.	9.4	36
819	Phase Ib Study of Ribociclib plus Fulvestrant and Ribociclib plus Fulvestrant plus PI3K Inhibitor (Alpelisib or Buparlisib) for HR+ Advanced Breast Cancer. Clinical Cancer Research, 2021, 27, 418-428.	7.0	16
820	Vitiligo-like lesions in patients with advanced breast cancer treated with cycline-dependent kinases 4 and 6 inhibitors. Breast Cancer Research and Treatment, 2021, 185, 247-253.	2.5	20
821	Drug repurposing for breast cancer therapy: Old weapon for new battle. Seminars in Cancer Biology, 2021, 68, 8-20.	9.6	74
822	Luminal A breast cancer resistance mechanisms and emerging treatments. , 2021, , 1-22.		2
823	The G1 phase optical reporter serves as a sensor of CDK4/6 inhibition <i>in vivo</i> . International Journal of Biological Sciences, 2021, 17, 728-741.	6.4	2
824	First Experiences with Alpelisib in Clinical Routine: Case Reports from a German Breast Center. Breast Care, 2021, 16, 129-134.	1.4	3
825	CDK4/6 inhibitors in the treatment of metastatic breast cancer. Choosing optimal therapy for estrogen-receptor-positive HER2-negative metastatic breast cancer: analysis of doctors' preferences ("Prometheusâ€) in Russia – first results of the survey. Opuholi Zenskoj Reproduktivnoj Sistemy, 2021, 16. 37-45.	0.4	0
826	Suggested Modifications to the Management of Patients With Breast Cancer During the COVID-19 Pandemic: Web-Based Survey Study. JMIR Cancer, 2021, 7, e27073.	2.4	3
827	Real-World Palbociclib Use in HR+/HER2â^ Advanced Breast Cancer in Canada: The IRIS Study. Current Oncology, 2021, 28, 678-688.	2.2	21
828	Elective Discontinuation of CDK4/6 Inhibitors in Patients with Metastatic Hormone Receptor-Positive, Her-2-Negative Breast Cancer: A Retrospective Single-Center Experience. Oncology Research and Treatment, 2021, 44, 443-449.	1.2	1

#	Article	IF	CITATIONS
829	Molecular Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor 2-Negative Metastatic Breast Cancer in Clinical Practice. Journal of Nippon Medical School, 2022, 89, 88-94.	0.9	0
830	Cost-effectiveness of ribociclib plus letrozole <i>versus</i> palbociclib plus letrozole or letrozole as monotherapy in first-line treatment of postmenopausal women with HR+/HER2â <sup>-</sup> locally advanced or metastatic breast cancer: a Brazilian private payer perspective. Therapeutic Advances in Medical Oncology. 2021. 13. 175883592110005.	3.2	6
831	Major clinical research advances in gynecologic cancer in 2020. Journal of Gynecologic Oncology, 2021, 32, e53.	2.2	19
832	A novel humanized Frizzled-7-targeting antibody enhances antitumor effects of Bevacizumab against triple-negative breast cancer via blocking Wnt/β-catenin signaling pathway. Journal of Experimental and Clinical Cancer Research, 2021, 40, 30.	8.6	23
833	CDK4/6 inhibitor plus endocrine therapy for hormone receptorâ€positive, HER2â€negative metastatic breast cancer: The new standard of care. Asia-Pacific Journal of Clinical Oncology, 2021, 17, 3-14.	1.1	11
834	MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit. Npj Breast Cancer, 2021, 7, 2.	5.2	7
835	Overall Survival in Patients with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer Treated with a CDK 4/6 Inhibitor Plus Fulvestrant: A U.S. Food and Drug Administration Pooled Analysis. SSRN Electronic Journal, 0, , .	0.4	0
836	Hormone Receptor Positive/HER2 Negative Breast Cancer With Isolated Bladder Metastasis: A Rare Case. Journal of Investigative Medicine High Impact Case Reports, 2021, 9, 232470962110221.	0.6	3
837	Anti-cancer therapy with cyclin-dependent kinase inhibitors: impact and challenges. Expert Reviews in Molecular Medicine, 2021, 23, e6.	3.9	10
838	A multicenter analysis of treatment patterns and clinical outcomes of subsequent therapies after progression on palbociclib in HR+/HER2â^ metastatic breast cancer. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110228.	3.2	16
839	Real-life prognosis of 5041 bone-only metastatic breast cancer patients in the multicenter national observational ESME program. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592098765.	3.2	13
841	Design, synthesis, molecular docking and ADME studies of novel indole-thiazolidinedione derivatives and their antineoplastic activity as CDK6 inhibitors. New Journal of Chemistry, 2021, 45, 18025-18038.	2.8	6
842	<i>BRCA1</i> Reversion Mutation Confers Resistance to Olaparib and Camrelizumab in a Patient with Breast Cancer Liver Metastasis. Journal of Breast Cancer, 2021, 24, 474.	1.9	5
843	A phase I trial of the CDK 4/6 inhibitor palbociclib in pediatric patients with progressive brain tumors: A Pediatric Brain Tumor Consortium study (PBTCâ€042). Pediatric Blood and Cancer, 2021, 68, e28879.	1.5	24
844	The emerging role of molecular pathology in directing the systemic treatment of endometrial cancer. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110359.	3.2	54
845	Patterns of treatment and outcome of palbociclib plus endocrine therapy in hormone receptor-positive/HER2 receptor-negative metastatic breast cancer: a real-world multicentre Italian study. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592098765.	3.2	12
846	Targeting transcriptional regulators for treatment of anaplastic thyroid cancer. , 2021, 7, .		3
847	Radiotherapy Delivered before CDK4/6 Inhibitors Mediates Superior Therapeutic Effects in ER+ Breast	7.0	41

#	Article	IF	CITATIONS
848	Metastatic hormone receptor-positive breast cancer in CDK 4/6 era: An outcome audit. Journal of Cancer Research and Therapeutics, 2021, 17, 994.	0.9	1
849	Recent Discoveries of Macromolecule- and Cell-Based Biomarkers and Therapeutic Implications in Breast Cancer. International Journal of Molecular Sciences, 2021, 22, 636.	4.1	29
850	Selective inhibition of CDK4/6: A safe and effective strategy for developing anticancer drugs. Acta Pharmaceutica Sinica B, 2021, 11, 30-54.	12.0	66
851	Nexus between PI3K/AKT and Estrogen Receptor Signaling in Breast Cancer. Cancers, 2021, 13, 369.	3.7	35
852	Population Pharmacokinetics of Palbociclib in a Real-World Situation. Pharmaceuticals, 2021, 14, 181.	3.8	4
853	Case Report: Long-Term Response to Pembrolizumab Combined With Endocrine Therapy in Metastatic Breast Cancer Patients With Hormone Receptor Expression. Frontiers in Immunology, 2021, 12, 610149.	4.8	5
855	Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer. Breast Cancer Research, 2021, 23, 26.	5.0	19
856	Solitary Pancreatic Head Metastasis from Ductal Carcinoma of Breast: A Case Report. Indian Journal of Surgical Oncology, 2021, 12, 193-196.	0.7	1
857	Molecular Biomarkers for Contemporary Therapies in Hormone Receptor-Positive Breast Cancer. Genes, 2021, 12, 285.	2.4	18
858	Frontiers in HER2-positive breast cancer in 2020. Current Opinion in Obstetrics and Gynecology, 2021, 33, 48-52.	2.0	1
859	Case Report: Significant Response to Immune Checkpoint Inhibitor Camrelizumab in a Heavily Pretreated Advanced ER+/HER2â^ Breast Cancer Patient With High Tumor Mutational Burden. Frontiers in Oncology, 2020, 10, 588080.	2.8	7
860	Leuprorelin combined with letrozole with/without everolimus in ovarian-suppressed premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer: The LEO study. European Journal of Cancer, 2021, 144, 341-350.	2.8	5
861	Intensity of metastasis screening and survival outcomes in patients with breast cancer. Scientific Reports, 2021, 11, 2851.	3.3	6
862	Machine learning and natural language processing (NLP) approach to predict early progression to first-line treatment in real-world hormone receptor-positive (HR+)/HER2-negative advanced breast cancer patients. European Journal of Cancer, 2021, 144, 224-231.	2.8	12
863	FGFR1 amplification or overexpression and hormonal resistance in luminal breast cancer: rationale for a triple blockade of ER, CDK4/6, and FGFR1. Breast Cancer Research, 2021, 23, 21.	5.0	22
864	Characterization of Oligometastatic Disease in a Real-World Nationwide Cohort of 3447 Patients With de Novo Metastatic Breast Cancer. JNCI Cancer Spectrum, 2021, 5, pkab010.	2.9	21
865	Predictive variables of palbociclib dose reduction and its impact on survival outcomes: A retrospective bicentric study. Breast Journal, 2021, 27, 415-416.	1.0	0
866	Vascular Inflammation and Cardiovascular Burden in Metastatic Breast Cancer Female Patients Receiving Hormonal Treatment and CDK 4/6 Inhibitors or Everolimus. Frontiers in Cardiovascular Medicine, 2021, 8, 638895.	2.4	6

#	Article	IF	CITATIONS
867	CDK 4/6 inhibitors are associated with a high incidence of thrombotic events in women with breast cancer in realâ€world practice. European Journal of Haematology, 2021, 106, 634-642.	2.2	28
868	Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. Lancet Oncology, The, 2021, 22, 212-222.	10.7	169
869	Targeting Aberrant FGFR Signaling to Overcome CDK4/6 Inhibitor Resistance in Breast Cancer. Cells, 2021, 10, 293.	4.1	27
870	Pan-ERBB kinase inhibition augments CDK4/6 inhibitor efficacy in oesophageal squamous cell carcinoma. Gut, 2022, 71, 665-675.	12.1	15
871	Review and Prospect of Tissue-agnostic Targeted Strategies in Anticancer Therapies. Current Topics in Medicinal Chemistry, 2021, 21, 404-425.	2.1	4
872	Cutaneous toxicities occurring during palbociclib (CDK4/6 inhibitor) and endocrine therapy in patients with advanced breast cancer: a single-centre experience. Breast Cancer Research and Treatment, 2021, 188, 535-545.	2.5	8
873	Stereotactic radiotherapy for oligoprogressive ER-positive breast cancer (AVATAR). BMC Cancer, 2021, 21, 303.	2.6	13
874	Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis. Cancers, 2021, 13, 1458.	3.7	17
876	Long-Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Updated Analysis with up to 5 Years of Follow-Up. Oncologist, 2021, 26, e749-e755.	3.7	33
877	Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2â <sup>~°</sup> metastatic breast cancer in US real-world clinical practice. Breast Cancer Research, 2021, 23, 37.	5.0	65
878	Patient, Oncologist, and Payer Preferences for Adjuvant Endocrine Therapy and CDK4/6 Inhibitor Regimens in Early-Stage Breast Cancer: A Discrete Choice Experiment. Patient Preference and Adherence, 2021, Volume 15, 611-623.	1.8	6
879	Complete and Durable Response to Tamoxifen and Ovarian Ablation in the Treatment of Metastatic Breast Cancer. Cureus, 2021, 13, e14088.	0.5	0
880	Validation and comparison of Breast Graded Prognostic Assessment scores in patients with breast cancer and brain metastases. Clinical and Translational Oncology, 2021, 23, 1761-1768.	2.4	3
881	Survival analysis of bevacizumab plus taxane treatment in luminal metastatic breast cancer. Future Science OA, 2021, 7, FSO672.	1.9	1
882	Active Targeting Nanoparticle Selfâ€Assembled from Cisplatinâ€Palbociclib Amphiphiles Ensures Optimal Drug Ratio for Combinatorial Chemotherapy. Advanced Therapeutics, 2021, 4, 2000261.	3.2	8
883	A Randomized Phase II Study of Androgen Deprivation Therapy with or without Palbociclib in RB-positive Metastatic Hormone-Sensitive Prostate Cancer. Clinical Cancer Research, 2021, 27, 3017-3027.	7.0	19
884	Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders. Nature Cancer, 2021, 2, 429-443.	13.2	29
885	Pre-existing effector T-cell levels and augmented myeloid cell composition denote response to CDK4/6 inhibitor palbociclib and pembrolizumab in hormone receptor-positive metastatic breast cancer. , 2021, 9, e002084.		16

#	Article	IF	CITATIONS
886	First clinical experience with CDK4/6 inhibitors in breast cancer therapy. Experimental and Therapeutic Medicine, 2021, 21, 522.	1.8	0
887	Epigenetic mechanisms in breast cancer therapy and resistance. Nature Communications, 2021, 12, 1786.	12.8	187
888	A Substantial Response from Adding Palbociclib to Endocrine Therapy in Brain Metastasis from Hormone Receptor-Positive, HER2-Negative Breast Cancer: Case Reports. Case Reports in Oncology, 2021, 14, 446-452.	0.7	2
889	CDK8 maintains stemness and tumorigenicity of glioma stem cells by regulating the c-MYC pathway. Oncogene, 2021, 40, 2803-2815.	5.9	33
890	Molecular characterization of long-term survivors of hepatocellular carcinoma. Aging, 2021, 13, 7517-7537.	3.1	5
891	Breast Cancer Brain Metastasis—Overview of Disease State, Treatment Options and Future Perspectives. Cancers, 2021, 13, 1078.	3.7	41
892	Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer. Npj Breast Cancer, 2021, 7, 44.	5.2	11
893	Pharmacokinetics, safety, activity, and biomarker analysis of palbociclib plus letrozole as first-line treatment for ER+/HER2– advanced breast cancer in Chinese women. Cancer Chemotherapy and Pharmacology, 2021, 88, 131-141.	2.3	8
894	Dose modifications of ribociclib and endocrine therapy for treatment of ER+ HER2â^' metastatic breast cancer. Breast Cancer Research and Treatment, 2021, 188, 799-809.	2.5	11
895	Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy. Breast Cancer, 2021, 28, 1038-1050.	2.9	10
896	Reporting of harms in oncological clinical study reports submitted to the European Medicines Agency compared to trial registries and publications—a methodological review. BMC Medicine, 2021, 19, 88.	5.5	5
897	Palbociclib with letrozole as second-line neo-systemic therapy after failure of neo-adjuvant chemotherapy for luminal type breast cancer. Medicine (United States), 2021, 100, e25175.	1.0	6
898	Assessment of Resistance Mechanisms and Clinical Implications in Patients with KRAS Mutated-Metastatic Breast Cancer and Resistance to CDK4/6 Inhibitors. Cancers, 2021, 13, 1928.	3.7	14
899	Preclinical Advances in Theranostics for the Different Molecular Subtypes of Breast Cancer. Frontiers in Pharmacology, 2021, 12, 627693.	3.5	10
900	CATCH: A Prospective Precision Oncology Trial in Metastatic Breast Cancer. JCO Precision Oncology, 2021, 5, 676-686.	3.0	20
901	Ki67 and progesterone receptor status predicts sensitivity to palbociclib: a real-world study. Annals of Translational Medicine, 2021, 9, 707-707.	1.7	11
902	Efficacy and mechanism of the combination of PARP and CDK4/6 inhibitors in the treatment of triple-negative breast cancer. Journal of Experimental and Clinical Cancer Research, 2021, 40, 122.	8.6	35
903	Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL. Annals of Oncology, 2021, 32, 488-499.	1.2	69

#	Article	IF	CITATIONS
904	Prognostic factors for patients with metastatic breast cancer: a literature review. Translational Cancer Research, 2021, 10, 1644-1655.	1.0	0
905	Invasive Lobular Carcinoma of the Breast: Ongoing Trials, Challenges, and Future Directions. Current Breast Cancer Reports, 2021, 13, 164-170.	1.0	1
906	Ribociclib Population Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Analysis of Neutrophils in Cancer Patients. Journal of Clinical Pharmacology, 2021, 61, 1054-1068.	2.0	13
907	Ribociclib induced acute kidney injury: A case report. Journal of Oncology Pharmacy Practice, 2021, 27, 2023-2026.	0.9	7
908	Efficacy and Safety of CDK4/6 Inhibitors Combined with Endocrine Therapy in HR+/HER-2â^ ABC Patients: A Systematic Review and Meta-Analysis. Cancer Investigation, 2021, 39, 369-378.	1.3	7
909	Challenge of Incorporating New Drugs for Breast Cancer in Brazil: A Proposed Framework for Improving Access to Innovative Therapies. JCO Global Oncology, 2021, 7, 474-485.	1.8	2
910	Real-World Clinical Data of Palbociclib in Asian Metastatic Breast Cancer Patients: Experiences from Eight Institutions. Cancer Research and Treatment, 2021, 53, 409-423.	3.0	10
911	A phase 1 study of dalpiciclib, a cyclin-dependent kinase 4/6 inhibitor in Chinese patients with advanced breast cancer. Biomarker Research, 2021, 9, 24.	6.8	14
913	Exploring the concepts and practices of advanced breast cancer treatment: a narrative review. Annals of Translational Medicine, 2021, 9, 721-721.	1.7	3
914	Severe drug eruption induced by cyclinâ€dependent kinase 4 and 6 inhibitor. Journal of Dermatology, 2021, 48, e339-e340.	1.2	1
915	Optimal treatment for aromatase inhibitor-resistant metastatic breast cancer patients: lessons from the PEARL study. Annals of Oncology, 2021, 32, 427-430.	1.2	1
916	Final results of the randomized phase 2 <scp>LEO</scp> trial and bone protective effects of everolimus for premenopausal hormone receptorâ€positive, <scp>HER2</scp> â€negative metastatic breast cancer. International Journal of Cancer, 2021, 149, 917-924.	5.1	5
918	Adjuvant cyclinâ€dependent kinase 4/6 inhibition in hormone receptor–positive breast cancer: One Monarch to rule them all?. Cancer, 2021, 127, 3302-3309.	4.1	3
919	Tripleâ€'negative breast cancer: A runâ€'through of features, classification and current therapies (Review). Oncology Letters, 2021, 22, 512.	1.8	52
920	Chemotherapy or endocrine therapy, first-line treatment for patients with hormone receptor-positive HER2-negative metastatic breast cancer in China: a real-world study. Annals of Translational Medicine, 2021, 9, 831-831.	1.7	5
921	Treatment and Monitoring Variability in US Metastatic Breast Cancer Care. JCO Clinical Cancer Informatics, 2021, 5, 600-614.	2.1	5
922	Current Landscape of Targeted Therapy in Hormone Receptor-Positive and HER2-Negative Breast Cancer. Current Oncology, 2021, 28, 1803-1822.	2.2	24
923	Targeting DNA Damage Repair for Immune Checkpoint Inhibition: Mechanisms and Potential Clinical Applications. Frontiers in Oncology, 2021, 11, 648687.	2.8	29

#	Article	IF	CITATIONS
924	Liquid Biopsy: A New Tool for Overcoming CDKi Resistance Mechanisms in Luminal Metastatic Breast Cancer. Journal of Personalized Medicine, 2021, 11, 407.	2.5	3
925	Phase I–II Open-Label Multicenter Study of Palbociclib + Vemurafenib in <i>BRAF</i> V600MUT Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism. Clinical Cancer Research, 2021, 27, 3876-3883.	7.0	8
926	Chemotherapeutic drugs: Cell death- and resistance-related signaling pathways. Are they really as smart as the tumor cells?. Translational Oncology, 2021, 14, 101056.	3.7	17
927	Evaluation of potential complication of interstitial lung disease with abemaciclib and palbociclib treatments. Cancer Reports, 2022, 5, e1402.	1.4	9
928	Current State of Breast Cancer Diagnosis, Treatment, and Theranostics. Pharmaceutics, 2021, 13, 723.	4.5	63
929	The therapeutic landscape of hepatocellular carcinoma. Med, 2021, 2, 505-552.	4.4	20
930	Cost-Effectiveness of Adding Ribociclib to Endocrine Therapy for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer Among Premenopausal or Perimenopausal Women. Frontiers in Oncology, 2021, 11, 658054.	2.8	9
932	Circulating Biomarkers of CDK4/6 Inhibitors Response in Hormone Receptor Positive and HER2 Negative Breast Cancer. Cancers, 2021, 13, 2640.	3.7	8
933	Don't let it disappear: new opportunities to prolong the life of HR+ HER2- advanced breast cancer patients. Event review of the satellite symposium. RUSSCO Big Conference «Breast Cancer» (online). January 28th, 2021. Journal of Modern Oncology, 2021, 23, 53-60.	0.3	0
934	Optimal integration of CDK4/6 inhibitors for treatment of hormone receptor-positive metastatic breast cancer. Practical Oncology, 2021, 4, 11-18.	0.1	0
935	Treatment Strategy for Patients with HR-Positive HER2-Negative Metastatic Breast Cancer That Progressed on CDK4/6 Inhibitors. Breast Care, 2022, 17, 1-8.	1.4	2
936	Model Development of CDK4/6 Predicted Efficacy in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced or Metastatic Breast Cancer. JCO Clinical Cancer Informatics, 2021, 5, 758-767.	2.1	1
937	Genetic variant within CDK6 regulates immune response to palbociclib treatment. Clinical Immunology, 2021, 235, 108777.	3.2	0
938	Hematologic safety of palbociclib in combination with endocrine therapy in patients with benign ethnic neutropenia and advanced breast cancer. Cancer, 2021, 127, 3622-3630.	4.1	8
939	Comparison of the Effectiveness and Clinical Outcome of Everolimus Followed by CDK4/6 Inhibitors with the Opposite Treatment Sequence in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer. Cancer Research and Treatment, 2022, 54, 469-477.	3.0	5
940	Recurrent Mutations in Cyclin D3 Confer Clinical Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia. Clinical Cancer Research, 2021, 27, 4003-4011.	7.0	7
941	First-Line Treatment with a Cyclin-Dependent Kinase 4/6 Inhibitor Plus an Aromatase Inhibitor for Metastatic Breast Cancer in Alberta. Current Oncology, 2021, 28, 2270-2280.	2.2	4
942	Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer. British Journal of Cancer, 2021, 125, 679-686	6.4	31

CITATION REPORT ARTICLE IF CITATIONS T Cell-Intrinsic CDK6 Is Dispensable for Anti-Viral and Anti-Tumor Responses In Vivo. Frontiers in 4.8 4 Immunology, 2021, 12, 650977. Oligometastatic Breast Cancer: How to Manage It?. Journal of Personalized Medicine, 2021, 11, 532. 2.5 Phase 1a study of the CDK4/6 inhibitor, FCN-437c, in Chinese patients with HR $\hat{a}\in \mathbb{W}$ + $\hat{a}\in \mathbb{W}$ /HER2- advanced breast 2.6 2 cancer. Investigational New Drugs, 2021, 39, 1549-1558. CDK4/6 inhibitors in HR+/HER2- advanced/metastatic breast cancer: a systematic literature review of 2.4 34 real-world evidence studies. Future Oncology, 2021, 17, 2107-2122. Role of the Combination of Cyclin-Dependent Kinase Inhibitors (CDKI) and Radiotherapy (RT) in the Treatment of Metastatic Breast Cancer (MBC): Advantages and Risks in Clinical Practice. Frontiers in 2.8 13 Oncology, 2021, 11, 643155. Bilateral Breast Carcinoma In Visceral Crisis. Revista De La Facultad De Medicina Humana, 2021, 21, 0.2 646-653. Clinical outcomes of platinum-based chemotherapy in patients with advanced breast cancer: An 11-year 2.2 6 single institutional experience. Breast, 2021, 57, 86-94. Evaluation of the Association of Polymorphisms With Palbociclib-Induced Neutropenia: 3.7 Pharmacogenetic Analysis of PALOMA-2/-3. Oncologist, 2021, 26, e1143-e1155. Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast 4.5 50 cancer patients in the 2008-2017 ESME cohort. ESMO Opén, 2021, 6, 100114. Palbociclib induces cell senescence and apoptosis of gastric cancer cells by inhibiting the Notch 1.8 pathway. Oncology Letters, 2021, 22, 603. Palbociclib as a Novel Therapy for Low-Grade Mucinous Carcinomatosis Peritonei of Appendiceal 3.01 Origin. JCO Precision Oncology, 2021, 5, 1069-1072. PARP14 regulates cyclin D1 expression to promote cell-cycle progression. Oncogene, 2021, 40, 4872-4883. Targeting cell-cycle machinery in cancer. Cancer Cell, 2021, 39, 759-778. 16.8 207 CDK4/6 inhibition synergizes with inhibition of P21-Activated Kinases (PAKs) in lung cancer cell lines. 2.5 PLoS ONE, 2021, 16, e0252927. Serial single-cell genomics reveals convergent subclonal evolution of resistance as patients with 13.2 34 early-stage breast cancer progress on endocrine plus CDK4/6 therapy. Nature Cancer, 2021, 2, 658-671. Drug induced vitiligoâ€like depigmentation from a CDK 4/6 inhibitor. Asia-Pacific Journal of Clinical 1.1 Oncology, 2022, 18, . A Review of Treatment-Induced Pulmonary Toxicity in Breast Cancer. Clinical Breast Cancer, 2022, 22, 2.4 6 1-9.

960	Tumor-Targeted Fluorescent Proteinoid Nanocapsules Encapsulating Synergistic Drugs for Personalized Cancer Therapy. Pharmaceuticals, 2021, 14, 648.	3.8	6
-----	--	-----	---

#

943

944

945

946

947

948

949

950

951

953

954

955

957

#	Article	IF	CITATIONS
961	Incidence and Severity of Myelosuppression With Palbociclib After Palliative Bone Radiation in Advanced Breast Cancer: A Single Center Experience and Review of Literature. Clinical Breast Cancer, 2022, 22, e65-e73.	2.4	10
962	Androgen receptor expression in breast cancer: Implications on prognosis and treatment, a brief review. Molecular and Cellular Endocrinology, 2021, 531, 111324.	3.2	13
963	Clinical and Pharmacologic Differences of CDK4/6 Inhibitors in Breast Cancer. Frontiers in Oncology, 2021, 11, 693104.	2.8	67
964	Integrated multiâ€omics profiling of highâ€grade estrogen receptorâ€positive, HER2â€negative breast cancer. Molecular Oncology, 2022, 16, 2413-2431.	4.6	3
965	The mechanisms involved in the resistance of estrogen receptor-positive breast cancer cells to palbociclib are multiple and change over time. Journal of Cancer Research and Clinical Oncology, 2021, 147, 3211-3224.	2.5	10
966	Combination of CDK4/6 and mTOR Inhibitors Suppressed Doxorubicin-resistant Osteosarcoma in a Patient-derived Orthotopic Xenograft Mouse Model: A Translatable Strategy for Recalcitrant Disease. Anticancer Research, 2021, 41, 3287-3292.	1.1	7
967	Synthesis, crystal structure and DFT study of a novel compound N-(4-(2,4-dimorpholinopyrido[2,3-d]pyrimidin-6-yl)phenyl)pyrrolidine-1-carboxamide. Journal of Molecular Structure, 2021, 1235, 130261.	3.6	16
968	GDC-9545 (Giredestrant): A Potent and Orally Bioavailable Selective Estrogen Receptor Antagonist and Degrader with an Exceptional Preclinical Profile for ER+ Breast Cancer. Journal of Medicinal Chemistry, 2021, 64, 11841-11856.	6.4	70
969	Posterior Reversible Encephalopathy Occurring During Treatment With Palbociclib. Cureus, 2021, 13, e16604.	0.5	0
970	Emulating Control Arms for Cancer Clinical Trials Using External Cohorts Created From Electronic Health Recordâ€Derived Realâ€World Data. Clinical Pharmacology and Therapeutics, 2022, 111, 168-178.	4.7	14
971	Demographic Characteristics and Treatment Patterns Among Patients Receiving Palbociclib for HR+/HER2â^ Advanced Breast Cancer: A Nationwide Real-World Experience. OncoTargets and Therapy, 2021, Volume 14, 3971-3981.	2.0	4
972	Mechanisms of endocrine therapy resistance in breast cancer. Molecular and Cellular Endocrinology, 2021, 532, 111322.	3.2	40
973	A clinical calculator to predict disease outcomes in women with hormone receptor-positive advanced breast cancer treated with first-line endocrine therapy. Breast Cancer Research and Treatment, 2021, 189, 15-23.	2.5	6
974	CDK4/6 inhibitor-induced colitis: a case report and review of the literature. BMJ Case Reports, 2021, 14, e242766.	0.5	2
975	Efficacy and safety of palbociclib and ribociclib in patients with estrogen and/or progesterone receptor positive, HER2 receptor negative metastatic breast cancer in routine clinical practice. PLoS ONE, 2021, 16, e0253722.	2.5	12
976	Landmark trials in the medical oncology management of metastatic breast cancer. Seminars in Oncology, 2021, 48, 246-258.	2.2	4
977	Phase I Study and Pilot Efficacy Analysis of Entinostat, a Novel Histone Deacetylase Inhibitor, in Chinese Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer. Targeted Oncology, 2021, 16, 591-599.	3.6	6
978	Current and emerging estrogen receptor-targeted therapies for the treatment of breast cancer. Essays in Biochemistry, 2021, 65, 985-1001.	4.7	10

#	Article	IF	CITATIONS
979	Clinical trial data and emerging immunotherapeutic strategies: hormone receptor-positive, HER2â^' negative breast cancer. Breast Cancer Research and Treatment, 2021, 189, 1-13.	2.5	3
980	Implications of Tamoxifen Resistance in Palbociclib Efficacy for Patients with Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Subgroup Analyses of KCSG-BR15-10 (YoungPEARL). Cancer Research and Treatment, 2021, 53, 695-702.	3.0	1
981	CDK4: A Novel Therapeutic Target for Extramammary Paget's Disease. Frontiers in Oncology, 2021, 11, 710378.	2.8	4
982	Endocrine Treatment and Targeted Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: ASCO Guideline Update. Journal of Clinical Oncology, 2021, 39, 3959-3977.	1.6	121
983	Potential Prospect of CDK4/6 Inhibitors in Triple-Negative Breast Cancer. Cancer Management and Research, 2021, Volume 13, 5223-5237.	1.9	30
984	Expression and Clinical Significance of Lactate Dehydrogenase A in Colon Adenocarcinoma. Frontiers in Oncology, 2021, 11, 700795.	2.8	7
985	Cyclin-Dependent Kinase 4 and 6 Inhibitors in Cell Cycle Dysregulation for Breast Cancer Treatment. Molecules, 2021, 26, 4462.	3.8	22
986	Targeting PI3K/AKT/mTOR Signaling Pathway in Breast Cancer. Cancers, 2021, 13, 3517.	3.7	68
987	Chemoresistance and Metastasis in Breast Cancer Molecular Mechanisms and Novel Clinical Strategies. Frontiers in Oncology, 2021, 11, 658552.	2.8	30
988	Regulation of aromatase expression: Potential therapeutic insight into breast cancer treatment. Molecular and Cellular Endocrinology, 2021, 531, 111321.	3.2	10
989	Hormonoterapia adyuvante en cáncer de mama. Revisión de la Evidencia y Abordaje Terapéutico en el Instituto Instituto Nacional de CancerologÃa, Bogotá, Colombia. Revista Colombiana De CancerologÃa, 0, 25, 130-141.	0.2	0
990	The efficacy and safety of paclitaxel plus bevacizumab therapy in breast cancer patients with visceral crisis. Breast, 2021, 58, 50-56.	2.2	4
991	Genome-wide screening identifies cell-cycle control as a synthetic lethal pathway with SRSF2P95H mutation. Blood Advances, 2022, 6, 2092-2106.	5.2	3
992	Epidemiology of De Novo Metastatic Breast Cancer. Clinical Breast Cancer, 2021, 21, 302-308.	2.4	38
993	Endocrine Therapy With or Without CDK4/6 Inhibitors in Women With Hormone-receptor Positive Breast Cancer: What do we Know About the Effects on Cognition?. Clinical Breast Cancer, 2022, 22, 191-199.	2.4	8
994	CDK4 has the ability to regulate Aurora B and Cenpp expression in mouse keratinocytes. Oncology Letters, 2021, 22, 732.	1.8	1
995	MicroRNAs as Potential Predictors of Response to CDK4/6 Inhibitor Treatment. Cancers, 2021, 13, 4114.	3.7	10
996	Response to Induction Neoadjuvant Hormonal Therapy Using Upfront 21-Gene Breast Recurrence Score Assay—Results From the SAFIA Phase III Trial. JCO Global Oncology, 2021, 7, 811-819.	1.8	7

	CITATION REPORT	
Article	IF	Citations
Senolysis Reduces Senescence in Veins and Cancer Cell Migration. Advanced Therapeutics, 2021, 2100149.	, 4, 3.2	6
Establishment of Prognostic Nomograms for Predicting the Survival of HR-Positive, HER2-Negativ Metastatic Breast Cancer Patients Treated with Everolimus. Drug Design, Development and Thera 2021, Volume 15, 3463-3473.	е ару, 4.3	2
Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor an endocrine therapy-resistant breast cancer. Nature Communications, 2021, 12, 5112.	nd 12.8	38
Hormonoterapia en cáncer de mama metastásico. Revisión de la Evidencia y Abordaje TerapÃ@ Instituto Nacional de CancerologÃa, Bogotá - Colombia. Revista Colombiana De CancerologÃa, C 142-151.	Dutico en el ), 25, 0.2	0
Real-World Tumor Response of Palbociclib Plus Letrozole Versus Letrozole for Metastatic Breast Cancer in US Clinical Practice. Targeted Oncology, 2021, 16, 601-611.	3.6	16
Breast Cancer Treatments: Updates and New Challenges. Journal of Personalized Medicine, 2021,	, 11, 808. 2.5	108
Cyclin-dependent kinase (CDK) inhibitors in solid tumors: a review of clinical trials. Clinical and Translational Oncology, 2022, 24, 161-192.	2.4	31
Capecitabine in Combination with Endocrine Therapy as Maintenance Therapy after Bevacizumab Paclitaxel Induction Therapy for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Ca KBCSG-TR1214. Cancers, 2021, 13, 4399.	Plus ncer: 3.7	1
The prolonged clinical benefit with metronomic chemotherapy (VEX regimen) in metastatic breas cancer patients. Anti-Cancer Drugs, 2022, 33, e628-e634.	it 1.4	4
Molecular targeted drugs resistance impairs double-strand break repair and sensitizes ER-positive breast cancer to PARP inhibitors. Breast Cancer, 2022, 29, 77-91.	2.9	1
Optimizing treatment selection, and sequencing decisions for Management of HR-Positive, HER2-Negative advanced breast cancer – Proceedings from breast cancer expert group meeting Proceedings, 2021, 15, 15.	g. BMC 1.6	5
Multicentric real world evidence with palbociclib in hormone positive HER2 negative metastatic breast cancer in Indian population. Scientific Reports, 2021, 11, 16236.	3.3	9
NP-ALT, a Liposomal:Peptide Drug, Blocks p27Kip1 Phosphorylation to Induce Oxidative Stress, Necroptosis, and Regression in Therapy-Resistant Breast Cancer Cells. Molecular Cancer Research 2021, 19, 1929-1945.	ı, 3.4	2
The role of CDK4/6 inhibitors in early breast cancer. Breast, 2021, 58, 160-169.	2.2	18
Outcomes of extra-cranial stereotactic body radiotherapy for metastatic breast cancer: Treatmen indication matters. Radiotherapy and Oncology, 2021, 161, 159-165.	t 0.6	14
The efficacy and safety of palbociclib combined with endocrine therapy in patients with hormone receptor-positive HER2-negative advanced breast cancer: a multi-center retrospective analysis. Anti-Cancer Drugs, 2022, 33, e635-e643.	1.4	4

1013	Efficacy of Fulvestrant in Women with Hormone-Resistant Metastatic Breast Cancer (mBC): A Canadian Province Experience. Cancers, 2021, 13, 4163.	3.7	3

1014Advanced Cancer as a Chronic Disease: Introduction. Seminars in Oncology Nursing, 2021, 37, 151176.1.57

#

#	Article	IF	CITATIONS
1015	Effectiveness of Adding Everolimus to the First-line Treatment of Advanced Breast Cancer in Premenopausal Women Who Experienced Disease Progression While Receiving Selective Estrogen Receptor Modulators. JAMA Oncology, 2021, 7, e213428.	7.1	18
1016	Development of a Prognostic Factor Index Among Women With HR+/HER2â^' Metastatic Breast Cancer in a Community Oncology Setting. Clinical Breast Cancer, 2021, 21, 317-328.e7.	2.4	2
1017	The evolution of cyclin dependent kinase inhibitors in the treatment of cancer. Expert Review of Anticancer Therapy, 2021, 21, 1105-1124.	2.4	26
1018	Discovery of LYC-55716: A Potent, Selective, and Orally Bioavailable Retinoic Acid Receptor-Related Orphan Receptor-γ (RORγ) Agonist for Use in Treating Cancer. Journal of Medicinal Chemistry, 2021, 64, 13410-13428.	6.4	11
1019	New drugs and options can enhance patient outcomes: But can they also erode them?. European Journal of Cancer, 2021, 154, 1-3.	2.8	1
1020	Everolimus plus aromatase inhibitors as maintenance therapy after first-line chemotherapy: Final results of the phase III randomised MAIN-A (MAINtenance Afinitor) trial. European Journal of Cancer, 2021, 154, 21-29.	2.8	8
1021	Phase I/II trial of palbociclib, pembrolizumabÂand letrozole in patients with hormone receptor-positive metastatic breast cancer. European Journal of Cancer, 2021, 154, 11-20.	2.8	34
1022	Realâ€world benefit of combination palbociclib and endocrine therapy for metastatic breast cancer and correlation with neutropenia. Cancer Medicine, 2021, 10, 7665-7672.	2.8	9
1023	Inhibition of CK1ε potentiates the therapeutic efficacy of CDK4/6 inhibitor in breast cancer. Nature Communications, 2021, 12, 5386.	12.8	22
1024	A practical guide to endocrine therapy in the management of estrogen receptor-positive male breast cancer. Breast Cancer Management, 2021, 10, BMT59.	0.2	2
1025	Pharmacodynamic Modeling of CDK4/6 Inhibition Related Biomarkers and the Characterization of the Relationship between Biomarker Response and Progression Free Survival in Patients with Advanced Breast Cancer. Journal of Clinical Pharmacology, 2021, , .	2.0	2
1026	Breast cancer treatment-related cardiovascular disturbances: advocacy for a watchful attitude in this never-ending story. Expert Opinion on Drug Safety, 2021, , 1-13.	2.4	Ο
1027	Evaluating Serum Thymidine Kinase 1 in Patients with Hormone Receptor–Positive Metastatic Breast Cancer Receiving First-line Endocrine Therapy in the SWOG S0226 Trial. Clinical Cancer Research, 2021, 27, 6115-6123.	7.0	9
1028	Integrating Immunotherapy with Chemotherapy: A New Approach to Drug Repurposing. , 0, , .		10
1029	Predictive biomarkers for systemic therapy of hepatocellular carcinoma. Expert Review of Molecular Diagnostics, 2021, 21, 1147-1164.	3.1	17
1030	Management of hormone receptor–positive, human epidermal growth factor 2–negative metastatic breast cancer. Breast Cancer Research and Treatment, 2021, 190, 189-201.	2.5	10
1031	IncRNA and breast cancer: Progress from identifying mechanisms to challenges and opportunities of clinical treatment. Molecular Therapy - Nucleic Acids, 2021, 25, 613-637.	5.1	52
1032	Palbociclib-induced severe hepatitis: A case study and literature review. Canadian Liver Journal, 0, , e20210015.	0.9	2

#	Article	IF	CITATIONS
1033	Endoxifen, an Estrogen Receptor Targeted Therapy: From Bench to Bedside. Endocrinology, 2021, 162, .	2.8	14
1035	Expanding control of the tumor cell cycle with a CDK2/4/6 inhibitor. Cancer Cell, 2021, 39, 1404-1421.e11.	16.8	71
1036	An Overview of the Treatment Efficacy and Side Effect Profile of Pharmacological Therapies in Asian Patients with Breast Cancer. Targeted Oncology, 2021, 16, 701-741.	3.6	7
1037	Combined endocrine and targeted therapy in luminal breast cancer. Expert Review of Anticancer Therapy, 2021, 21, 1237-1251.	2.4	12
1038	Adjuvant CDK4/6 inhibitors combined with endocrine therapy in HR-positive, HER2-negative early breast cancer: A meta-analysis of randomized clinical trials. Breast, 2021, 59, 165-175.	2.2	8
1039	Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor–positive metastatic breast cancer: Patient-reported outcomes in the PEARL study. European Journal of Cancer, 2021, 156, 70-82.	2.8	14
1040	Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey. Lancet Oncology, The, 2021, 22, 1367-1377.	10.7	69
1041	Efficacy and safety of palbociclib in patients with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer with preexisting conditions: A post hoc analysis of PALOMA-2. Breast, 2021, 59, 321-326.	2.2	13
1042	Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients. ESMO Open, 2021, 6, 100231.	4.5	28
1043	Clinical considerations of CDK4/6 inhibitors in triple-negative breast cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1876, 188590.	7.4	17
1044	The effects of anticancer therapies on bone metastases in breast cancer. , 2022, , 987-1002.		0
1045	Palbociclib Renders Human Papilloma Virus–Negative Head and Neck Squamous Cell Carcinoma Vulnerable to the Senolytic Agent Navitoclax. Molecular Cancer Research, 2021, 19, 862-873.	3.4	17
1046	Hormone Resistance. Advances in Experimental Medicine and Biology, 2021, 1187, 391-401.	1.6	1
1047	Determination and clinical significance of bone pseudoprogression in hormone receptor-positive metastatic breast cancer. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110228.	3.2	5
1048	Mutant SF3B1 promotes AKT- and NF-κB–driven mammary tumorigenesis. Journal of Clinical Investigation, 2021, 131, .	8.2	22
1050	Mechanisms of resistance to cyclin-dependent kinase 4/6 inhibitors. Molecular Biology Reports, 2021, 48, 915-925.	2.3	20
1051	Pancreatic adenocarcinoma: molecular drivers and the role of targeted therapy. Cancer and Metastasis Reviews, 2021, 40, 355-371.	5.9	6
1052	Real-world safety of palbociclib in breast cancer patients in the United States: a new user cohort study. BMC Cancer, 2021, 21, 97.	2.6	12

#	Article	IF	CITATIONS
1053	Aromatase and CDK4/6 Inhibitor-Induced Musculoskeletal Symptoms: A Systematic Review. Cancers, 2021, 13, 465.	3.7	7
1054	Breast Cancer Therapeutics and Biomarkers: Past, Present, and Future Approaches. Breast Cancer: Basic and Clinical Research, 2021, 15, 117822342199585.	1.1	22
1055	Therapeutic Options for Metastatic Breast Cancer. Advances in Experimental Medicine and Biology, 2019, 1152, 131-172.	1.6	20
1056	Endocrine Therapy in Clinical Practice. Cancer Drug Discovery and Development, 2019, , 215-240.	0.4	1
1057	First-line endocrine therapy for postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and meta-analysis. Breast Cancer, 2020, 27, 340-346.	2.9	12
1058	Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences. Drugs, 2021, 81, 317-331.	10.9	173
1059	Comparative efficacy and safety of CDK4/6 and PI3K/AKT/mTOR inhibitors in women with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and network meta-analysis. Current Problems in Cancer, 2020, 44, 100606.	2.0	11
1060	CDK4/6 inhibitors in breast cancer therapy: Current practice and future opportunities. , 2018, 191, 65-73.		50
1061	Predictive factors of 5-year relapse-free survival in HR+/HER2- breast cancer patients treated with neoadjuvant endocrine therapy: pooled analysis of two phase 2 trials. British Journal of Cancer, 2020, 122, 759-765.	6.4	15
1062	Efficacy and safety of anticancer drug combinations: a meta-analysis of randomized trials with a focus on immunotherapeutics and gene-targeted compounds. Oncolmmunology, 2020, 9, 1710052.	4.6	17
1069	CDK4/6 inhibition in low burden and extensive metastatic breast cancer: summary of an ESMO Open—Cancer Horizons pro and con discussion. ESMO Open, 2019, 4, e000565.	4.5	8
1070	Differential Regulation of Cancer Progression by CDK4/6 Plays a Central Role in DNA Replication and Repair Pathways. Cancer Research, 2021, 81, 1332-1346.	0.9	20
1071	Exome-capture RNA sequencing of decade-old breast cancers and matched decalcified bone metastases. JCI Insight, 2017, 2, .	5.0	111
1073	Targeted Therapies: Treatment Options for Patients With Metastatic Breast Cancer. Clinical Journal of Oncology Nursing, 2019, 23, 434-438.	0.6	3
1074	Recent advances in understanding breast cancer and emerging therapies with a focus on luminal and triple-negative breast cancer. F1000Research, 2019, 8, 591.	1.6	15
1075	Elevated liver function tests in a patient on palbociclib and fulvestrant. Journal of Community and Supportive Oncology, 2018, 16, e277-e279.	0.1	3
1076	Can cyclin-dependent kinase 4/6 inhibitors convert inoperable breast cancer relapse to operability? A case report. World Journal of Clinical Cases, 2020, 8, 517-521.	0.8	1
1077	Combination of palbociclib with enzalutamide shows in vitro activity in RB proficient and androgen receptor positive triple negative breast cancer cells. PLoS ONE, 2017, 12, e0189007.	2.5	45

#	Article	IF	CITATIONS
1078	Characterization of circulating breast cancer cells with tumorigenic and metastatic capacity. EMBO Molecular Medicine, 2020, 12, e11908.	6.9	77
1079	Overcoming CDK4/6 inhibitor resistance in ER-positive breast cancer. Endocrine-Related Cancer, 2019, 26, R15-R30.	3.1	96
1080	Cyclin E1 and cyclin E2 in ER+ breast cancer: prospects as biomarkers and therapeutic targets. Endocrine-Related Cancer, 2020, 27, R93-R112.	3.1	16
1081	Identification of the molecular mechanisms associated with acute type A aortic dissection through bioinformatics methods. Brazilian Journal of Medical and Biological Research, 2019, 52, e8950.	1.5	11
1082	Palbociclib-Induced Liver Failure. Kansas Journal of Medicine, 2020, 13, 81-83.	0.4	5
1083	A hypothesis-driven approach identifies CDK4 and CDK6 inhibitors as candidate drugs for treatments of adrenocortical carcinomas. Aging, 2017, 9, 2695-2716.	3.1	29
1084	CDK4/6 inhibition as maintenance and combination therapy for high grade serous ovarian cancer. Oncotarget, 2018, 9, 15658-15672.	1.8	51
1085	A pilot study of durvalumab and tremelimumab and immunogenomic dynamics in metastatic breast cancer. Oncotarget, 2018, 9, 18985-18996.	1.8	83
1086	ERα-mediated cell cycle progression is an important requisite for CDK4/6 inhibitor response in HR+ breast cancer. Oncotarget, 2018, 9, 27736-27751.	1.8	11
1087	Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study. Oncotarget, 2018, 9, 31877-31887.	1.8	4
1088	CDK4/6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer: Are we at the finish line?. Oncotarget, 2018, 9, 34193-34195.	1.8	2
1089	CDK4/6 inhibition stabilizes disease in patients with p16-null non-small cell lung cancer and is synergistic with mTOR inhibition. Oncotarget, 2018, 9, 37352-37366.	1.8	33
1090	Antineoplastic effects of selective CDK9 inhibition with atuveciclib on cancer stem-like cells in triple-negative breast cancer. Oncotarget, 2018, 9, 37305-37318.	1.8	19
1091	The p21 levels have the potential to be a monitoring marker for ribociclib in breast cancer. Oncotarget, 2019, 10, 4907-4918.	1.8	20
1092	Central nervous system-specific efficacy of CDK4/6 inhibitors in randomized controlled trials for metastatic breast cancer. Oncotarget, 2019, 10, 6317-6322.	1.8	30
1093	New drug: Palbociclib for breast cancer. Australian Prescriber, 2018, 41, 127-128.	1.0	1
1094	Lipid metabolic reprogramming as an emerging mechanism of resistance to kinase inhibitors in breast cancer. , 2020, 3, .		20
1095	Management of hormone-receptor positive human epidermal receptor 2 negative advanced or metastatic breast cancers. Annals of Translational Medicine, 2018, 6, 284-284.	1.7	7

#	Article	IF	CITATIONS
1096	Ribociclib for the treatment of hormone-positive HER2-negative breast cancer. Meditsinskiy Sovet, 2019, , 72-80.	0.5	3
1097	Recent Progress and Development of Small Molecule Kinase Inhibitors for the Treatment of Breast Cancer. Current Enzyme Inhibition, 2020, 16, 4-19.	0.4	3
1098	Reliability of an e-PRO Tool of EORTC QLQ-C30 for Measurement of Health-Related Quality of Life in Patients With Breast Cancer: Prospective Randomized Trial. Journal of Medical Internet Research, 2017, 19, e322.	4.3	48
1099	RENATA study—Latin American prospective experience: clinical outcome of patients treated with palbociclib in hormone receptor-positive metastatic breast cancer—real-world use. Ecancermedicalscience, 2020, 14, 1058.	1.1	10
1100	Cost-effectiveness Analysis of Ribociclib plus Letrozole versus Palbociclib plus Letrozole in the United Kingdom. Journal of Health Economics and Outcomes Research, 2019, 6, 20-31.	1.2	11
1101	PARAGON (ANZGOG-0903): a phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progression. Journal of Gynecologic Oncology, 2019, 30, e86.	2.2	18
1102	Analysis of the selection of CDK4/6 inhibitors based on experience using palbociclib. Biomedical Reports, 2019, 11, 253-256.	2.0	6
1103	Targeting retinoblastoma protein phosphorylation in combination with EGFR inhibition in pancreatic cancer cells. International Journal of Oncology, 2019, 54, 527-536.	3.9	7
1104	HSulf‑1 and palbociclib exert synergistic antitumor effects on RB‑positive triple‑negative breast cancer. International Journal of Oncology, 2020, 57, 223-236.	3.3	8
1105	Palbociclib added to ongoing endocrine therapy for hormone receptor†positive HER2†negative metastatic breast cancer: A case report series. Molecular and Clinical Oncology, 2020, 12, 456-460.	1.0	1
1106	Expression of TRPC1 and SBEM protein in breast cancer tissue and its relationship with clinicopathological features and prognosis of patients. Oncology Letters, 2020, 20, 1-1.	1.8	15
1107	Acute Lymphoblastic Leukemia in a Patient Treated with Letrozole and Palbociclib. Journal of Breast Cancer, 2020, 23, 100.	1.9	3
1108	Protein Phosphatase 1H, Cyclin-Dependent Kinase Inhibitor p27, and Cyclin-Dependent Kinase 2 in Paclitaxel Resistance for Triple Negative Breast Cancers. Journal of Breast Cancer, 2020, 23, 162.	1.9	5
1109	Metastatic breast cancer: Endocrine therapy landscape reshaped. Avicenna Journal of Medicine, 2017, 07, 144-152.	0.8	7
1110	Letrozole and Palbociclib in Advanced Breast Cancer: Outcome from Cancer Institute, Chennai. Indian Journal of Medical and Paediatric Oncology, 2020, 41, 182-186.	0.2	2
1111	Efficacy of Palbociclib and Endocrine Treatment in Heavily Pretreated Hormone Receptor-positive/HER2-negative Advanced Breast Cancer: Retrospective Multicenter Trial. Balkan Medical Journal, 2020, 37, 104-107.	0.8	2
1112	Efficacy and toxicity of palbociclib in heavily treated patients with metastatic breast cancer. Annals of Cancer Research and Therapy, 2018, 26, 105-109.	0.3	3
1113	Role of senescence induction in cancer treatment. World Journal of Clinical Oncology, 2018, 9, 180-187.	2.3	30

#	Article	IF	CITATIONS
1114	Circulating Tumor DNA in a Breast Cancer Patient's Plasma Represents Driver Alterations in the Tumor Tissue. Genomics and Informatics, 2017, 15, 48.	0.8	7
1115	Optimizing Palbociclib Therapy Across the Age Spectrum: Hypothetical, Illustrative Case Scenarios in HR+, HER2– Metastatic Breast Cancer. Journal of the Advanced Practitioner in Oncology, 2020, 11, 700-719.	0.4	1
1116	Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 452-478.	4.9	848
1117	A paradigm shift for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer: a review of CDK inhibitors. Drugs in Context, 2018, 7, 1-6.	2.2	8
1118	Bullous Skin Rash: A Rare Case of Palbociclib-Induced Dermatological Toxicity. Cureus, 2020, 12, e10229.	0.5	4
1119	Updates in endocrine therapy for metastatic breast cancer. Cancer Biology and Medicine, 2021, 18, 0-0.	3.0	6
1120	Phase II trial of humanized anti-Lewis Y monoclonal antibody for advanced hormone receptor-positive breast cancer that progressed following endocrine therapy. Clinics, 2021, 76, e3146.	1.5	2
1121	Metastatic Breast Cancer. UNIPA Springer Series, 2021, , 467-479.	0.1	0
1122	Clinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter Experience. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, , 1-8.	4.9	36
1123	Which Clinicopathologic Parameters Suggest Primary Resistance to Palbociclib in Combination With Letrozole as the First-Line Treatment for Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer?. Frontiers in Oncology, 2021, 11, 759150.	2.8	7
1124	Synaptotagmin 13 Is Highly Expressed in Estrogen Receptor-Positive Breast Cancer. Current Oncology, 2021, 28, 4080-4092.	2.2	3
1125	Clinicopathological characteristics and treatment outcomes of luminal B1 breast cancer in Taiwan. Journal of the Chinese Medical Association, 2022, 85, 190-197.	1.4	3
1126	SABR in oligometastatic breast cancer: Current status and future directions. Breast, 2021, 60, 223-229.	2.2	6
1127	The Place of Chemotherapy in The Evolving Treatment Landscape for Patients With HR-positive/HER2-negative MBC. Clinical Breast Cancer, 2022, 22, 223-234.	2.4	2
1128	Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor–Positive, <i>ERBB2</i> -Negative Advanced Breast Cancer. JAMA Oncology, 2021, 7, 1791.	7.1	56
1129	Small Molecule Kinase Inhibitor Drugs (1995–2021): Medical Indication, Pharmacology, and Synthesis. Journal of Medicinal Chemistry, 2022, 65, 1047-1131.	6.4	114
1130	The Therapeutic Challenge of Disseminated Bone Marrow Metastasis From HR-Positive HER2-Negative Breast Cancer: Case Report and Review of the Literature. Frontiers in Oncology, 2021, 11, 651723.	2.8	9
1131	Endocrine resistance in breast cancer: from molecular mechanisms to therapeutic strategies. Journal of Molecular Medicine, 2021, 99, 1691-1710.	3.9	40

	CITATION	CITATION REPORT	
#	Article	IF	CITATIONS
1132	Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study. Annals of Oncology, 2021, 32, 1571-1581.	1.2	225
1133	Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis. Lancet Oncology, The, 2021, 22, 1573-1581.	10.7	23
1134	Progression-free survival on endocrine therapy, before or after chemotherapy, in hormone receptor-positive HER2-negative metastatic breast cancer. Breast Cancer Research and Treatment, 2022, 191, 191-207.	2.5	0
1135	Breast Cancer Consensus Subtypes: A system for subtyping breast cancer tumors based on gene expression. Npj Breast Cancer, 2021, 7, 136.	5.2	20
1136	Effects of the Moderate CYP3A4 Inhibitor Erythromycin on the Pharmacokinetics of Palbociclib: A Randomized Crossover Trial in Patients With Breast Cancer. Clinical Pharmacology and Therapeutics, 2022, 111, 477-484.	4.7	4
1137	Polyphyllin I, a lethal partner of Palbociclib, suppresses non-small cell lung cancer through activation of p21/CDK2/Rb pathway <i>in vitro</i> and <i>in vivo</i> . Cell Cycle, 2021, 20, 2494-2506.	2.6	13
1138	Clinical Review on the Management of Hormone Receptor–Positive Metastatic Breast Cancer. JCO Oncology Practice, 2022, 18, 319-327.	2.9	40
1139	Type 1 Nuclear Receptor Activity in Breast Cancer: Translating Preclinical Insights to the Clinic. Cancers, 2021, 13, 4972.	3.7	9
1140	Palbociclib as an early-line treatment for Japanese patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer: a review of clinical trial and real-world data. International Journal of Clinical Oncology, 2021, 26, 2179-2193.	2.2	4
1141	Implications of TGFÎ <sup>2</sup> Signaling and CDK Inhibition for the Treatment of Breast Cancer. Cancers, 2021, 13, 5343.	3.7	5
1142	Peritoneal Metastasis After Treated With Abemaciclib Plus Fulvestrant for Metastatic Invasive Lobular Breast Cancer: A Case Report and Review of the Literature. Frontiers in Endocrinology, 2021, 12, 659537.	3.5	1
1143	Biomarkers of Response and Resistance to Palbociclib Plus Letrozole in Patients With ER+/HER2â^' Breast Cancer. Clinical Cancer Research, 2022, 28, 163-174.	7.0	8
1144	ESR1 mutations and therapeutic resistance in metastatic breast cancer: progress and remaining challenges. British Journal of Cancer, 2022, 126, 174-186.	6.4	37
1145	A deep dive into CDK4/6 inhibitors: Evaluating real world toxicities and treatment paradigms in the elderly population. Journal of Oncology Pharmacy Practice, 2023, 29, 14-21.	0.9	7
1146	Breast Cancer Drug Approvals Issued by EMA: A Review of Clinical Trials. Cancers, 2021, 13, 5198.	3.7	10
1147	CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer. Scientific Reports, 2021, 11, 20059.	3.3	53
1148	De novo metastatic breast cancer arising in young women: review of the current evidence. Clinical Breast Cancer, 2021, , .	2.4	6
1149	Safety of cyclin-dependent kinase4/6 inhibitor combined with palliative radiotherapy in patients with metastatic breast cancer. Breast, 2021, 60, 163-167.	2.2	17

# 1150	ARTICLE Complete metabolic response with letrozole and palbociclib in advanced breast cancer. International	IF 0.0	CITATIONS
1151	Neue Arzneimittel 2016. , 2017, , 55-135.		0
1152	Invasive Breast Cancer Therapy 2017: How Well Are We Hitting the Target?. Resistance To Targeted Anti-cancer Therapeutics, 2017, , 1-34.	0.1	0
1154	Invasive Carcinomas. , 2018, , 191-232.		1
1156	Palbociclib. Pharma-Kritik (discontinued), 2017, 39, .	0.0	0
1157	News in hormonal therapy for breast cancer. Onkologie (Czech Republic), 2017, 11, 257-262.	0.1	0
1158	Onkologika. , 2018, , 645-691.		1
1159	Combination Therapies †in Advanced, Hormone †Receptor†Positive Breast Cancer. Journal of the Advanced Practitioner in Oncology, 2018, 9, .	0.4	3
1160	Practical consensus recommendations regarding the use of hormonal therapy in metastatic breast cancer. South Asian Journal of Cancer, 2018, 07, 137-141.	0.6	2
1162	Palbociclib in the first line combination hormone therapy of HER2- negative metastatic hormone-dependent breast cancer. Clinical follow-up. Meditsinskiy Sovet, 2018, , 158-160.	0.5	1
1163	PHARMACOECONOMIC EVALUATION OF RIBOCICLIB FOR THE FIRST-LINE TREATMENT OF HR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER. Opuholi Zenskoj Reproduktivnoj Sistemy, 2018, 14, 21-35.	0.4	2
1164	Congrès de l'association américaine de recherche contre le cancer — AACR 2018. Oncologie, 2018, 20, 49-70.	0.7	0
1166	PREVENTION AND MONITORING OF CARDIOVASCULAR COMPLICATIONS IN PATIENTS WITH LUMINAL HER2-NEGATIVE METASTATIC BREAST CANCER. Opuholi Zenskoj Reproduktivnoj Sistemy, 2018, 14, 61-71.	0.4	0
1167	Palbociclib to reverse endocrine resistance in breast cancer: a TREnd in the right direction?. Oncotarget, 2018, 9, 34031-34032.	1.8	Ο
1168	Endocrine Therapy of Metastatic Breast Cancer. , 2019, , 533-555.		0
1169	Ribociclib in the first-line therapy for metastatic hormone-dependent HER2-negative breast cancer in patients with intact ovarian function. Meditsinskiy Sovet, 2018, , 28-30.	0.5	0
1172	Clinical Aspects of Estrogen and Progesterone Receptors and ERBB2 Testing. , 2019, , 143-161.		0
1173	Onkologika. , 2019, , 817-875.		0

ARTICLE IF CITATIONS Breast Cancer in Older Women., 2019, , 325-335. 1 1174 Treatment of Metastatic Breast Cancer: Endocrine Therapy., 2019, , 419-447. A Case of Esophageal Stenosis due to Breast Cancer Metastasis. Nihon Gekakei Rengo Gakkaishi 1177 0.0 0 (Journal of Japanese College of Surgeons), 2019, 44, 883-888. The Unfolded Protein Response as an Integrator of Response to Endocrine Therapy in Estrogen 1178 0.4 Receptor Positive Breast Cancer. Cancer Drug Discovery and Development, 2019, , 163-180. Preparing for The Era of Precision Medicine to Improve Individualized Outcomes in Women with 1179 1.0 0 Breast Cancer. Eurasian Journal of Medicine and Oncology, 2019, , . Dynamics of Sequencing of Cyclin-Dependent Kinase Inhibitors and Cost Expenditure Analysis in the Management of Metastatic Hormone-Receptor Positive, Human Epidermal Growth Factor 2-Negative Advanced Breast Cancer. Indian Journal of Medical and Paediatric Oncology, 2019, 40, 311-313. 0.2 1181 Cyclin-dependent kinase inhibitors: efficacy and safety. Meditsinskiy Sovet, 2019, , 42-55. 0.5 2 '乳癌æ²»ç™,ã«ãŠã¹ä,<, å^†åæ<sup>..</sup>™çš"è−¬ãƒ»æŠ—ä½″医è−¬ã® ç¾çжã፥展æœ>. Journal of Otolaryngology of J**api**an, 2010, 122, Role of palbociclib in the treatment of hormone receptor-positive HER2-negative metastatic breast 1183 cancer. Generalizing results of randomized trials and real clinical practice. Meditsinskiy Sovet, 2019, , 0.5 1 56-62. EvaluaciÃ<sup>3</sup>n y Manejo del CÃ;ncer de Mama MetastÃ;sico, Irresecable o Recurrente: 1er Consenso 1184 Nacional del CÃ;ncer de Mama de la Sociedad Panameña de OncologÃa (SPO). Revista Medica De Panama, 2019, 39, . Hormone therapy for premenopausal women with metastatic breast cancer: combinations with 1185 0 0.4 cyclin-dependent kinase inhibitors. Opuholi Zenskoj Reproduktivnoj Sistemy, 2019, 15, 30-41. Neurological Complications of Targeted Therapies., 2020, , 341-363. Aktuelle medizinisch-onkologische Aspekte der Onkologischen Rehabilitation., 2020,, 65-69. 1188 0 Protocole homéopathique d'accompagnement des inhibiteurs oraux des kinases dépendantes des cyclines 4Âet 6 (CDK 4/6), dans le cancer du sein post-ménopausique métastatique hormonodépendant. Revue D'Homeopathie, 2019, 10, 193-198. 0.1 1190 Fulvestrant in treatment for metastatic breast cancer. Meditsinskiy Sovet, 2019, , 58-64. 0 0.5Systemic Therapy of Brain Metastases: Breast Cancer., 2020, , 219-233. 1191 Onkologika., 2020, , 671-732. 1192 2 Pharmacoeconomic analysis of using cyclin-dependent kinase 4 and 6 inhibitors in the first line 1194 1.2 treatment of HR-positive HER2-negative advanced breast cancer. Farmakoekonomika, 2020, 12, 279-290.

#	Article	IF	CITATIONS
1195	Hormone Receptor–Positive, HER2-Negative Breast Cancer: Recent Advances and Best Practices. Journal of the Advanced Practitioner in Oncology, 2020, 11, 275-279.	0.4	0
1196	Thymidine kinase-1 as a biomarker in breast cancer: estimating prognosis and early recognition of treatment resistance. Biomarkers in Medicine, 2020, 14, 495-498.	1.4	3
1197	Breast Cancer in Patients 80 Years-Old and Older. The Journal of Breast Health, 2020, 16, 208-212.	1.0	13
1198	Palbociclib-Induced Pneumonitis: A Case Report and Review of the Literature. Cureus, 2020, 12, e8929.	0.5	3
1199	Options for Endocrine-Refractory, Hormone Receptor–Positive Breast Cancer: Which Target and When?. Journal of Clinical Oncology, 2021, 39, 3890-3896.	1.6	0
1200	Resistance Mechanisms to Combined CDK4/6 Inhibitors and Endocrine Therapy in ER+/HER2â <sup>°</sup> Advanced Breast Cancer: Biomarkers and Potential Novel Treatment Strategies. Cancers, 2021, 13, 5397.	3.7	7
1201	U.S. FDA Drug Approvals for Breast Cancer: A Decade in Review. Clinical Cancer Research, 2022, 28, 1072-1086.	7.0	31
1202	Adverse events of targeted therapies approved for women's cancers. International Journal of Women's Dermatology, 2021, 7, 552-559.	2.0	0
1203	Matching-Adjusted Indirect Comparison of Ribociclib Plus Fulvestrant versus Palbociclib Plus Letrozole as First-Line Treatment of HR+/HER2â^' Advanced Breast Cancer. Cancer Management and Research, 2021, Volume 13, 8179-8189.	1.9	2
1204	Mechanisms of Resistance to CDK4/6 Blockade in Advanced Hormone Receptor–positive, HER2-negative Breast Cancer and Emerging Therapeutic Opportunities. Clinical Cancer Research, 2022, 28, 821-830.	7.0	26
1205	Palbociclib in combination with aromatase inhibitors in patients ≥ 75 years with oestrogen receptor-positive, human epidermal growth factor receptor 2 negative advanced breast cancer: A real-world multicentre UK study. Breast, 2021, 60, 199-205.	2.2	9
1206	A therapeutic approach to low-grade serous ovarian carcinoma. Libri Oncologici, 2020, 48, 109-115.	0.1	0
1207	CDKN2A (p16INK4A) affects the anti‑tumor effect of CDK inhibitor in somatotroph adenomas. International Journal of Molecular Medicine, 2020, 47, 500-510.	4.0	5
1208	Efficiency and tolerability of abemaciclib in elderly patients. Meditsinskiy Sovet, 2020, , 32-38.	0.5	0
1209	Synthesis and Clinical Development of Palbociclib: An Overview. Medicinal Chemistry, 2022, 18, 2-25.	1.5	8
1210	Inhibitors of cyclin-dependent kinases 4/6 for breast cancer patients with different somatic mutations of the PIK3CA gene. Meditsinskiy Sovet, 2020, , 40-46.	0.5	1
1211	Cardiovascular Toxicities of Targeted Therapy. , 2020, , 165-178.		0
1212	Palliative care access in the elderly metastatic breast cancer population: obstacles and opportunities. Translational Cancer Research, 2020, 9, S110-S115.	1.0	1

#	Article	IF	CITATIONS
1213	Real-World Outcomes of Treating Advanced Breast Cancer Patients With Palbociclib: A Multicenter Retrospective Cohort Study in Japan—The KBCOG-14 Study. Breast Cancer: Basic and Clinical Research, 2020, 14, 117822342098384.	1.1	11
1214	An unusual durable response with palbociclib plus letrozole in hormone receptor positive metastatic breast cancer after multiple lines of therapy. Indian Journal of Cancer, 2020, 57, 348-350.	0.2	0
1215	Why CDK 4/6 Inhibitors are Practice Changing in Advanced Breast Cancer. Oncology & Hematology Review, 2020, 16, 23.	0.2	0
1216	The Therapeutic Effect of Cyclin-Dependent Kinase 4/6 Inhibitor on Relapsed Ectopic Male Breast Cancer. Journal of Breast Cancer, 2020, 23, 560.	1.9	0
1217	Comparison of Endocrine Therapies in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced or Metastatic Breast Cancer: A Network Meta-Analysis. Journal of Breast Cancer, 2020, 23, 460.	1.9	1
1218	A Comparative Study on the Clinical Efficacy and Safety between Combination Therapy with CDK 4/6 Inhibitor and AI Versus AI Monotherapy in HR+/HER type2- Advanced Breast Cancer: Updated Meta-analysis. Korean Journal of Clinical Pharmacy, 2020, 30, 1-10.	0.3	0
1219	CYCLIN-EPENDENT KINASES 4/6 INHIBITORS IN COMBINATION WITH AROMATASE INHIBITORS IN TREATMENT OF METASTATIC BREAST CANCER (clinical observation). International Medical Journal, 2020, , 39-41.	0.0	0
1220	ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Annals of Oncology, 2021, 32, 1475-1495.	1.2	454
1221	Realâ€World Data of Palbociclib in Combination With Endocrine Therapy for the Treatment of Metastatic Breast Cancer in Men. Clinical Pharmacology and Therapeutics, 2022, 111, 302-309.	4.7	21
1222	Surgery to Oligometastatic Breast Cancer after Excellent Response to Palbociclib and Letrozole Therapy: Pitfall of Ultrasound Therapeutic Evaluation. Case Reports in Oncology, 2021, 14, 1601-1607.	0.7	Ο
1223	The Use of Inhibitors of Tyrosine Kinase in Paediatric Haemato-Oncology—When and Why?. International Journal of Molecular Sciences, 2021, 22, 12089.	4.1	8
1224	Abemaciclib as an original inhibitor of cyclin-dependent kinase for the treatment of luminal HER2-negative disseminated breast cancer. Meditsinskiy Sovet, 2020, , 27-42.	0.5	Ο
1226	Collaborative Management of Patients With Estrogen Receptor-Positive Breast Cancer. Journal of the Advanced Practitioner in Oncology, 2017, 8, 250-254.	0.4	0
1227	Combination Therapies in Advanced, Hormone Receptor-Positive Breast Cancer. Journal of the Advanced Practitioner in Oncology, 2018, 9, 43-54.	0.4	5
1228	Present and Future Prospect of Small Molecule & Related Targeted Therapy Against Human Cancer. Vivechan International Journal of Research, 2018, 9, 36-49.	0.0	4
1229	CDK4/6 Inhibitors: Game Changers in the Management of Hormone Receptor–Positive Advanced Breast Cancer?. Oncology, 2018, 32, 216-22.	0.5	43
1230	Palbociclib improves cardiac dysfunction in diabetic cardiomyopathy by regulating Rb phosphorylation. American Journal of Translational Research (discontinued), 2019, 11, 3481-3489.	0.0	2
1231	ER+ metastatic breast cancer: past, present, and a prescription for an apoptosis-targeted future. American Journal of Cancer Research, 2019, 9, 2821-2831.	1.4	24

#	Article	IF	CITATIONS
1233	Palbociclib-Induced Liver Failure. Kansas Journal of Medicine, 2020, 13, 81-82.	0.4	2
1234	Clinical Outcomes of 130 Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Treated with Palbociclib plus Endocrine Therapy and Subsequent Therapy: A Real-World Single-Center Retrospective Study in China. Medical Science Monitor. 2020. 26. e927187.	1.1	4
1235	Quality-of-life methodology in hormone receptor–positive advanced breast cancer: Current tools and perspectives for the future. Cancer Treatment Reviews, 2022, 102, 102321.	7.7	4
1236	Endocrine Treatment for Breast Cancer Patients Revisited—History, Standard of Care, and Possibilities of Improvement. Cancers, 2021, 13, 5643.	3.7	16
1237	Place of CDK 4/6 and PARP inhibitors in the modern treatment approach of HER2-negative breast cancer. Journal of Modern Oncology, 2021, 23, 470-476.	0.3	0
1238	Palbociclib-mediated cell cycle arrest can occur in the absence of the CDK inhibitors p21 and p27. Open Biology, 2021, 11, 210125.	3.6	16
1239	Real-world treatment of patients with palbociclib for HR+/HER2-advanced/metastatic breast cancer: the Europe IRIS study. Future Oncology, 2022, 18, 349-362.	2.4	8
1240	A Randomized Trial of Fulvestrant, Everolimus, and Anastrozole for the Front-line Treatment of Patients with Advanced Hormone Receptor–positive Breast Cancer, SWOG S1222. Clinical Cancer Research, 2022, 28, 611-617.	7.0	4
1241	Gallium-68 Labeling of the Cyclin-Dependent Kinase 4/6 Inhibitors as Positron Emission Tomography Radiotracers for Tumor Imaging. ACS Omega, 2021, 6, 32253-32261.	3.5	2
1242	Câncer de Mama no Homem: uma Revisão Narrativa/ Breast Cancer in Man: a Narrative Review. Brazilian Journal of Health Review, 2021, 4, 23921-23942.	0.1	1
1243	Standard of Care in Hormone Receptor–Positive Metastatic Breast Cancer: Can We Improve the Current Regimens or Develop Better Selection Tools?. JCO Oncology Practice, 2022, 18, 331-334.	2.9	4
1244	Resistance to CDK4/6 Inhibitors in Estrogen Receptor-Positive Breast Cancer. International Journal of Molecular Sciences, 2021, 22, 12292.	4.1	31
1245	Phase 1 trial of entinostat as monotherapy and combined with exemestane in Japanese patients with hormone receptor-positive advanced breast cancer. BMC Cancer, 2021, 21, 1269.	2.6	10
1246	Second-Degree Type 2 Atrioventricular Block Requiring Permanent Cardiac Pacing in Patients on CDK4/6 Inhibitors: Report of Two Cases. Breast Care, 2022, 17, 330-335.	1.4	4
1247	Tolerability of palbociclib in younger and older patients with advanced breast cancer. Journal of Oncology Pharmacy Practice, 2023, 29, 96-104.	0.9	1
1248	Genomic characterization of de novo metastatic breast cancer. Clinical Breast Cancer, 2021, , .	2.4	1
1249	Chondroprotective effects of CDK4/6 inhibition via enhanced ubiquitin-dependent degradation of JUN in synovial fibroblasts. Rheumatology, 2022, 61, 3427-3438.	1.9	7
1250	The Obesity-Related Metabolic Gene HSD17B8 Protects Against Breast Cancer: High RNA/Protein Expression Means a Better Prognosis. Medical Science Monitor, 2022, 28, e934424.	1.1	0

#	Article	IF	CITATIONS
1251	Palbociclib dose reductions and the effect on clinical outcomes in patients with advanced breast cancer. Breast, 2021, 60, 263-271.	2.2	13
1252	Risk of venous and arterial thromboembolic events in women with advanced breast cancer treated with CDK 4/6 inhibitors: A systematic review and meta-analysis. Thrombosis Research, 2021, 208, 190-197.	1.7	9
1254	Pharmacoeconomic evaluations of CDK4/6 inhibitors plus endocrine therapy for advanced hormone receptor-positive (HR+) and human epidermal growth factor receptor-2 negative (HER2â^') breast cancer: a systematic review. Annals of Translational Medicine, 2022, 10, 233-233.	1.7	5
1255	Research Progress on Resistance Mechanism and Biomarker of CDK4/6 Inhibitor in HR+/HER-2â^' Breast Cancer. Advances in Clinical Medicine, 2021, 11, 5754-5761.	0.0	0
1256	Surrogate endpoints for early-stage breast cancer: a review of the state of the art, controversies, and future prospects. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110595.	3.2	10
1257	Onkologika. , 2021, , 579-638.		0
1258	Vitiligo-Like Lesions in a Patient with Metastatic Breast Cancer Treated with Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor: A Case Report and Literature Review. Clinical, Cosmetic and Investigational Dermatology, 2022, Volume 15, 5-10.	1.8	8
1259	Impact of body mass index on the efficacy of aromatase inhibitors in patients with metastatic breast cancer. Breast Cancer Research and Treatment, 2022, 192, 313-319.	2.5	4
1260	Sapanisertib plus Fulvestrant in Postmenopausal Women with Estrogen Receptor–Positive/HER2-Negative Advanced Breast Cancer after Progression on Aromatase Inhibitor. Clinical Cancer Research, 2022, 28, 1107-1116.	7.0	7
1261	Breast Cancer Treatment in the Era of Precision Medicine. Healthbook TIMES Oncology Hematology, 2020, , .	0.1	1
1262	Clinical Outcomes of 130 Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Treated with Palbociclib plus Endocrine Therapy and Subsequent Therapy: A Real-World Single-Center Retrospective Study in China. Medical Science Monitor, 2020, 26, e927187.	1.1	8
1263	Endocrine Treatment of Breast Cancer. , 2022, , 1783-1789.		Ο
1264	A Search for Cyclin-Dependent Kinase 4/6 Inhibitors by Pharmacophore-Based Virtual Screening, Molecular Docking, and Molecular Dynamic Simulations. International Journal of Molecular Sciences, 2021, 22, 13423.	4.1	5
1265	Lineage-specific silencing of PSAT1 induces serine auxotrophy and sensitivity to dietary serine starvation in luminal breast tumors. Cell Reports, 2022, 38, 110278.	6.4	14
1266	Pharmacological CDK4/6 inhibition reveals a p53â€dependent senescent state with restricted toxicity. EMBO Journal, 2022, 41, e108946.	7.8	35
1267	Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03). Journal of Clinical Oncology. 2022. 40. 449-458.	1.6	25
1268	CDK4/6-USP51 axis regulates lung adenocarcinoma metastasis through ZEB1. Cancer Gene Therapy, 2022, 29, 1181-1192.	4.6	10
1269	Epigenetic Therapies and Biomarkers in Breast Cancer. Cancers, 2022, 14, 474.	3.7	16

#	Article	IF	CITATIONS
1270	Patient preferences for breast cancer treatments: a discrete choice experiment in France, Ireland, Poland and Spain. Future Oncology, 2022, 18, 1115-1132.	2.4	8
1271	Hormonal and Targeted Treatments in Breast Cancer. , 2022, , 443-463.		3
1272	Barriers and facilitators to taking CDK4/6 inhibitors among patients with metastatic breast cancer: a qualitative study. Breast Cancer Research and Treatment, 2022, 192, 385-399.	2.5	5
1273	Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2–advanced breast cancer: GEICAM/2014–12 (FLIPPER). European Journal of Cancer, 2022, 161, 26-37.	2.8	11
1274	CDK4 and CDK6 kinases: From basic science to cancer therapy. Science, 2022, 375, eabc1495.	12.6	142
1275	Thrombotic events in patients using cyclin dependent kinase 4/6 inhibitors, analysis of existing ambulatory risk assessment models and the potential influences of tumor specific risk factors. Current Problems in Cancer, 2022, 46, 100832.	2.0	2
1276	Medication adherence reporting in pivotal clinical trials: overview of oral oncological drugs. European Journal of Hospital Pharmacy, 2023, 30, 328-332.	1.1	4
1277	Subsequent-abemaciclib Treatment After Disease Progression on Palbociclib in Patients With ER-positive HER2-negative Metastatic Breast Cancer. Anticancer Research, 2022, 42, 1099-1106.	1.1	4
1278	Prioritising systemic cancer therapies applying ESMO's tools and other resources to assist in improving cancer care globally: the Kazakh experience. ESMO Open, 2022, 7, 100362.	4.5	8
1279	Systematic Review of Molecular Biomarkers Predictive of Resistance to CDK4/6 Inhibition in Metastatic Breast Cancer. JCO Precision Oncology, 2022, 6, e2100002.	3.0	36
1280	Eligibility Criteria Can Be Deceiving: How Direct and Indirect Exclusion Criteria Affects Recruitment of Under-Served Groups in Breast Cancer Trials. SSRN Electronic Journal, 0, , .	0.4	0
1281	Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03). Journal of Clinical Oncology, 2022, 40, 282-293.	1.6	88
1282	Biomarkers of everolimus efficacy in breast cancer therapy. Journal of Oncology Pharmacy Practice, 2022, , 107815522110736.	0.9	2
1283	Clinicopathological Features Related to the Efficacy of CDK4/6 Inhibitor-Based Treatments in Metastatic Breast Cancer. Breast Cancer: Basic and Clinical Research, 2022, 16, 117822342110651.	1.1	5
1284	Representation and Outcomes of Older Adults in Practice-Changing Oncology Trials in the Era of Novel Therapies: A Guideline Appraisal. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 37-44.	4.9	7
1286	Expert consensus to optimize the treatment of elderly patients with luminal metastatic breast cancer. Clinical and Translational Oncology, 2022, 24, 1033-1046.	2.4	5
1287	Exploiting the tumor-suppressive activity of the androgen receptor by CDK4/6 inhibition in castration-resistant prostate cancer. Molecular Therapy, 2022, 30, 1628-1644.	8.2	10
1288	Dicyanoanilines as potential and dual inhibitors of α-amylase and α-glucosidase enzymes: Synthesis, characterization, in vitro, in silico, and kinetics studies. Arabian Journal of Chemistry, 2022, 15, 103651.	4.9	14

#	Article	IF	CITATIONS
1289	Exploratory analysis of biomarkers associated with clinical outcomes from the study of palbociclib plus endocrine therapy in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer. Breast, 2022, 62, 52-60.	2.2	13
1290	Challenges and opportunities in metastatic breast cancer treatments: Nano-drug combinations delivered preferentially to metastatic cells may enhance therapeutic response. , 2022, 236, 108108.		25
1291	Palbociclib plus endocrine therapy significantly enhances overall survival of <scp>HR</scp> +/ <scp>HER2</scp> â'' metastatic breast cancer patients compared to endocrine therapy alone in the secondâ€line setting: A large institutional study. International Journal of Cancer, 2022, 150, 2025-2037.	5.1	16
1292	Treatment of locally recurrent and advanced breast cancer. Surgery, 2022, 40, 147-151.	0.3	0
1293	Reply to comments on: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients. ESMO Open, 2022, 7, 100381.	4.5	1
1294	CDK4/6 inhibitors: mechanisms of resistance and potential biomarkers of responsiveness in breast cancer. Future Oncology, 2022, 18, 1143-1157.	2.4	8
1295	Update Breast Cancer 2021 Part 5 – Advanced Breast Cancer. Geburtshilfe Und Frauenheilkunde, 2022, 82, 215-225.	1.8	6
1296	The Role of the CDK4/6 Inhibitor Ribociclib in Locally Advanced and Oligometastatic Hormone Receptor Positive, Her2 Negative, Advanced Breast Cancer: Case Series and Review of the Literature. Frontiers in Oncology, 2022, 12, 797157.	2.8	1
1297	Reply to: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients. ESMO Open, 2022, 7, 100393.	4.5	0
1298	Should Ki-67 be adopted to select breast cancer patients for treatment with adjuvant abemaciclib?. Annals of Oncology, 2022, 33, 234-238.	1.2	11
1299	Combination of Modern Radiotherapy and New Targeted Treatments for Breast Cancer Management. Cancers, 2021, 13, 6358.	3.7	8
1300	Systemic Therapies Following Progression on First-line CDK4/6-inhibitor Treatment: Analysis of Real-world Data. Oncologist, 2022, 27, 441-446.	3.7	10
1301	AMEERA-5: a randomized, double-blind phase 3 study of amcenestrant plus palbociclib <i>versus</i> letrozole plus palbociclib for previously untreated ER+/HER2– advanced breast cancer. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592210839.	3.2	16
1302	Breast cancer management in 2021: A primer for the obstetrics and gynecology. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2022, 82, 30-45.	2.8	18
1303	Real-World Treatment Patterns and Clinical Effectiveness of Palbociclib Plus an Aromatase Inhibitor as First-Line Therapy in Advanced/Metastatic Breast Cancer: Analysis from the US Syapse Learning Health Network. Current Oncology, 2022, 29, 1047-1061.	2.2	4
1304	A genome-scale CRISPR screen reveals PRMT1 as a critical regulator of androgen receptor signaling in prostate cancer. Cell Reports, 2022, 38, 110417.	6.4	17
1305	Biological Effects of Cyclin-Dependent Kinase Inhibitors Ribociclib, Palbociclib and Abemaciclib on Breast Cancer Bone Microenvironment. International Journal of Molecular Sciences, 2022, 23, 2477.	4.1	7
1306	PALVEN: phase lb trial of palbociclib, letrozole and venetoclax in estrogen receptor- and BCL2-positive advanced breast cancer. Future Oncology, 2022, 18, 1805-1816.	2.4	10

#	Article	IF	CITATIONS
1307	Clinicopathologic Features of Acute Kidney Injury Associated With CDK4/6 Inhibitors. Kidney International Reports, 2022, 7, 618-623.	0.8	16
1308	High Mutation Burden in ER-Positive/HER2-Negative/Luminal Breast Cancers. Journal of Clinical Medicine, 2022, 11, 1605.	2.4	2
1309	The Resistance of Cancer Cells to Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, is Mediated by the ABCB1 Transporter. Frontiers in Pharmacology, 2022, 13, 861642.	3.5	7
1310	Ribociclib efficacy in special populations and analysis of patient-reported outcomes in the MONALEESA trials. Expert Review of Anticancer Therapy, 2022, 22, 343-351.	2.4	6
1311	The Impact of Real-World Alternative Dosing Strategies of Palbociclib on Progression-Free Survival in Patients with Metastatic Breast Cancer. Current Oncology, 2022, 29, 1761-1772.	2.2	1
1312	Evolution of Molecular Targeted Cancer Therapy: Mechanisms of Drug Resistance and Novel Opportunities Identified by CRISPR-Cas9 Screening. Frontiers in Oncology, 2022, 12, 755053.	2.8	12
1313	Thromboembolic Events in Patients with HER2-Negative, Hormone Receptor-Positive, Metastatic Breast Cancer Treated with Ribociclib Combined with Letrozole or Fulvestrant: A Real-World Data. Cancer Management and Research, 2022, Volume 14, 1033-1041.	1.9	8
1314	Cyclin-Dependent Kinase 4/6 Inhibitor Outcomes in Patients With Advanced Breast Cancer Carrying Germline Pathogenic Variants in DNA Repair–Related Genes. JCO Precision Oncology, 2022, 6, e2100140.	3.0	14
1315	Therapeutic potential of CDK4/6 inhibitors in renal cell carcinoma. Nature Reviews Urology, 2022, 19, 305-320.	3.8	9
1316	2021 Update on Systemic Therapy for Breast Cancer. Healthbook TIMES Oncology Hematology, 2022, , .	0.1	0
1317	Expanding the Clinical Use of CDK4/6 Inhibitors in the Treatment of Hormone Receptor-Positive, HER2-Negative Breast Cancer from Metastatic Setting to Adjuvant Setting. Drug Design, Development and Therapy, 2022, Volume 16, 727-735.	4.3	2
1318	Underserved groups remain underserved as eligibility criteria routinely exclude them from breast cancer trials. Journal of Clinical Epidemiology, 2022, 147, 132-141.	5.0	5
1319	How to Treat HR+/HER2- Metastatic Breast Cancer Patients after CDK4/6 Inhibitors: An Unfinished Story. Life, 2022, 12, 378.	2.4	8
1320	Efficacy and safety of palbociclib plus endocrine therapy for patients with HR+/HER2â^ advanced breast cancer in real-world clinical practice. Annals of Translational Medicine, 2022, 10, 362-362.	1.7	5
1321	Real-world treatment patterns of palbociclib and blood count monitoring in patients with advanced breast cancer in Japan. Future Oncology, 2022, 18, 2101-2111.	2.4	3
1322	Review on the Synthesis and Therapeutic Potential of Pyrido[2,3-d], [3,2-d], [3,4-d] and [4,3-d]pyrimidine Derivatives. Pharmaceuticals, 2022, 15, 352.	3.8	10
1323	Feasibility of Adjuvant Treatment with Abemaciclib—Real-World Data from a Large German Breast Center. Journal of Personalized Medicine, 2022, 12, 382.	2.5	5
1324	Oral targeted therapy dose adaptation in older patients with cancer: A realâ€life French cohort. British Journal of Clinical Pharmacology, 2022, , .	2.4	0

			2
#		IF.	CITATIONS
1325	A phase II trial of an alternative schedule of palbociclib and embedded serum TK1 analysis. Npj Breast Cancer, 2022, 8, 35.	5.2	7
1326	Impact of lobular versus ductal histology on overall survival in metastatic breast cancer: a French retrospective multicentre cohort study. European Journal of Cancer, 2022, 164, 70-79.	2.8	14
1327	Targeting CDK4 and CDK6 in cancer. Nature Reviews Cancer, 2022, 22, 356-372.	28.4	125
1328	Toward Targeted Therapies in Oesophageal Cancers: An Overview. Cancers, 2022, 14, 1522.	3.7	3
1329	Phase Ib/II Dose Expansion Study of Lenvatinib Combined with Letrozole in Postmenopausal Women with Hormone Receptor–Positive Breast Cancer. Clinical Cancer Research, 2022, 28, 2248-2256.	7.0	3
1330	Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival. ESMO Open, 2022, 7, 100409.	4.5	25
1331	Effectiveness and Safety of Palbociclib plus Endocrine Therapy in Hormone Receptor– Positive, HER2-Negative Metastatic Breast Cancer: Real-World Results. Canadian Journal of Hospital Pharmacy, 2022, 75, 26-33.	0.1	5
1332	A Review of the Recent Developments of Molecular Hybrids Targeting Tubulin Polymerization. International Journal of Molecular Sciences, 2022, 23, 4001.	4.1	18
1333	Cyclin-Dependent Kinase 4 and 6 Inhibitors: A Quantum Leap in the Treatment of Advanced Breast Cancers. Cureus, 2022, 14, e23901.	0.5	1
1334	Palbociclib regulates intracellular lipids in mammary tumor cells by secreting lipoprotein lipase. Pharmacological Reports, 2022, , .	3.3	0
1335	Interstitial lung disease in patients treated with Cyclin-Dependent Kinase 4/6 inhibitors: A systematic review and meta-analysis of randomized controlled trials. Breast, 2022, 62, 162-169.	2.2	16
1336	Association between age at initial diagnosis and post-metastasis mortality among women with recurrent metastatic breast cancer in China. BMC Cancer, 2022, 22, 385.	2.6	10
1337	Low social and family well-being is associated with greater RAGE ligand s100A8/A9 and interleukin-1 beta levels in metastatic breast cancer patients. Brain, Behavior, & Immunity - Health, 2022, 21, 100433.	2.5	3
1338	Palbociclib and letrozole in hormone-receptor positive advanced breast cancer: Predictive response and prognostic factors. Current Problems in Cancer, 2022, 46, 100859.	2.0	6
1339	Palbociclib in combination with sunitinib exerts a synergistic anti-cancer effect in patient-derived xenograft models of various human cancers types. Cancer Letters, 2022, 536, 215665.	7.2	1
1340	Pfizer and Palbociclib in China: Analyzing an Oncology Pay-for-Performance Plan. Value in Health Regional Issues, 2022, 31, 34-38.	1.2	2
1341	Neuroendocrine Neoplasms of the Breast: The Latest WHO Classification and Review of the Literature. Cancers, 2022, 14, 196.	3.7	4
1342	A murine mesenchymal stem cell model for initiating events in osteosarcomagenesis points to CDK4/CDK6 inhibition as a therapeutic target. Laboratory Investigation, 2022, 102, 391-400.	3.7	5
#	Article	IF	CITATIONS
------	---	-----	-----------
1343	Molecular features evaluation of metastatic foci as the basis for metastatic breast cancer treatment personalization. Is there a place of CDK4/6-inhibitors in late-line therapy after chemotherapeutic regimens?. Meditsinskiy Sovet, 2021, , 54-61.	0.5	0
1344	Palbociclib plus letrozole as treatment for postmenopausal women with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer for whom letrozole therapy is deemed appropriate: An expanded access study in Australia and India. Asia-Pacific Iournal of Clinical Oncology, 2021	1.1	2
1345	Integrating CDK4/6 inhibitors in the treatment of patients with early breast cancer. Breast, 2022, 62, S70-S79.	2.2	10
1346	Clinical case of the treatment of metastatic luminal breast cancer. Meditsinskiy Sovet, 2021, , 160-166.	0.5	0
1347	Comparison of Anticancer Drug Toxicities: Paradigm Shift in Adverse Effect Profile. Life, 2022, 12, 48.	2.4	49
1348	RB depletion is required for the continuous growth of tumors initiated by loss of RB. PLoS Genetics, 2021, 17, e1009941.	3.5	6
1349	Unilateral lowerâ€limb vasculopathy: A rare adverse event of <scp>CDK4</scp> /6 inhibitor in breast cancer. Kaohsiung Journal of Medical Sciences, 2022, 38, 494-495.	1.9	1
1350	Tucatinib has Selective Activity in HER2-Positive Cancers and Significant Combined Activity with Approved and Novel Breast Cancer–Targeted Therapies. Molecular Cancer Therapeutics, 2022, 21, 751-761.	4.1	10
1351	Analysis of a Real-World Progression Variable and Related Endpoints for Patients with Five Different Cancer Types. Advances in Therapy, 2022, 39, 2831-2849.	2.9	5
1353	Evaluation of Information Theoretic Network Meta-analysis to Rank First-Line Anticancer Regimens for Hormone Receptor–Positive, <i>ERBB2</i> -Negative Metastatic Breast Cancer. JAMA Network Open, 2022, 5, e224361.	5.9	2
1354	Navigating Systemic Therapeutic Options for First-Line Metastatic Hormone Receptor–Positive, <i>ERBB2</i> -Negative Breast Cancer Treatment. JAMA Network Open, 2022, 5, e224380.	5.9	0
1355	Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study. European Journal of Cancer, 2022, 168, 12-24.	2.8	9
1356	Cost-Utility of the CDK 4/6 Inhibitors for Postmenopausal Women With Luminal Advanced Breast Cancer in Brazil. Value in Health Regional Issues, 2022, 31, 47-52.	1.2	1
1361	Treatment patterns, effectiveness, and patientâ€reported outcomes of palbociclib therapy in Chinese patients with advanced breast cancer: A multicenter ambispective realâ€world study. Cancer Medicine, 2022, , .	2.8	3
1362	Functional Genomic Analysis of <i>CDK4</i> and <i>CDK6</i> Gene Dependency across Human Cancer Cell Lines. Cancer Research, 2022, 82, 2171-2184.	0.9	12
1363	Natural History and Characteristics of <i>ERBB2</i> -mutated Hormone Receptor–positive Metastatic Breast Cancer: A Multi-institutional Retrospective Case–control Study from AACR Project GENIE. Clinical Cancer Research, 2022, 28, 2118-2130.	7.0	3
1365	Real-world treatment patterns and clinical outcomes in patients receiving palbociclib combinations for HR+/HER2– advanced/metastatic breast cancer in Japan: Results from the IRIS study. Cancer Treatment and Research Communications, 2022, 32, 100573.	1.7	5
1367	Real world incidence and management of adverse events in patients with HR+, HER2â^ metastatic breast cancer receiving CDK4 and 6 inhibitors in a United States community setting. Current Medical Research and Opinion, 2022, 38, 1319-1331.	1.9	9

#	Article	IF	CITATIONS
1368	Proton pump inhibitors may reduce the efficacy of ribociclib and palbociclib in metastatic breast cancer patients based on an observational study. BMC Cancer, 2022, 22, 516.	2.6	11
1369	Real-World Treatment Patterns and Outcomes of Palbociclib Plus an Aromatase Inhibitor for Metastatic Breast Cancer: Flatiron Database Analysis. Clinical Breast Cancer, 2022, 22, 601-610.	2.4	10
1371	Ribociclib plus letrozole in patients with hormone receptor-positive, HER2-negative advanced breast cancer with no prior endocrine therapy: subgroup safety analysis from the phase 3b CompLEEment-1 trial. Radiology and Oncology, 2022, 56, 238-247.	1.7	3
1372	Oncological Treatment-Related Fatigue in Oncogeriatrics: A Scoping Review. Cancers, 2022, 14, 2470.	3.7	4
1373	Everolimus Added to Adjuvant Endocrine Therapy in Patients With High-Risk Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Primary Breast Cancer. Journal of Clinical Oncology, 2022, 40, 3699-3708.	1.6	11
1374	Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer. Annals of Oncology, 2022, 33, 769-785.	1.2	37
1375	Integrating radiation therapy with targeted treatments for breast cancer: From bench to bedside. Cancer Treatment Reviews, 2022, 108, 102417.	7.7	11
1376	The History of Early Breast Cancer Treatment. Genes, 2022, 13, 960.	2.4	16
1377	Racial disparities in neutrophil counts among patients with metastatic breast cancer during treatment with CDK4/6 inhibitors. Breast Cancer Research and Treatment, 2022, 194, 337-351.	2.5	4
1378	Cyclin-dependent kinase 4/6 inhibitor treatment use in women treated for advanced breast cancer: Integrating ASCO/NCODA patient-centered standards in a community pharmacy. Journal of Oncology Pharmacy Practice, 2023, 29, 1144-1153.	0.9	4
1379	CDK4/6 Inhibitors in Combination Therapies: Better in Company Than Alone: A Mini Review. Frontiers in Oncology, 0, 12, .	2.8	14
1380	Contemporary breast cancer treatment-associated thrombosis. Thrombosis Research, 2022, 213, S8-S15.	1.7	2
1381	Fucoxanthin Is a Potential Therapeutic Agent for the Treatment of Breast Cancer. Marine Drugs, 2022, 20, 370.	4.6	12
1382	Combination of palbociclib with adjuvant endocrine therapy for treatment of hormone receptorâ€positive and human epidermal growth factor receptor 2â€negative metastatic breast cancer: An experience at two cancer centers in Saudi Arabia. Molecular and Clinical Oncology, 2022, 17, .	1.0	Ο
1384	β‑catenin blockers enhance the effect of CDK4/6 inhibitors on stemness and proliferation suppression in endocrine‑resistant breast cancer cells. Oncology Reports, 2022, 48, .	2.6	2
1385	Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. New England Journal of Medicine, 2022, 387, 9-20.	27.0	854
1386	Transcriptional coactivator MED1 in the interface of anti-estrogen and anti-HER2 therapeutic resistance. Cancer Drug Resistance (Alhambra, Calif ), 2022, 5, 498-510.	2.1	1
1387	Liquid biopsies to predict CDK4/6 inhibitor efficacy and resistance in breast cancer. Cancer Drug Resistance (Alhambra, Calif ), 2022, 5, 727-48.	2.1	3

		15	6
#	ARTICLE The Combination of the CDK4/6 Inhibitor, Palbociclib, With the Vitamin D3 Analog, Inecalcitol, Has	IF	CITATIONS
1389	Potent In Vitro and In Vivo Anticancer Effects in Hormone-Sensitive Breast Cancer, But Has a More Limited Effect in Triple-Negative Breast Cancer. Frontiers in Endocrinology, 0, 13, .	3.5	3
1390	<i>InÂvivo</i> visualization of fluorescence reflecting CDK4 activity in a breast cancer mouse model. MedComm, 2022, 3, .	7.2	1
1391	Optimizing hormone therapy for breast cancer: Translating gains to the early-stage setting. Cell Reports Medicine, 2022, 3, 100664.	6.5	1
1392	Three-Year Progression-Free Survival of Metastatic Breast Cancer Treated With the Palbociclib and Letrozole Combination. American Journal of Therapeutics, 0, Publish Ahead of Print, .	0.9	0
1393	Liver Metastatic Breast Cancer: Epidemiology, Dietary Interventions, and Related Metabolism. Nutrients, 2022, 14, 2376.	4.1	7
1394	Exploring new pathways in endocrine-resistant breast cancer. Exploration of Targeted Anti-tumor Therapy, 0, , 337-361.	0.8	2
1395	Breast Cancer Metastasis: Mechanisms and Therapeutic Implications. International Journal of Molecular Sciences, 2022, 23, 6806.	4.1	74
1396	Breast Cancer Epidemiology and Contemporary Breast Cancer Care: A Review of the Literature and Clinical Applications. Clinical Obstetrics and Gynecology, 2022, 65, 461-481.	1.1	6
1397	Population Pharmacokinetics of Palbociclib and Its Correlation with Clinical Efficacy and Safety in Patients with Advanced Breast Cancer. Pharmaceutics, 2022, 14, 1317.	4.5	3
1398	Genomic Aberrations in Circulating Tumor DNAs from Palbociclib-Treated Metastatic Breast Cancer Patients Reveal a Novel Resistance Mechanism. Cancers, 2022, 14, 2872.	3.7	1
1399	Efficacy, safety and toxicity management of adjuvant abemaciclib in early stage HR+/HER2- high-risk breast cancer. Expert Review of Anticancer Therapy, 2022, 22, 805-814.	2.4	2
1400	Targeting Cell Cycle Progression in HER2+ Breast Cancer: An Emerging Treatment Opportunity. International Journal of Molecular Sciences, 2022, 23, 6547.	4.1	11
1401	Occurrence and characteristics of patients with de novo advanced breast cancer according to patient and tumor characteristics $\hat{a} \in $ " A retrospective analysis of a real world registry. European Journal of Cancer, 2022, 172, 13-21.	2.8	1
1402	Systemic Treatment of Breast Cancer. 1st Central-Eastern European Professional Consensus Statement on Breast Cancer. Pathology and Oncology Research, 0, 28, .	1.9	12
1404	Genomic Markers of CDK 4/6 Inhibitor Resistance in Hormone Receptor Positive Metastatic Breast Cancer. Cancers, 2022, 14, 3159.	3.7	5
1405	Role of Intrinsic Subtype Analysis with PAM50 in Hormone Receptors Positive HER2 Negative Metastatic Breast Cancer: A Systematic Review. International Journal of Molecular Sciences, 2022, 23, 7079.	4.1	4
1406	Biomarkers for Cyclin-Dependent Kinase 4/6 Inhibitors in the Treatment of Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced/Metastatic Breast Cancer: Translation to Clinical Practice. JCO Precision Oncology, 2022, , .	3.0	4
1407	Venous and arterial thrombosis associated with abemaciclib therapy for metastatic breast cancer. Cancer, 2022, 128, 3224-3232.	4.1	12

#	Article	IF	CITATIONS
1408	The role of epigenetic modifications in drug resistance and treatment of breast cancer. Cellular and Molecular Biology Letters, 2022, 27, .	7.0	36
1409	Recent Advances in Adjuvant Endocrine Therapy in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer. Journal of Clinical Oncology, 0, , .	1.6	0
1410	Appraising Adjuvant Endocrine Therapy in Hormone Receptor Positive HER2-Negative Breast Cancer—A Literature Review. Current Oncology, 2022, 29, 4956-4969.	2.2	3
1411	nextMONARCH Phase 2 randomized clinical trial: overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with endocrine-refractory HR + , HER2– metastatic breast cancer. Breast Cancer Research and Treatment, 2022, 195, 55-64.	2.5	3
1413	The oligometastatic spectrum in the era of improved detection and modern systemic therapy. Nature Reviews Clinical Oncology, 2022, 19, 585-599.	27.6	39
1414	Targeted Therapeutic Options and Future Perspectives for HER2-Positive Breast Cancer. Cancers, 2022, 14, 3305.	3.7	11
1415	Current treatment aspects of hormone-dependent ERBB2-negative metastatic breast cancer: overall survival outcomes. Journal of Modern Oncology, 2022, 24, 226-233.	0.3	0
1416	Palbociclib regulates the expression of dihydrofolate reductase and the cell cycle to inhibit t (11;14) multiple myeloma. Annals of Translational Medicine, 2022, 10, 746-746.	1.7	2
1417	Cyclin-dependent kinase inhibition and its intersection with immunotherapy in breast cancer: more than CDK4/6 inhibition. Expert Opinion on Investigational Drugs, 2022, 31, 933-944.	4.1	0
1418	Current State of Cell Therapies for Breast Cancer. Cancer Journal (Sudbury, Mass ), 2022, 28, 301-309.	2.0	5
1419	The origins of resident macrophages in mammary gland influence the tumorigenesis of breast cancer. International Immunopharmacology, 2022, 110, 109047.	3.8	8
1420	Structure-guided design and development of cyclin-dependent kinase 4/6 inhibitors: A review on therapeutic implications. International Journal of Biological Macromolecules, 2022, 218, 394-408.	7.5	13
1421	A multicentre study with real-world data of the use of palbociclib in the treatment of breast cancer: Treatment duration correlates with dose reductions. Journal of Oncology Pharmacy Practice, 2023, 29, 1806-1815.	0.9	2
1422	Comparison of endocrine therapy and chemotherapy as different systemic treatment modes for metastatic luminal HER2-negative breast cancer patients $\hat{a} \in A$ retrospective study. Frontiers in Oncology, 0, 12, .	2.8	2
1423	Development of Potent ERÎ $\pm$ Inhibitors: Effectively Inhibit the Growth of Breast Cancer Cells. ChemistrySelect, 2022, 7, .	1.5	1
1424	Everolimus for Treating Hormone Receptor-positive Metastatic Breast Cancer Previously Treated With Cyclin-dependent Kinase 4/6 Inhibitors. Anticancer Research, 2022, 42, 3913-3919.	1.1	4
1425	Expression patterns and therapeutic implications of CDK4 across multiple carcinomas: a molecular docking and MD simulation study. , 2022, 39, .		27
1426	Radiation Therapy With Cyclin-Dependent Kinase 4/6 Inhibitors: A Multi-institutional Safety and Toxicity Study. International Journal of Radiation Oncology Biology Physics, 2022, 114, 399-408.	0.8	11

#	Article	IF	Citations
1427	CDK 4/6 inhibitors for the treatment of meningioma. Frontiers in Oncology, 0, 12, .	2.8	9
1428	CCND1 Copy Number Variation in Circulating Tumor DNA from Luminal B Breast Cancer Patients. Anticancer Research, 2022, 42, 4071-4077.	1.1	5
1429	Clinical subtype, treatment response, and survival in De Novo and recurrent metastatic breast cancer. Breast Cancer Research and Treatment, 2022, 196, 153-162.	2.5	8
1430	Targeted Approaches to HER2-Low Breast Cancer: Current Practice and Future Directions. Cancers, 2022, 14, 3774.	3.7	10
1431	Work productivity among patients with metastatic breast cancer in the United States. Expert Review of Pharmacoeconomics and Outcomes Research, 0, , 1-9.	1.4	0
1432	Real world evidence study on treatment patterns and health resource utilization in patients with HR+/HER2- locally advanced or metastatic breast cancer in Korea. Journal of Drug Assessment, 2022, 11, 12-19.	2.2	2
1433	Regional Variations in Clinical Trial Outcomes in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 879-886.e2.	4.9	2
1434	Regression of choroidal metastasis from breast carcinoma with palbociclib. International Journal of Retina and Vitreous, 2022, 8, .	1.9	2
1435	Severe acute radiation dermatitis after palbociclib therapy in the setting of palliative radiotherapy. Journal of Oncology Pharmacy Practice, 2023, 29, 764-767.	0.9	0
1436	Shaky OS results of palbociclib in ER-positive/HER2-negative breast cancerÂ. , 0, , .		0
1437	Improved prediction of gene expression through integrating cell signalling models with machine learning. BMC Bioinformatics, 2022, 23, .	2.6	1
1438	2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). European Heart Journal Cardiovascular Imaging, 2022, 23 e333-e465	1.2	97
1439	Comparative biomarker analysis of PALOMA-2/3 trials for palbociclib. Npj Precision Oncology, 2022, 6, .	5.4	9
1440	Treatment patterns and clinical outcomes in patients with metastatic breast cancer treated with palbociclib-based therapies: real-world data in the Han population. Chinese Medical Journal, 0, Publish Ahead of Print, .	2.3	1
1441	Prospective Cohort Study of Combination Therapy With Abemaciclib and Hormonal Therapy for Chemotherapy-Treated Patients With Hormone Receptor-Positive Metastatic Breast Cancer. World Journal of Oncology, 2022, 13, 216-221.	1.5	2
1442	Targeting CDK4 and 6 in Cancer Therapy: Emerging Preclinical Insights Related to Abemaciclib. Oncologist, 0, , .	3.7	11
1443	Phase I trial of ribociclib with platinum chemotherapy in ovarian cancer. JCI Insight, 2022, 7, .	5.0	6
1444	TROP2 (trophoblast cell-surface antigen 2): a drug target for breast cancer. Expert Opinion on Therapeutic Targets, 2022, 26, 593-602.	3.4	6

#	Article	IF	CITATIONS
1445	2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). European Heart Journal, 2022, 43, 4229-4361.	2.2	705
1446	CDK4/6 inhibitors versus PI3K/AKT/mTOR inhibitors in women with hormone receptor-positive, HER2-negative metastatic breast cancer: An updated systematic review and network meta-analysis of 28 randomized controlled trials. Frontiers in Oncology, 0, 12, .	2.8	3
1447	Prospective Cohort Study of Palbociclib Treatment in Postmenopausal Patients With Unresectable and Metastatic Hormone Receptor-Positive Breast Cancer: Study Protocol for a CSPOR-BC Palbociclib Cohort Trial. World Journal of Oncology, 2022, 13, 190-194.	1.5	3
1448	Racial disparities in breast cancer preclinical and clinical models. Breast Cancer Research, 2022, 24, .	5.0	5
1449	CDK4/6 inhibitors downregulate the ubiquitin-conjugating enzymes UBE2C/S/T involved in the ubiquitin–proteasome pathway in ER + breast cancer. Clinical and Translational Oncology, 2022, 24, 2120-2135.	2.4	5
1450	Predictive biomarkers for molecularly targeted therapies and immunotherapies in breast cancer. Archives of Pharmacal Research, 2022, 45, 597-617.	6.3	6
1451	Targeted therapy for breast cancer: An overview of drug classes and outcomes. Biochemical Pharmacology, 2022, 204, 115209.	4.4	38
1452	Efficacy of taxanes rechallenge in first-line treatment of early metastatic relapse of patients with HER2-negative breast cancer previously treated with a (neo)adjuvant taxanes regimen: A multicentre retrospective observational study. Breast, 2022, 65, 136-144.	2.2	2
1453	Identification of estrogen receptor down-regulators for endocrine resistant breast cancer. Journal of Steroid Biochemistry and Molecular Biology, 2022, 224, 106162.	2.5	3
1454	Resistance to CDK4/6 inhibition: Mechanisms and strategies to overcome a therapeutic problem in the treatment of hormone receptor-positive metastatic breast cancer. Biochimica Et Biophysica Acta - Molecular Cell Research, 2022, 1869, 119346.	4.1	13
1455	Clinico-Immunological Effects of a Single-Agent CDK4/6 Inhibitor in Advanced HR+/HER2â^' Breast Cancer Based on a Window of Opportunity Study. Current Issues in Molecular Biology, 2022, 44, 4255-4267.	2.4	0
1456	Controversial topics in metastatic HR+/HER2- breast cancer: Guiding treatment by a modified Delphi approach. Frontiers in Oncology, 0, 12, .	2.8	0
1457	Pre-operative ribociclib plus letrozole versus chemotherapy: Health-related quality of life outcomes from the SOLTI CORALLEEN trial. European Journal of Cancer, 2022, 174, 232-242.	2.8	3
1458	Palbociclib plus letrozole versus placebo plus letrozole in Asian postmenopausal women with oestrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer: Primary results from PALOMA-4. European Journal of Cancer, 2022, 175, 236-245.	2.8	16
1459	Molecular alterations in anti-apoptotic BCL2 family proteins in breast cancer cell line models, drug sensitivities and dependencies to guide the development of BCL2 inhibitors. Gene, 2022, 847, 146881.	2.2	2
1460	Cell Division/Death: Cell Cycle – Cyclins, Cyclin-Dependent Kinases, and Cyclin-Dependent Kinase Inhibitors. , 2022, , .		0
1461	Time to Chemotherapy for Patients With Estrogen Receptor-Positive Breast Cancer and Cyclin-Dependent Kinase 4 and 6 Inhibitor Use. Journal of Breast Cancer, 2022, 25, 296.	1.9	1
1462	Pd-Catalyzed regio- and stereoselective allylic substitution of vinylethylene carbonates with 1,2,4-triazoles. Organic and Biomolecular Chemistry, 2022, 20, 6532-6536.	2.8	4

#	Article	IF	CITATIONS
1463	Next-generation selective estrogen receptor degraders and other novel endocrine therapies for management of metastatic hormone receptor-positive breast cancer: current and emerging role. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592211136.	3.2	34
1464	Stealth Liposomal Chemotherapeutic Agent for Triple Negative Breast Cancer with Improved Pharmacokinetics. Nanotheranostics, 2022, 6, 424-435.	5.2	7
1465	Estrogen Receptor Alpha and ESR1 Mutations in Breast Cancer. Advances in Experimental Medicine and Biology, 2022, , 171-194.	1.6	2
1466	Clinical management of metastatic hormone receptor-positive, HER2-negative breast cancer (MBC) after CDK 4/6 inhibitors: a retrospective single-institution study. Breast Cancer Research and Treatment, 2022, 196, 229-237.	2.5	3
1467	Prognostic Significance of Low HER2 Expression in Patients With Metastatic Hormone Receptor-positive Breast Cancer Treated With First Line CDK4/6 Inhibitors: A Greek Multicenter Real-world Data Analysis. Cancer Diagnosis & Prognosis, 2022, 2, 585-591.	0.7	7
1468	Effect of Bevacizumab on a Human Breast Cancer Model that Exhibited Palbociclib-resistance by RB Knockout. Cancer Diagnosis & Prognosis, 2022, 2, 533-541.	0.7	3
1469	The Molecular Predictive and Prognostic Biomarkers in Metastatic Breast Cancer: The Contribution of Molecular Profiling. Cancers, 2022, 14, 4203.	3.7	5
1470	Endocrine therapy resistance: what we know and future directions. Exploration of Targeted Anti-tumor Therapy, 0, , 480-496.	0.8	5
1471	S6K1 amplification confers innate resistance to CDK4/6 inhibitors through activating c-Myc pathway in patients with estrogen receptor-positive breast cancer. Molecular Cancer, 2022, 21, .	19.2	13
1472	Clinical trial design in the era of precision medicine. Genome Medicine, 2022, 14, .	8.2	68
1473	Treatment of HR+/HER2â^' breast cancer in urban mainland China: results from the CancerMPact Survey 2019. Breast Cancer Research and Treatment, 2022, 195, 441-451.	2.5	2
1475	Safety and Efficacy of Ribociclib in Combination with Letrozole in Patients with HR+, HER2â^ Advanced Breast Cancer: Results from the Italian Subpopulation of Phase 3b CompLEEment-1 Study. Targeted Oncology, 0, , .	3.6	1
1476	Can EGFR be a therapeutic target in breast cancer?. Biochimica Et Biophysica Acta: Reviews on Cancer, 2022, 1877, 188789.	7.4	14
1477	Real-World Patient Characteristics, Utilization Patterns, and Outcomes of US Patients with HR+, HER2â^' Metastatic Breast Cancer Treated with Abemaciclib. Drugs - Real World Outcomes, 2022, 9, 681-693.	1.6	4
1478	<scp>PFKFB4</scp> facilitates palbociclib resistance in oestrogen receptorâ€positive breast cancer by enhancing stemness. Cell Proliferation, 2023, 56, .	5.3	5
1479	A Phase II, Two-Stage Study of Letrozole and Abemaciclib in Estrogen Receptor–Positive Recurrent Endometrial Cancer. Journal of Clinical Oncology, 2023, 41, 599-608.	1.6	21
1480	High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer. Nature Communications, 2022, 13, .	12.8	32
1482	Do body composition parameters correlate with response to targeted therapy in ER+/HER2- metastatic breast cancer patients? Role of sarcopenia and obesity. Frontiers in Oncology, 0, 12, .	2.8	3

#	Article	IF	CITATIONS
1484	Prognostic role of tumor subtype and germline BRCA mutation in advanced breast cancer patients treated with palbociclib plus endocrine therapy. Breast Cancer Research and Treatment, 2022, 196, 121-128.	2.5	2
1485	Efficacy of cyclin-dependent kinase 4/6 inhibitors in patients with metastatic hormone positive breast cancer: a single institutional study from India. Ecancermedicalscience, 0, 16, .	1.1	2
1486	Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncology, The, 2022, 23, 1367-1377.	10.7	92
1487	Development and validation of a reversedâ€phase highâ€performance liquid chromatography–ultraviolet method for abemaciclibâ€related substance detection in bulk drugs. Journal of Separation Science, 0, , .	2.5	0
1488	Mechanisms of Resistance to CDK4/6 Inhibitors in Hormone Receptor-Positive (HR +) Breast Cancer: Spotlight on Convergent CDK6 Upregulation and Immune Signaling. Current Breast Cancer Reports, 0, , .	1.0	0
1489	Oncologists' Perspectives on Individualizing Dose Selection for Patients With Metastatic Cancer. JCO Oncology Practice, 2022, 18, e1807-e1817.	2.9	7
1490	Phase II Study Combining Pembrolizumab with Aromatase Inhibitor in Patients with Metastatic Hormone Receptor Positive Breast Cancer. Cancers, 2022, 14, 4279.	3.7	2
1491	Patient-centered dosing: oncologists' perspectives about treatment-related side effects and individualized dosing for patients with metastatic breast cancer (MBC). Breast Cancer Research and Treatment, 2022, 196, 549-563.	2.5	3
1492	Endothelial cell cycle state determines propensity for arterial-venous fate. Nature Communications, 2022, 13, .	12.8	22
1493	Clinical outcomes of cyclin-dependent kinase 4–6 (CDK 4–6) inhibitors in patients with male breast cancer: A multicenter study. Breast, 2022, 66, 85-88.	2.2	4
1494	Risk factors associated with palbociclib-induced neutropenia in patients with metastatic breast cancer. Supportive Care in Cancer, 2022, 30, 9803-9809.	2.2	4
1495	Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2â^' metastatic breast cancer. Npj Breast Cancer, 2022, 8, .	5.2	35
1496	Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. Journal of Hematology and Oncology, 2022, 15, .	17.0	59
1497	Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial. Oncologist, 2023, 28, 23-32.	3.7	6
1498	Consequences of Discontinuing a 4/6 Cyclin D-Dependent Kinase Inhibitor During Endocrine Treatment in Hormone-Sensitive Metastatic Breast Cancer Patients in the Context of the COVID-19 Outbreak. Clinical Breast Cancer, 2023, 23, 32-37.	2.4	0
1500	HER2-Low Status Does Not Affect Survival Outcomes of Patients with Metastatic Breast Cancer (MBC) Undergoing First-Line Treatment with Endocrine Therapy plus Palbociclib: Results of a Multicenter, Retrospective Cohort Study. Cancers, 2022, 14, 4981.	3.7	14
1501	Small molecule inhibitors targeting the cancers. MedComm, 2022, 3, .	7.2	25
1502	Safety of CDK4/6 inhibitors and concomitant radiation therapy in patients affected by metastatic breast cancer. Radiotherapy and Oncology, 2022, , .	0.6	5

#	Article	IF	CITATIONS
1504	Molecular Mechanisms of Anti-Estrogen Therapy Resistance and Novel Targeted Therapies. Cancers, 2022, 14, 5206.	3.7	14
1506	Optimizing CDK4/6 inhibitors in advanced HR+/HER2- breast cancer: A personalized approach. Critical Reviews in Oncology/Hematology, 2022, 180, 103848.	4.4	4
1507	The Renaissance of CDK Inhibitors in Breast Cancer Therapy: An Update on Clinical Trials and Therapy Resistance. Cancers, 2022, 14, 5388.	3.7	10
1508	Systemic treatment for hormone receptor-positive/HER2-negative advanced/metastatic breast cancer: A review of European real-world evidence studies. Critical Reviews in Oncology/Hematology, 2022, 180, 103866.	4.4	2
1509	Molecular targets for the treatment of AML in the forthcoming 5th World Health Organization Classification of Haematolymphoid Tumours. Expert Review of Hematology, 2022, 15, 973-986.	2.2	1
1510	Clinical outcomes of tucidinostat-based therapy after prior CDK4/6 inhibitor progression in hormone receptor-positive heavily pretreated metastatic breast cancer. Breast, 2022, 66, 255-261.	2.2	5
1511	Concomitant administration of proton pump inhibitors does not significantly affect clinical outcomes in metastatic breast cancer patients treated with ribociclib. Breast, 2022, 66, 157-161.	2.2	4
1512	The Combination of CDK 4/6 Inhibitors plus Endocrine Treatment versus Endocrine Treatment Alone in Hormone-receptor (HR)-Positive breast Cancer: a Systematic Review and Meta-analysis. Medicinski Arhiv = Medical Archives = Archives De Médecine, 2022, 76, 333.	0.9	1
1513	PKMYT1 inhibits lung adenocarcinoma progression by abrogating AKT1 activity. Cellular Oncology (Dordrecht), 2023, 46, 195-209.	4.4	2
1514	Realâ€world data for the renal safety of abemaciclib combined with bisphosphonate in <scp>HR</scp> +/ <scp>HER2</scp> â' advanced breast cancer. Thoracic Cancer, 2023, 14, 68-72.	1.9	2
1515	Effectiveness research in oncology with electronic health record data: A retrospective cohort study emulating the <scp>PALOMA</scp> â€2 trial. Pharmacoepidemiology and Drug Safety, 0, , .	1.9	0
1516	Effect of palbociclib plus endocrine therapy on time to chemotherapy across subgroups of patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer: Post hoc analyses from PALOMA-2 and PALOMA-3. Breast, 2022, 66, 324-331.	2.2	1
1518	Rapid Capillary Electrophoresis Method for Simultaneous Determination of Abemaciclib, Ribociclib, and Palbociclib in Pharmaceutical Dosage Forms: A Green Approach. Molecules, 2022, 27, 7603.	3.8	5
1519	Discovery, Optimization, and Evaluation of Selective CDK4/6 Inhibitors for the Treatment of Breast Cancer. Journal of Medicinal Chemistry, 2022, 65, 15102-15122.	6.4	5
1521	Impact of the latest clinical data among patients with breast cancer in low- and middle-income countries. Breast Care, 0, , .	1.4	0
1522	Combined immunotherapy for metastatic triple-negative breast cancer based on PD-1/PD-L1 immune checkpoint blocking. International Immunopharmacology, 2022, 113, 109444.	3.8	6
1523	Health-related quality of life in breast cancer patients treated with CDK4/6 inhibitors: a systematic review. ESMO Open, 2022, 7, 100629.	4.5	8
1524	Targeting cell cycle and apoptosis to overcome chemotherapy resistance in acute myeloid leukemia. Leukemia, 2023, 37, 143-153.	7.2	12

#	Article	IF	CITATIONS
1525	Real-world outcomes from use of CDK4/6 inhibitors in the management of advanced/metastatic breast cancer in Asia. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592211396.	3.2	1
1526	Trilaciclib: A First-in-class Therapy to Reduce Chemotherapy-induced Myelosuppression. Touch Reviews in Oncology & Haematology, 2022, 18, 152.	0.2	1
1527	Clinical implications of the intrinsic molecular subtypes in hormone receptor-positive and HER2-negative metastatic breast cancer. Cancer Treatment Reviews, 2023, 112, 102496.	7.7	18
1528	Transcription-associated cyclin-dependent kinase 12 (CDK12) as a potential target for cancer therapy. Biochimica Et Biophysica Acta: Reviews on Cancer, 2023, 1878, 188842.	7.4	4
1529	Engineering nanoparticle communication in living systems by stigmergy: An application to enhance antitumor therapy in triple-negative breast cancer. Nano Today, 2023, 48, 101692.	11.9	9
1530	Haematopoietic cytopenia associated with cyclin-dependent kinase 4/6 inhibitors: A real-world study of data from the food and drug administration adverse event reporting system database. International Journal of Immunopathology and Pharmacology, 2022, 36, 039463202211455.	2.1	1
1531	Circulating tumor DNA profile and its clinical significance in patients with hormone receptor-positive and HER2-negative mBC. Frontiers in Endocrinology, 0, 13, .	3.5	0
1532	Antitumor response and quality of life: is there a need to sacrifice? Clinical observation: long-term and safe control of the disease using a combination of ribociclib with letrozole. Case report. Journal of Modern Oncology, 2022, 24, 373-379.	0.3	0
1533	Crystal structure of active CDK4-cyclin D and mechanistic basis for abemaciclib efficacy. Npj Breast Cancer, 2022, 8, .	5.2	6
1534	Liver metastasis in estrogen receptor-positive HER 2-negative breast cancer. Ribociclib as prognosis-changing therapy. Medical Alphabet, 2022, , 13-19.	0.2	0
1535	Use of Anticancer Therapies and Economic Burden Near the End of Life in Japan: Results From Claims Database. JCO Global Oncology, 2022, , .	1.8	1
1536	PERFORM: a non-interventional study assessing the patients' treatment starting with 1L palbociclib in HR+/HER2- ABC. Future Oncology, 2022, 18, 3971-3982.	2.4	1
1537	Brazilian breast cancer patient-reported outcomes: What really matters for these women. Frontiers in Medical Technology, 0, 4, .	2.5	1
1538	Racial disparities in overall survival after the introduction of cyclin-dependent kinase 4/6 inhibitors for patients with hormone receptor-positive, HER2-negative metastatic breast cancer. Breast Cancer Research and Treatment, 2023, 198, 75-88.	2.5	5
1539	Case report: 18F-FES PET/CT predicted treatment responses of second-line and third-line CDK4/6 inhibitors after disease progression on first-line CDK4/6 inhibitor in a HR+/HER2- metastatic breast cancer patient. Frontiers in Oncology, 0, 12, .	2.8	1
1540	Real clinical practice patterns of palbociclib usage in Russian Federation. Meditsinskiy Sovet, 2022, , 30-35.	0.5	0
1541	Loco-Regional Treatment of the Primary Tumor in De Novo Metastatic Breast Cancer Patients Undergoing Front-Line Chemotherapy. Cancers, 2022, 14, 6237.	3.7	2
1542	Endocrine Therapy-Based Strategies for Metastatic Breast Cancer with Different Endocrine Sensitivity Statuses: A Systematic Review and Network Meta-Analysis. Cancers, 2022, 14, 6100.	3.7	4

#	Article	IF	CITATIONS
1543	CDK4/6 Inhibitors as Upfront Treatment in a Patient with Breast Cancer Presenting with a Clinical Critic Situation: A Case Report and Review of the Literature. Current Oncology, 2022, 29, 9630-9639.	2.2	0
1544	The effect of concomitant use of proton pump inhibitors with CDK 4/6 inhibitors on survival in metastatic breast cancer. European Journal of Clinical Pharmacology, 2023, 79, 243-248.	1.9	4
1545	Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future. Molecules, 2022, 27, 8828.	3.8	7
1546	A phase II single-arm study of palbociclib in patients with HER2-positive breast cancer with brain metastases and analysis of ctDNA in patients with active brain metastases. Clinical Breast Cancer, 2022,	2.4	4
1547	Real-world Treatment Patterns and Clinical Outcomes Associated With Palbociclib Combination Therapy: A Multinational, Pooled Analysis From the Ibrance Real World Insights Study. Clinical Therapeutics, 2022, 44, 1588-1601.	2.5	5
1548	Therapeutic drug monitoring in breast cancer therapy – LC-MS/MS method for quantification of the CDK4/6 inhibitors abemaciclib, palbociclib, ribociclib, and major metabolites abemaciclib M20 and M2 in human serum. Journal of Pharmaceutical and Biomedical Analysis, 2023, 225, 115211.	2.8	8
1549	OPTIMAL Breast Cancer Care: Effect of an Outpatient Pharmacy Team to Improve Management and Adherence to Oral Cancer Treatment. JCO Oncology Practice, 2023, 19, e306-e314.	2.9	2
1550	CDK4/6 inhibitor resistance: A bibliometric analysis. Frontiers in Oncology, 0, 12, .	2.8	3
1551	Preclinical evaluation of <scp>CDK4</scp> phosphorylation predicts high sensitivity of pleural mesotheliomas to <scp>CDK4</scp> /6 inhibition. Molecular Oncology, 0, , .	4.6	5
1552	Role of ribociclib in treatment of luminal Her-2-negative mBC with CNS metastases. Meditsinskiy Sovet, 2022, , 42-51.	0.5	0
1554	Histology-based survival outcomes in hormone receptor-positive metastatic breast cancer treated with targeted therapies. Npj Breast Cancer, 2022, 8, .	5.2	4
1555	Transporting observational study results to a target population of interest using inverse odds of participation weighting. PLoS ONE, 2022, 17, e0278842.	2.5	1
1556	The impact of letrozole on oocyte quality in assisted reproductive technology (ART); a randomized double-blind clinical trial. Gynecological Endocrinology, 0, , 1-6.	1.7	1
1557	On-treatment derived neutrophil-to-lymphocyte ratio and survival with palbociclib and endocrine treatment: analysis of a multicenter retrospective cohort and the PALOMA-2/3 study with immune correlates. Breast Cancer Research, 2023, 25, .	5.0	4
1559	Hormone receptor-positive, HER2-negative, metastatic breast cancer responded well to abemaciclib and exemestane after palbociclib and fulvestrant failure: A case report and literature review. Frontiers in Oncology, 0, 12, .	2.8	1
1560	Molecular Alterations and Putative Therapeutic Targeting of Planar Cell Polarity Proteins in Breast Cancer. Journal of Clinical Medicine, 2023, 12, 411.	2.4	2
1561	A phase II study of palbociclib plus letrozole plus trastuzumab as neoadjuvant treatment for clinical stages II and III ER+ HER2+ breast cancer (PALTAN). Npj Breast Cancer, 2023, 9, .	5.2	4
1562	ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC). PLoS Genetics, 2023, 19, e1010563.	3.5	5

#	Article	IF	CITATIONS
1563	SETDB1 Modulates Degradation of Phosphorylated RB and Anticancer Efficacy of CDK4/6 Inhibitors. Cancer Research, 2023, 83, 875-889.	0.9	6
1564	Carrier-free nanomedicines self-assembled from palbociclib dimers and Ce6 for enhanced combined chemo-photodynamic therapy of breast cancer. RSC Advances, 2023, 13, 1617-1626.	3.6	5
1565	Breast cancer sub-types display heterogeneity in gene amplification and mRNA expression of the anti-apoptotic members of BCL2 family. Gene, 2023, 857, 147179.	2.2	0
1566	Cost-Effectiveness and Cost-Utility of Palbociclib versus Ribociclib in Women with Stage IV Breast Cancer: A Real-World Data Evaluation. International Journal of Environmental Research and Public Health, 2023, 20, 512.	2.6	4
1567	A rapid reduction in tumor size by cyclin-dependent kinase inhibition in hormone receptor-positive postpartum breast cancer: a case report of two patients and a review of the literature. Annals of Translational Medicine, 2022, 10, 1413-1413.	1.7	0
1568	Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis. Nature Cancer, 0, , .	13.2	13
1569	Cyclin-dependent kinase 4/6 inhibitor-associated thromboembolism: a critical evaluation of the current evidence. Journal of Thrombosis and Haemostasis, 2023, 21, 758-770.	3.8	1
1570	Systemic treatment with or without ablative therapies in oligometastatic breast cancer: A single institution analysis of patient outcomes. Breast, 2023, 67, 102-109.	2.2	7
1571	Real-world treatment outcomes in HR+ HER2- metastatic breast cancer patients treated with CDK4/6 inhibitors: Results from a reference center in Brazil. Cancer Treatment and Research Communications, 2023, 35, 100683.	1.7	2
1572	Recurrent Glioblastoma: Ongoing Clinical Challenges and Future Prospects. OncoTargets and Therapy, 0, Volume 16, 71-86.	2.0	6
1573	Survival advantage of locoregional and systemic therapy in oligometastatic breast cancer: an international retrospective cohort study (OLIGO-BC1). Breast Cancer, 2023, 30, 412-423.	2.9	2
1574	Investigation on acquired palbociclib resistance by LC-MS based multi-omics analysis. Frontiers in Molecular Biosciences, 0, 10, .	3.5	1
1575	Pretreatment neutrophil to lymphocyte ratio as prognostic factor in metastatic breast cancer treated with cyclin dependent kinase 4/6 inhibitors. Frontiers in Oncology, 0, 12, .	2.8	2
1576	Quality of life with palbociclib plus fulvestrant <i>versus</i> placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial. Therapeutic Advances in Medical Oncology, 2023, 15, 175883592211489.	3.2	3
1577	Axillary chest wall solid-papillary carcinoma: A case report on presentation and management. Rare Tumors, 2023, 15, 203636132311559.	0.6	0
1578	Development and Validation of a Quantitative LC-MS/MS Method for CDK4/6 Inhibitors Palbociclib, Ribociclib, Abemaciclib, and Abemaciclib-M2 in Human Plasma. Therapeutic Drug Monitoring, 2023, 45, 327-336.	2.0	6
1579	Neoadjuvant endocrine therapy with or without palbociclib in low-risk patients: a phase III randomized double-blind SAFIA trial. Journal of Cancer Research and Clinical Oncology, 2023, 149, 6171-6179.	2.5	3
1581	Network Analysis Identifies Potential Small-Molecule Drugs Sensitizing Triple-Negative Breast Cancer to Tamoxifen. , 2022, , .		0

#	Article	IF	CITATIONS
1582	Is another class of molecular targeted therapy an appropriate decision as the next treatment for progressive disease with initial molecular targeted therapy for luminal advanced/metastatic breast cancer?. Journal of Nippon Medical School, 2023, , .	0.9	0
1583	CDK4/6 Inhibitors—Overcoming Endocrine Resistance Is the Standard in Patients with Hormone Receptor-Positive Breast Cancer. Cancers, 2023, 15, 1763.	3.7	4
1584	The CDK4/6 Inhibitor Palbociclib Inhibits Estrogen-Positive and Triple Negative Breast Cancer Bone Metastasis In Vivo. Cancers, 2023, 15, 2211.	3.7	0
1585	A phase I trial of palbociclib and bosutinib with fulvestrant in patients with metastatic hormone receptor positive and HER2 negative (HR+ HER2-) breast cancer refractory to an aromatase inhibitor and a CDK4/6 inhibitor. Contemporary Clinical Trials Communications, 2023, 33, 101110.	1.1	2
1586	Cost-effectiveness Analysis of Ribociclib plus Letrozole versus Palbociclib plus Letrozole in the United Kingdom. Journal of Health Economics and Outcomes Research, 0, , 20-31.	1.2	0
1588	Real-world comparative effectiveness of palbociclib plus letrozole versus letrozole in older patients with metastatic breast cancer. Breast, 2023, 69, 375-381.	2.2	6
1590	The likelihood of being helped or harmed as a patient-centred tool to assess cyclin dependent kinase 4/6 inhibitors clinical impact and safety in metastatic breast cancer: a systematic review and sensitivity-analysis. EClinicalMedicine, 2023, 56, 101824.	7.1	1
1591	Biolayer Interferometry Assay for Cyclin-Dependent Kinase-Cyclin Association Reveals Diverse Effects of Cdk2 Inhibitors on Cyclin Binding Kinetics. ACS Chemical Biology, 2023, 18, 431-440.	3.4	3
1592	Hänatologische Neoplasien und solide Tumore. , 2022, , 85-151.		0
1593	Palbociclib impairs the proliferative capacity of activated T cells while retaining their cytotoxic efficacy. Frontiers in Pharmacology, 0, 14, .	3.5	4
1594	Molecular profiling in contemporary breast cancer management. British Journal of Surgery, 2023, 110, 743-745.	0.3	2
1595	The oncogenic roles and clinical implications of YAP/TAZ in breast cancer. British Journal of Cancer, 2023, 128, 1611-1624.	6.4	13
1596	Overall survival associated with CDK4/6 inhibitors in patients with HR+/HER2– metastatic breast cancer in the United States: A SEERâ€Medicare populationâ€based study. Cancer, 2023, 129, 1051-1063.	4.1	13
1597	Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy. BMC Cancer, 2023, 23, .	2.6	9
1598	Real-World Evaluation of Disease Progression After CDK 4/6 Inhibitor Therapy in Patients With Hormone Receptor-Positive Metastatic Breast Cancer. Oncologist, 2023, 28, 682-690.	3.7	3
1599	Real-world palbociclib effectiveness in patients with metastatic breast cancer: Focus on neutropenia-related treatment modification strategies and clinical outcomes. Cancer Treatment and Research Communications, 2023, 35, 100691.	1.7	1
1600	Regulatory Approval, Reimbursement, and Clinical Use of Cyclin-Dependent Kinase 4/6 Inhibitors in Metastatic Breast Cancer in the Netherlands. JAMA Network Open, 2023, 6, e2256170.	5.9	0
1602	Thromboembolism profiles associated with cyclin-dependent kinase 4/6 inhibitors: a real-world pharmacovigilance study and a systematic review. Expert Opinion on Drug Safety, 2023, 22, 599-609.	2.4	1

#	Article	IF	CITATIONS
1603	Cost-effectiveness of ribociclib versus palbociclib in combination with an aromatase inhibitor as first-line treatment of postmenopausal women with HR+/HER2â^ advanced breast cancer: analysis based on final OS results of MONALEESA-2 and PALOMA-2. Journal of Medical Economics, 2023, 26, 357-365.	2.1	3
1604	Palbociclib (PD 0332991) Interaction with Kinases. Theoretical and Comparative Molecular Docking Study. Chemistry and Biodiversity, 2023, 20, .	2.1	0
1605	Cyclin-dependent kinase (CDK) 4/6 inhibition in non-small cell lung cancer with epidermal growth factor receptor (EGFR) mutations. Investigational New Drugs, 0, , .	2.6	1
1606	p27Kip1 V109G as a biomarker for CDK4/6 inhibitors indication in hormone receptor–positive breast cancer. JNCI Cancer Spectrum, 2023, 7, .	2.9	0
1607	Targeted Therapy and Mechanisms of Drug Resistance in Breast Cancer. Cancers, 2023, 15, 1320.	3.7	13
1608	Targeting Human Proteins for Antiviral Drug Discovery and Repurposing Efforts: A Focus on Protein Kinases. Viruses, 2023, 15, 568.	3.3	2
1609	Advances in medical treatment of breast cancer in 2022. , 2023, 2, 1-17.		2
1610	Singleâ€cell dissection reveals the role of <scp>DNA</scp> damage response patterns in tumor microenvironment components contributing to colorectal cancer progression and immunotherapy. Genes To Cells, 2023, 28, 348-363.	1.2	1
1611	Carboxypeptidase vitellogenic like facilitates resistance to <scp>CDK4</scp> /6 inhibitors in breast cancer. Thoracic Cancer, 2023, 14, 983-991.	1.9	1
1612	Response and Resistance to Trametinib in MAP2K1-Mutant Triple-Negative Melanoma. International Journal of Molecular Sciences, 2023, 24, 4520.	4.1	2
1613	Drugging the PI3K/AKT/mTOR Pathway in ER+ Breast Cancer. International Journal of Molecular Sciences, 2023, 24, 4522.	4.1	16
1615	Phase II Study of Palbociclib (PD-0332991) in <i>CCND1</i> , <i>2</i> , or <i>3</i> Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B. Clinical Cancer Research, 2023, 29, 1477-1483.	7.0	3
1617	Therapeutic Implications of CDKs in Breast Cancer. , 2023, , 233-252.		0
1618	Novel CDK Inhibitors in Breast Cancer. , 2023, , 253-267.		0
1619	CDKs in Cell-Cycle Progression and Therapeutic Strategies in Human Breast Cancer. , 2023, , 291-311.		0
1620	CDK13 phosphorylates the translation machinery and promotes tumorigenic protein synthesis. Oncogene, 2023, 42, 1321-1330.	5.9	1
1621	Improving palbociclib adherence among women with metastatic breast cancer using a CONnected CUstomized Treatment Platform: A pilot study. Journal of Oncology Pharmacy Practice, 2023, 29, 1957-1964.	0.9	1
1622	Cell cycle exits and U-turns: Quiescence as multiple reversible forms of arrest. Faculty Reviews, 0, 12, .	3.9	2

#	Article	IF	CITATIONS
1624	Case report: Vitiligo-like toxicity due to ribociclib during first-line treatment of metastatic breast cancer: two cases of premature interruption of therapy and exceptional response. Frontiers in Oncology, 0, 13, .	2.8	2
1625	Does Proton Pump Inhibitors Decrease the Efficacy of Palbociclib and Ribociclib in Patients with Metastatic Breast Cancer?. Medicina (Lithuania), 2023, 59, 557.	2.0	1
1626	Position paper on CDK4/6 inhibitors in early breast cancer. Memo - Magazine of European Medical Oncology, 0, , .	0.5	0
1627	Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2â^' Metastatic Breast Cancer in Postmenopausal Women in the USA. Pharmacoeconomics, 2023, 41, 709-718.	3.3	6
1628	Novel therapeutics in low-grade serous ovarian cancer. International Journal of Gynecological Cancer, 2023, 33, 377-384.	2.5	4
1629	Post-CDK 4/6 Inhibitor Therapy: Current Agents and Novel Targets. Cancers, 2023, 15, 1855.	3.7	1
1630	Systemic therapy for hormone receptorâ€positive/human epidermal growth factor receptor 2â€negative early stage and metastatic breast cancer. Ca-A Cancer Journal for Clinicians, 2023, 73, 480-515.	329.8	23
1631	CDK4/6 inhibitor resistance in estrogen receptor positive breast cancer, a 2023 perspective. Frontiers in Cell and Developmental Biology, 0, 11, .	3.7	6
1632	Stromal Senescence following Treatment with the CDK4/6 Inhibitor Palbociclib Alters the Lung Metastatic Niche and Increases Metastasis of Drug-Resistant Mammary Cancer Cells. Cancers, 2023, 15, 1908.	3.7	5
1633	Osteonecrosis of the jaw under palbociclib: A case series description. Journal of Oncology Pharmacy Practice, 2023, 29, 1990-1997.	0.9	3
1634	CDK4/6 inhibitors in metastatic breast cancer, a comparison of toxicity and efficacy across agents in a real-world dataset. Journal of Oncology Pharmacy Practice, 2023, 29, 1825-1835.	0.9	2
1635	First diagnosed invasive lobular carcinoma of the breast combined with gastric metastasis and bone metastasis: a case report and review of the literature. BMC Women's Health, 2023, 23, .	2.0	Ο
1636	Using Oncotype DX breast recurrence score® assay to define the role of neoadjuvant endocrine therapy in early-stage hormone receptor-positive breast cancer. Breast Cancer Research and Treatment, 2023, 199, 91-98.	2.5	3
1637	The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer. Npj Breast Cancer, 2023, 9, .	5.2	9
1638	Olaparib efficacy in patients with germline <scp>BRCA</scp> â€mutated, <scp>HER2</scp> â€negative metastatic breast cancer: Subgroup analyses from the phase <scp>III OlympiAD</scp> trial. International Journal of Cancer, 2023, 153, 803-814.	5.1	4
1639	Filling the Gap after CDK4/6 Inhibitors: Novel Endocrine and Biologic Treatment Options for Metastatic Hormone Receptor Positive Breast Cancer. Cancers, 2023, 15, 2015.	3.7	3
1640	<scp>CDK4</scp> /6 inhibitor modulating active and quiescent intestinal stem cells for prevention of chemotherapyâ€induced diarrhea. Journal of Pathology, 0, , .	4.5	1
1641	Advances in Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer. Current Oncology Reports, 2023, 25, 689-698.	4.0	2

#	Article	IF	CITATIONS
1642	A retrospective, non-interventional study of breast cancer patients diagnosed with ER+/HER2 negative, locally advanced or metastatic breast cancer treated with palbociclib in Denmark. Acta Oncológica, 2023, 62, 290-297.	1.8	0
1643	Fulvestrant plus palbociclib in advanced or metastatic hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer after fulvestrant monotherapy: Japan Breast Cancer Research Group-M07 (FUTURE trial). Breast Cancer Research and Treatment, 2023, 199, 253-263.	2.5	3
1644	Role of Cyclin-Dependent Kinase Inhibitors (CKIs) as a Prognostic Biomarker for Cancer. , 2022, , 1-54.		0
1645	An emerging generation of endocrine therapies in breast cancer: a clinical perspective. Npj Breast Cancer, 2023, 9, .	5.2	18
1646	Second-line Endocrine Therapy of Hormone Receptor-Positive/HER2-negative Advanced Breast Cancer: A Systematic Review and Network Meta-analysis. Current Cancer Drug Targets, 2023, 23, .	1.6	0
1647	Observational study of HR+/HER2â^' metastatic breast cancer patients treated with abemaciclib in Spain in the Named Patient Use Program (AbemusS). Clinical and Translational Oncology, 0, , .	2.4	0
1648	Recent Advances with Precision Medicine Treatment for Breast Cancer including Triple-Negative Sub-Type. Cancers, 2023, 15, 2204.	3.7	10
1649	Advances in pharmacotherapies that target the cell cycle for treatment of breast cancer: where are we at today?. Expert Opinion on Pharmacotherapy, 2023, 24, 887-900.	1.8	2
1650	Efficacy of Limited Dose Modifications for Palbociclib-Related Grade 3 Neutropenia in Hormone Receptor–Positive Metastatic Breast Cancer. Cancer Research and Treatment, 2023, 55, 1198-1209.	3.0	1
1651	Ribociclib-Induced Delayed Dermatological Reaction: Case Report of a Rare Adverse Effect and Review of Literature. Indian Journal of Medical and Paediatric Oncology, 0, , .	0.2	0
1652	Palbociclib Adherence and Persistence in Patients with Hormone Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer. Patient Preference and Adherence, 0, Volume 17, 1049-1062.	1.8	0
1653	Kinome Reprogramming Is a Targetable Vulnerability in ESR1 Fusion-Driven Breast Cancer. Cancer Research, 2023, 83, 3237-3251.	0.9	2
1655	Place in Therapy of Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: A Targeted Literature Review. Targeted Oncology, 2023, 18, 327-358.	3.6	2
1656	Treatment Patterns and Health Resource Utilization in Patients With HR+/ HER2- Locally Advanced or Metastatic Breast Cancer in a Real-World Setting in Taiwan. Value in Health Regional Issues, 2023, 36, 98-104.	1.2	0
1657	Chemotherapeutic and targeted drugs-induced immunogenic cell death in cancer models and antitumor therapy: An update review. Frontiers in Pharmacology, 0, 14, .	3.5	13
1658	Pyrrolysine-Inspired in Cellulo Synthesis of an Unnatural Amino Acid for Facile Macrocyclization of Proteins. Journal of the American Chemical Society, 2023, 145, 10249-10258.	13.7	1
1659	P-REALITY X: A Real-World Analysis of Palbociclib Plus an Aromatase Inhibitor in HR+/HER2â^' Metastatic Breast Cancer—A Podcast. Targeted Oncology, 2023, 18, 321-326.	3.6	1
1660	Overview of the therapeutic strategies for ER positive breast cancer. Biochemical Pharmacology, 2023, 212, 115552.	4.4	4

#	Article	IF	CITATIONS
1661	New Developments in Systemic Management for High-Risk Early-Stage Hormone-Receptor-Positive, HER2-Negative Breast Cancer. Current Treatment Options in Oncology, 2023, 24, 594-610.	3.0	2
1663	Targeting protein tyrosine phosphatases for CDK6-induced immunotherapy resistance. Cell Reports, 2023, 42, 112314.	6.4	0
1664	Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer. Future Oncology, 2023, 19, 727-736.	2.4	1
1665	Long-lasting complete remission in a patient with systemic metastases of recurrent breast cancer treated with cyclin-dependent kinases 4/6 inhibitors: a case report. Journal of Medical Case Reports, 2023, 17, .	0.8	0
1666	Social determinants of health and CDK4/6 inhibitor use and outcomes among patients with metastatic breast cancer. Breast Cancer Research and Treatment, 2023, 200, 85-92.	2.5	2
1669	Multimodal perturbation analyses of cyclin-dependent kinases reveal a network of synthetic lethalities associated with cell-cycle regulation and transcriptional regulation. Scientific Reports, 2023, 13, .	3.3	0
1670	Antagonizing the irreversible thrombomodulin-initiated proteolytic signaling alleviates age-related liver fibrosis via senescent cell killing. Cell Research, 2023, 33, 516-532.	12.0	7
1671	An Interpretable Multitask Framework BiLAT Enables Accurate Prediction of Cyclin-Dependent Protein Kinase Inhibitors. Journal of Chemical Information and Modeling, 2023, 63, 3350-3368.	5.4	0
1672	Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HR+ HER2â^' metastatic breast cancer patients receiving palbociclib and endocrine therapy: primary outcome analysis of the multicenter randomized AGO-B WSG PreCycle trial. Annals of Oncology, 2023, 34, 660-669.	1.2	9
1673	The effect of CDK4/6 inhibitors on the overall survival in patients with advanced HR+/HER2- BC in the entire population and in special clinical subgroups of unfavorable prognosis: A review. Journal of Modern Oncology, 2023, 25, 55-62.	0.3	0
1674	PRECYCLE: multicenter, randomized phase IV intergroup trial to evaluate the impact of eHealth-based patient-reported outcome (PRO) assessment on quality of life in patients with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer treated with palbociclib and an aromatase inhibitor or palbociclib and fulvestrant. Trials, 2023, 24, .	1.6	1
1675	Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: MAINTAIN Trial. Journal of Clinical Oncology, 2023, 41, 4004-4013.	1.6	21
1676	Role of Molecular Targeted Therapeutic Drugs in Treatment of Breast Cancer: A Review Article. Global Medical Genetics, 2023, 10, 079-086.	0.9	2
1677	An Overview of Breast Cancer Epidemiology, Risk Factors, Classification, Genetics, Diagnosis and Treatment. Vantage: Journal of Thermatic Analysis, 2023, 4, 45-67.	0.0	0
1678	Molecular profiling of a real-world breast cancer cohort with genetically inferred ancestries reveals actionable tumor biology differences between European ancestry and African ancestry patient populations. Breast Cancer Research, 2023, 25, .	5.0	6
1679	Clinical trial designs for evaluating and exploiting cancer evolution. Cancer Treatment Reviews, 2023, 118, 102583.	7.7	2
1681	An overview of molecular targeting of glioblastoma. , 2023, , 211-226.		0

Hiá<sup>21</sup>Ì,u quaì‰ Ä'iêÌ€u triÌ£ ná»Ì,i tiêÌt kêÌt hÆjÌ£p thuÃÎc ưÌc chêÌ•CDK4/6 treÌ,n bá<sup>21</sup>Ì,nh nhaÌ,n ung thuÌ› vuÌ•taÌi phaÌt di caì†n th dưol›ng tilnh, HER2 aÌ,m tilnh. Journal of Clinical Medicine- Hue Central Hospital, 2023, , .

#	Article	IF	CITATIONS
1684	Hybridization of the Pharmacophoric Features of Discoipyrrole C and Combretastatin Aâ€4 toward New Anticancer Leads. ChemMedChem, 2023, 18, .	3.2	1
1685	HR+/HER2– Advanced Breast Cancer Treatment in the First-Line Setting: Expert Review. Current Oncology, 2023, 30, 5425-5447.	2.2	4
1686	Clinical impact of body mass index on palbociclib treatment outcomes and effect on exposure. Biomedicine and Pharmacotherapy, 2023, 164, 114906.	5.6	5
1687	Safety of CDK4/6 Inhibitors Combined with Radiotherapy in Patients with Metastatic Breast Cancer: A Review of the Literature. Current Oncology, 2023, 30, 5485-5496.	2.2	1
1689	Ribociclib in newly diagnosed hepatitis B infection: A case report. Frontiers in Oncology, 0, 13, .	2.8	0
1690	Trends in estrogen and progesterone receptors in prostate cancer: a bibliometric analysis. Frontiers in Oncology, 0, 13, .	2.8	0
1691	Adverse Cardiovascular Events Associated With Cyclinâ€Dependent Kinase 4/6 Inhibitors in Patients With Metastatic Breast Cancer. Journal of the American Heart Association, 2023, 12, .	3.7	3
1692	CDK4/6 Inhibition in the Metastatic Setting: Where Are We Headed?. Current Treatment Options in Oncology, 0, , .	3.0	0
1693	The effect of low HER2 expression on treatment outcomes in metastatic hormone receptor positive breast cancer patients treated with a combination of a CDK4/6 inhibitor and endocrine therapy: A multicentric retrospective study. Breast, 2023, 70, 56-62.	2.2	3
1694	Safety profile of cyclin-dependent kinase (CDK) 4/6 inhibitors with concurrent radiation therapy: A systematic review and meta-analysis. Cancer Treatment Reviews, 2023, 119, 102586.	7.7	3
1696	Cost-effectiveness of the addition of CDK4/6 inhibitors to standard endocrine therapy in first-line treatment of women with advanced HR+/HER2â^ breast cancer in Mexico. Clinical and Translational Oncology, 2024, 26, 239-244.	2.4	1
1697	Liver X receptors induce antiproliferative effects in basalâ€like breast cancer. Molecular Oncology, 2023, 17, 2041-2055.	4.6	0
1698	Capecitabine efficacy after cycline-dependent-kinase 4/6 inhibitor plus endocrine therapy in metastatic hormone receptor-positive breast cancer. Cancer Treatment and Research Communications, 2023, 36, 100738.	1.7	0
1699	Beyond PARP Inhibitors in Advanced Breast Cancer Patients with Germline BRCA1/2 Mutations: Focus on CDK4/6-Inhibitors and Data Review on Other Biological Therapies. Cancers, 2023, 15, 3305.	3.7	0
1700	Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor–Positive Metastatic Breast Cancers. Cancer Research, 2023, 83, 3264-3283.	0.9	3
1701	Incorporating clinicopathological and molecular risk prediction tools to improve outcomes in early HR+/HER2– breast cancer. Npj Breast Cancer, 2023, 9, .	5.2	2
1702	Outcomes and toxicity of concurrent <scp>CDK4</scp> /6 inhibitor and locoregional radiotherapy for patients with de novo metastatic breast cancer. International Journal of Cancer, 2023, 153, 1386-1396.	5.1	1
1703	Cell facilitation promotes growth and survival under drug pressure in breast cancer. Nature Communications, 2023, 14, .	12.8	4

#	Article	IF	CITATIONS
1704	Effectiveness of palbociclib with aromatase inhibitors for the treatment of advanced breast cancer in an exposure retrospective cohort study: implications for clinical practice. Breast Cancer Research, 2023, 25, .	5.0	1
1705	CDK4/6 Inhibitors in the First-Line Treatment of Postmenopausal Women with HR+/HER2â^' Advanced or Metastatic Breast Cancer: An Updated Network Meta-Analysis and Cost-Effectiveness Analysis. Cancers, 2023, 15, 3386.	3.7	2
1706	Cyclin-Dependent Kinase 4/6 Inhibitors for Treatment of Hormone Receptor–Positive, ERBB2-Negative Breast Cancer. JAMA Oncology, 2023, 9, 1273.	7.1	6
1707	Ribociclib-induced acute kidney injury in patients with advanced-stage breast cancer: A case series and literature review. Current Problems in Cancer Case Reports, 2023, 11, 100243.	0.1	0
1708	Primary cilia shape hallmarks of health and aging. Trends in Molecular Medicine, 2023, 29, 567-579.	6.7	3
1709	Maintained complete response to talazoparib in a BRCA-2 mutated metastatic luminal breast cancer: case report and review of literature. Frontiers in Oncology, 0, 13, .	2.8	0
1710	Abemaciclib, Palbociclib, and Ribociclib in Real-World Data: A Direct Comparison of First-Line Treatment for Endocrine-Receptor-Positive Metastatic Breast Cancer. International Journal of Molecular Sciences, 2023, 24, 8488.	4.1	6
1711	Targeting CDK4/6 in glioblastoma <i>via in situ</i> injection of a cellulose-based hydrogel. Nanoscale, 2023, 15, 12518-12529.	5.6	2
1712	Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2023, 24, 646-657.	10.7	11
1713	Prognostic Parameters of Palbociclib in HR+/HER2- Advanced Breast Cancer: A Narrative Review. Technology in Cancer Research and Treatment, 2023, 22, 153303382311735.	1.9	1
1714	Regulation of the Cell Cycle by ncRNAs Affects the Efficiency of CDK4/6 Inhibition. International Journal of Molecular Sciences, 2023, 24, 8939.	4.1	2
1715	Risk Factors for Palbociclib-Induced Early Developing Neutropenia in Patients with Hormone Receptor-Positive Metastatic Breast Cancer. Cancers, 2023, 15, 2810.	3.7	0
1716	Effect of Concurrent Proton Pump Inhibitors With Palbociclib Tablets for Metastatic Breast Cancer. Clinical Breast Cancer, 2023, , .	2.4	1
1718	Palbociclib-Induced Cellular Senescence Is Modulated by the mTOR Complex 1 and Autophagy. International Journal of Molecular Sciences, 2023, 24, 9284.	4.1	0
1719	A bi-steric mTORC1-selective inhibitor overcomes drug resistance in breast cancer. Oncogene, 2023, 42, 2207-2217.	5.9	4
1720	Treatment of De-Differentiated Liposarcoma in the Era of Immunotherapy. International Journal of Molecular Sciences, 2023, 24, 9571.	4.1	4
1721	Implementation and evaluation of a shared care model between oncologists and pharmacists for breast cancer patients at a Canadian regional ambulatory cancer centre. Journal of Oncology Pharmacy Practice, 0, , 107815522311791.	0.9	0
1722	Ribociclib-induced visual hallucination in a patient with metastatic breast cancer. Journal of Oncology Pharmacy Practice, 2023, 29, 1529-1532.	0.9	2

#	Article	IF	CITATIONS
1723	Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer. Current Oncology, 2023, 30, 6097-6110.	2.2	0
1724	CDK4/6 Inhibitors: Existing and Emerging Differences. JNCI Cancer Spectrum, 0, , .	2.9	2
1725	Targeting the Estrogen Receptor for the Treatment of Breast Cancer: Recent Advances and Challenges. Journal of Medicinal Chemistry, 2023, 66, 8339-8381.	6.4	13
1726	TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2– breast cancer. Future Oncology, 0, , .	2.4	7
1727	Molecular portraits of cell cycle checkpoint kinases in cancer evolution, progression, and treatment responsiveness. Science Advances, 2023, 9, .	10.3	0
1728	Real World Experience of Second-Line Treatment Strategies after Palbociclib and Letrozole: Overall Survival in Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer. Cancers, 2023, 15, 3431.	3.7	1
1729	Vitiligo-like lesions induced by cyclin-dependent kinase 4/6 inhibitor Palbociclib: a case report and literature review. Pathology and Oncology Research, 0, 29, .	1.9	1
1730	Disproportionality Analysis of Abemaciclib inÂtheÂFDA Adverse Event Reporting System: AÂReal-World Post-Marketing Pharmacovigilance Assessment. Drug Safety, 2023, 46, 881-895.	3.2	2
1732	Real-World Tumor Response of Palbociclib in Combination With an Aromatase Inhibitor as First-Line Therapy in Pre/Perimenopausal Women With Metastatic Breast Cancer. Targeted Oncology, 2023, 18, 543-558.	3.6	2
1733	Optimizing the Treatment for Pregnancy-Associated Breast Cancer: a Case Example and Review of the Literature. Current Breast Cancer Reports, 0, , .	1.0	0
1734	First-line treatment of hormone-sensitive metastatic breast cancer. , 2023, , .		0
1735	Luminal breast cancer treatment beyond cell cycle inhibitors. , 2023, , .		0
1737	Efficacy of probiotics and trimebutine maleate for abemaciclib-induced diarrhea: A randomized, open-label phase II trial (MERMAID, WJOG11318B). Breast, 2023, 71, 22-28.	2.2	1
1739	Advancing Cancer Therapy Predictions with Patient-Derived Organoid Models of Metastatic Breast Cancer. Cancers, 2023, 15, 3602.	3.7	2
1740	The RNA-binding protein LRPPRC promotes resistance to CDK4/6 inhibition in lung cancer. Nature Communications, 2023, 14, .	12.8	2
1741	Real-world analysis of the economic and therapeutic burden in advanced breast cancer patients in Italy. Expert Review of Pharmacoeconomics and Outcomes Research, 0, , 1-8.	1.4	0
1743	Cost of Drug Wastage From Dose Modification and Discontinuation of Oral Anticancer Drugs. JAMA Oncology, 2023, 9, 1238.	7.1	3
1744	Real-World Effectiveness of Palbociclib Plus Aromatase Inhibitors in African American Patients With Metastatic Breast Cancer. Oncologist, 0, , .	3.7	0

#	Article	IF	CITATIONS
1745	Detection of high-risk patients resistant to CDK4/6 inhibitors with hormone receptor-positive HER2-negative advanced and metastatic breast cancer in Japan (KBCSG-TR-1316). Breast Cancer, 0, , .	2.9	0
1746	CDK4/6 Inhibitor Resistance in Hormone Receptor-Positive Metastatic Breast Cancer: Translational Research, Clinical Trials, and Future Directions. International Journal of Molecular Sciences, 2023, 24, 11791.	4.1	2
1747	Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients. Clinical Cancer Research, 2023, 29, 4166-4177.	7.0	3
1748	Intracellular spatiotemporal metabolism in connection to target engagement. Advanced Drug Delivery Reviews, 2023, , 115024.	13.7	Ο
1749	A real-world study of the first use of palbociclib for the treatment of advanced breast cancer within the UK National Health Service as part of the novel Ibrance® Patient Program. British Journal of Cancer, 2023, 129, 852-860.	6.4	0
1750	"Diagnostic and Prognostic Biomarkers of Luminal Breast Cancer: Where are We Now?― Breast Cancer: Targets and Therapy, 0, Volume 15, 525-540.	1.8	1
1751	Differences in Treatment Outcomes Between Patients with HER2-Low versus HER2-Zero, Hormone Receptor-Positive Advanced-Stage Breast Cancer Treated with Ribociclib. Breast Cancer: Targets and Therapy, 0, Volume 15, 541-548.	1.8	2
1752	Place of fulvestrant in the treatment of patients with metastatic luminal Her2-negative breast cancer. Meditsinskiy Sovet, 2023, , 41-47.	0.5	0
1753	Palbociclib: efficacy and safety in older patients. Meditsinskiy Sovet, 2023, , 150-157.	0.5	0
1754	The Efficacy of CB-103, a First-in-Class Transcriptional Notch Inhibitor, in Preclinical Models of Breast Cancer. Cancers, 2023, 15, 3957.	3.7	1
1755	The immune microenvironment characterisation and dynamics in hormone <scp>receptor–positive</scp> breast cancer before and after neoadjuvant endocrine therapy. Cancer Medicine, 0, , .	2.8	0
1756	Impact of BMI in Patients With Early Hormone Receptor–Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial. Journal of Clinical Oncology, 2023, 41, 5118-5130.	1.6	2
1758	Radiomic predicts early response to CDK4/6 inhibitors in hormone receptor positive metastatic breast cancer, 2023, 9, .	5.2	0
1759	Successful continuance of CDK4/6 inhibitor treatment with palbociclib after abemaciclib-induced hepatotoxicity in breast cancer: a case report. Anti-Cancer Drugs, 2024, 35, 89-92.	1.4	1
1761	Long non-coding RNAs as the critical regulators of PI3K/AKT, TGF-β, and MAPK signaling pathways during breast tumor progression. Journal of Translational Medicine, 2023, 21, .	4.4	5
1762	Hormonal-Receptors-Positive and HER2-Negative Patients with Metastatic Breast Cancer Treated with First-Line Palbociclib and Hormonal Therapy: Impact of First-Cycle Neutropenia and Dose Reduction on Therapeutic Outcome. Breast Journal, 2023, 2023, 1-10.	1.0	0
1763	A bibliometric analysis of metastatic breast cancer: two-decade report (2002-2022). Frontiers in Oncology, 0, 13, .	2.8	2
1764	Surrogate endpoints for HTA decisions of breast cancer drugs: utility and pitfalls. Current Opinion in	2.4	0

#	Article	IF	CITATIONS
1765	Breast cancers arising in subjects with germline BRCA1 or BRCA2 mutations: Different biological and clinical entities with potentially diverse therapeutic opportunities. Critical Reviews in Oncology/Hematology, 2023, 190, 104109.	4.4	0
1766	Evolving treatment paradigms in metastatic or recurrent low-grade endometrial cancer: When is hormonal-based therapy the preferred option?. International Journal of Gynecological Cancer, 2023, 33, 1675-1681.	2.5	1
1767	Recent advances in targeted strategies for triple-negative breast cancer. Journal of Hematology and Oncology, 2023, 16, .	17.0	13
1769	CDK4/6 inhibitors, PI3K/mTOR inhibitors, and HDAC inhibitors as second-line treatments for hormone receptor-positive, HER2-negative advanced breast cancer: a network meta-analysis. BMC Cancer, 2023, 23, .	2.6	2
1770	Small-molecule inhibitors of kinases in breast cancer therapy: recent advances, opportunities, and challenges. Frontiers in Pharmacology, 0, 14, .	3.5	0
1771	Singleâ€cell combined with <scp>bulkâ€RNA</scp> data reveal a pattern related to angiogenesis in breast cancer patients: Individualized medicine. Environmental Toxicology, 0, , .	4.0	Ο
1772	Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2â^' advanced breast cancer receiving first-line ribociclib plus fulvestrant. Breast Cancer Research, 2023, 25, .	5.0	5
1773	The Therapeutic Potential of CDK4/6 Inhibitors, Novel Cancer Drugs, in Kidney Diseases. International Journal of Molecular Sciences, 2023, 24, 13558.	4.1	Ο
1774	An Overview of the Safety Profile and Clinical Impact of CDK4/6 Inhibitors in Breast Cancer—A Systematic Review of Randomized Phase II and III Clinical Trials. Biomolecules, 2023, 13, 1422.	4.0	2
1775	Cyclinâ€dependent kinases: Masters of the eukaryotic universe. Wiley Interdisciplinary Reviews RNA, 2024, 15, .	6.4	0
1776	Hematological Events Potentially Associated with CDK4/6 Inhibitors: An Analysis from the European Spontaneous Adverse Event Reporting System. Pharmaceuticals, 2023, 16, 1340.	3.8	0
1777	Clinical Experience with Abemaciclib in Patients Previously Treated with Another CDK 4/6 Inhibitor in a Tertiary Hospital: A Case Series Study. Cancers, 2023, 15, 4452.	3.7	1
1778	Efficacy, safety, and biomarker analysis of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer: a phase II study (WJOG11418B NEWFLAME trial). , 2023, 11, e007126.		3
1779	Nifuroxazide boosts the anticancer efficacy of palbociclib-induced senescence by dual inhibition of STAT3 and CDK2 in triple-negative breast cancer. Cell Death Discovery, 2023, 9, .	4.7	2
1780	Vinorelbine thiotepa in metastatic breast cancer: a large real-life retrospective study. Acta Oncológica, 0, , 1-6.	1.8	0
1781	Expanded Access Study of Palbociclib Plus Letrozole for Postmenopausal Women with HR+/HER2â <sup>-,</sup> Advanced Breast Cancer in Latin America for Whom Letrozole Therapy is Deemed Appropriate. Clinical Drug Investigation, 2023, 43, 699-706.	2.2	0
1782	Real-world treatment patterns and effectiveness of palbociclib plus an aromatase inhibitor in patients with metastatic breast cancer aged 75 years or older. Frontiers in Oncology, 0, 13, .	2.8	1
1783	In Vitro microRNA Expression Profile Alterations under CDK4/6 Therapy in Breast Cancer. Biomedicines, 2023, 11, 2705.	3.2	0

#	Article	IF	CITATIONS
1784	Real-World Predictors of Severe Neutropenia Associated with Palbociclib and Endocrine Therapy for Metastatic Breast Cancer in Japanese Patients. Biological and Pharmaceutical Bulletin, 2023, 46, 1105-1111.	1.4	0
1785	Mass Spectrometry-Based Proteomics: Analyses Related to Drug-Resistance and Disease Biomarkers. Medicina (Lithuania), 2023, 59, 1722.	2.0	1
1786	Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models. Npj Breast Cancer, 2023, 9, .	5.2	2
1787	The Evolving Pathways of the Efficacy of and Resistance to CDK4/6 Inhibitors in Breast Cancer. Cancers, 2023, 15, 4835.	3.7	1
1788	PROPSEA, safety evaluation of palbociclib and ribociclib in older patients with breast cancer: A prospective real-world TOG study. Journal of Geriatric Oncology, 2023, 14, 101604.	1.0	0
1789	CDK4 phosphorylation status and rational use for combining CDK4/6 and BRAF/MEK inhibition in advanced thyroid carcinomas. Frontiers in Endocrinology, 0, 14, .	3.5	0
1790	Novel Strategies Using Sagacious Targeting for Site-Specific Drug Delivery in Breast Cancer Treatment: Clinical Potential and Applications. Critical Reviews in Therapeutic Drug Carrier Systems, 2024, 41, 35-84.	2.2	0
1791	Efficacy and safety of cyclinâ€dependent kinase 4/6 inhibitor in patients with advanced breast cancer: A realâ€world experience. Thoracic Cancer, 2023, 14, 3012-3019.	1.9	0
1792	The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2022 edition. Breast Cancer, 2023, 30, 872-884.	2.9	1
1793	Sacituzumab Govitecan for the Treatment of HR+/HER2- Breast Cancer in Heavily Pre-treated Patients. Touch Reviews in Oncology & Haematology, 2023, 19, 1.	0.2	0
1794	The Treatment Landscape of Elderly Patients with Hormone Receptor-Positive Her2 Negative Advanced Breast Cancer: Current Perspectives and Future Directions. Journal of Clinical Medicine, 2023, 12, 6012.	2.4	0
1795	Quality of Life and Treatment-Related Side Effects in Patients With HR+/HER2â^' Advanced Breast Cancer: Findings From a Multicountry Survey. Oncologist, 2023, 28, 856-865.	3.7	0
1796	CDK4/6 inhibitors: basics, pros, and major cons in breast cancer treatment with specific regard to cardiotoxicity – a narrative review. Therapeutic Advances in Medical Oncology, 2023, 15, .	3.2	3
1797	Real-world outcomes of patients with metastatic endocrine-responsive breast cancer receiving palbociclib-based combinations. Future Oncology, 2023, 19, 1473-1483.	2.4	0
1798	Dermatologic toxicities to inhibitors of cyclin-dependent kinases CDK 4 and 6: An updated review for clinical practice. Annales De Dermatologie Et De Venereologie, 2023, 150, 208-212.	1.0	3
1799	Anti-hormonal maintenance treatment with the CDK4/6 inhibitor ribociclib after 1st line chemotherapy in hormone receptor positive / HER2 negative metastatic breast cancer: A phase II trial (AMICA). Breast, 2023, 72, 103575.	2.2	2
1800	Genomic Alterations Associated with Estrogen Receptor Pathway Activity in Metastatic Breast Cancer Have a Differential Impact on Downstream ER Signaling. Cancers, 2023, 15, 4416.	3.7	0
1801	Updated Austrian treatment algorithm for metastatic triple-negative breast cancer. Wiener Klinische Wochenschrift, 0, , .	1.9	0

~		<u> </u>	
		IV F D(	<b>DDT</b>
$\sim$	IIAI	IVE F	

#	Article	IF	CITATIONS
1802	A comprehensive update of hormone-related pharmacokinetic variations associated with breast cancer drugs. Expert Opinion on Drug Metabolism and Toxicology, 2023, 19, 389-403.	3.3	0
1803	Cardiotoxicity in breast cancer treatment: Causes and mitigation. Cancer Treatment and Research Communications, 2023, 37, 100760.	1.7	1
1804	Ribociclib may potentiate rosuvastatin effect in causing late onset rhabdomyolysis. BMJ Case Reports, 2023, 16, e255632.	0.5	1
1805	Indirect Treatment Comparison of First-Line CDK4/6-Inhibitors in Post-Menopausal Patients with HR+/HER2â <sup>~?</sup> Metastatic Breast Cancer. Cancers, 2023, 15, 4558.	3.7	1
1806	Progression after First-Line Cyclin-Dependent Kinase 4/6 Inhibitor Treatment: Analysis of Molecular Mechanisms and Clinical Data. International Journal of Molecular Sciences, 2023, 24, 14427.	4.1	2
1807	Real-World Analysis of Clinical and Demographic Characteristics, Treatment Patterns, and Outcomes in Predominantly Older Patients with HR+/HER2â^' Metastatic Breast Cancer Receiving Abemaciclib in Routine Clinical Practice. Drugs - Real World Outcomes, 0, , .	1.6	0
1808	The CDK4/6 inhibitors biomarker landscape: The most relevant biomarkers of response or resistance for further research and potential clinical utility. Critical Reviews in Oncology/Hematology, 2023, 192, 104148.	4.4	1
1809	Non-surgical Cancer Treatments. , 2023, , 131-147.		0
1811	Recent Developments in the Therapeutic Landscape of Advanced or Metastatic Hormone Receptor–Positive Breast Cancer. Cancer Research and Treatment, 2023, 55, 1065-1076.	3.0	1
1812	LncRNA EILA promotes CDK4/6 inhibitor resistance in breast cancer by stabilizing cyclin E1 protein. Science Advances, 2023, 9, .	10.3	1
1814	A new perspective on the proper timing of radiotherapy during CDK4/6 inhibitor therapy in patients with "bone-only―metastatic breast cancer. Pathology and Oncology Research, 0, 29, .	1.9	0
1815	Realâ€world treatment patterns for palbociclib plus an aromatase inhibitor, or an aromatase inhibitor alone, for patients with metastatic breast cancer in the Flatiron Database. International Journal of Cancer, 2024, 154, 701-711.	5.1	0
1816	Favorable impact of therapy management by an interactive eHealth system on severe adverse events in patients with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer treated by palbociclib and endocrine therapy. Cancer Treatment Reviews, 2023, 121, 102631.	7.7	2
1817	Updated Review Article: Cyclin-Dependent Kinase 4/6 Inhibitor Impact, FDA Approval, and Resistance Pathways. Journal of Pharmacy Technology, 2023, 39, 298-308.	1.0	1
1818	The Association between Proton Pump Inhibitors and the Effectiveness of CDK Inhibitors in HR+/HER- Advanced Breast Cancer Patients: A Systematic Review and Meta-Analysis. Cancers, 2023, 15, 5133.	3.7	0
1819	Changes in cell-free DNA after short-term palbociclib and fulvestrant treatment for advanced or metastatic hormone receptor-positive and human epidermal growth factor 2-negative breast cancer. Breast Cancer Research and Treatment, 2024, 203, 225-234.	2.5	0
1820	Clinical Impact of CDK4/6 Inhibitors in De Novo or PRâ^' or Very Elderly Post-Menopausal ER+/HER2â^' Advanced Breast Cancers. Cancers, 2023, 15, 5164.	3.7	0
1821	Additivity predicts the efficacy of most approved combination therapies for advanced cancer. Nature Cancer, 2023, 4, 1693-1704.	13.2	0

#	Article	IF	CITATIONS
1822	Lobular Carcinoma of the Breast: A Comprehensive Review with Translational Insights. Cancers, 2023, 15, 5491.	3.7	1
1823	First-line real-world treatment patterns and survival outcomes in women younger or older than 40 years with metastatic breast cancer in the real-life multicenter French ESME cohort. European Journal of Cancer, 2024, 196, 113422.	2.8	0
1824	Cost-utility analysis of Palbociclib + letrozole and ribociclib + letrozole versus Letrozole monoth in the first-line treatment of metastatic breast cancer in Iran using partitioned survival model. Health Economics Review, 2023, 13, .	erapy 2.0	0
1825	RECENT ADVANCES IN THE DISCOVERY OF CYCLIN-DEPENDENT KINASE 2 (CDK2) SELECTIVE INHIBITORS. Medicinal Chemistry Reviews, 0, , 283-311.	0.1	0
1826	Is there a role for continuation of CDK4/6 inhibition after progression on a prior CDK4/6 inhibitor in HR+/HER2â^' metastatic breast cancer?. Annals of Oncology, 2023, , .	1.2	0
1827	Efficacy of cyclin-dependent kinase 4/6 inhibitors in combination with hormonal therapy in patients with recurrent granulosa cell tumor of the ovary: A case series. Gynecologic Oncology Reports, 2023, 50, 101297.	0.6	0
1828	TWIST1 Upregulation Is a Potential Target for Reversing Resistance to the CDK4/6 Inhibitor in Metastatic Luminal Breast Cancer Cells. International Journal of Molecular Sciences, 2023, 24, 16294.	4.1	4
1829	Current and emerging treatment approaches for hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. Cancer Treatment Reviews, 2024, 123, 102670.	7.7	1
1830	A Review of the Advancements in Targeted Therapies for Breast Cancer. Cureus, 2023, , .	0.5	0
1831	Outcomes of male patients with HR+/HER2– advanced breast cancer receiving palbociclib in the real-world POLARIS study. Breast Cancer Research and Treatment, 0, , .	2.5	0
1832	Phase Ia/b Study of Giredestrant ± Palbociclib and ± Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor–Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer. Clinical Cancer Research, 2024, 30, 754-766.	7.0	1
1833	Mathematical Modeling Identifies Optimum Palbociclib-fulvestrant Dose Administration Schedules for the Treatment of Patients with Estrogen Receptor–positive Breast Cancer. Cancer Research Communications, 2023, 3, 2331-2344.	1.7	0
1834	Overall Survival With Circulating Tumor Cell Count–Driven Choice of Therapy in Advanced Breast Cancer: A Randomized Trial. Journal of Clinical Oncology, 0, , .	1.6	1
1835	Intrinsic Subtype and Overall Survival of Patients with Advanced HR+/HER2â^ Breast Cancer Treated with Ribociclib and ET: Correlative Analysis of MONALEESA-2, -3, -7. Clinical Cancer Research, 2024, 30, 793-802.	7.0	1
1836	Analysis of data from the PALOMA-3 trial confirms the efficacy of palbociclib and offers alternatives for novel assessment of clinical trials. Breast Cancer Research and Treatment, 0, , .	2.5	0
1837	The Clinical Relevance of the NATALEE Study: Application of the NATALEE Criteria to a Real-World Cohort from Two Large German Breast Cancer Centers. International Journal of Molecular Sciences, 2023, 24, 16366.	4.1	0
1839	Interstitial lung disease and CDK4/6 inhibitors in the treatment of breast cancer. Expert Opinion on Drug Safety, 2023, 22, 1149-1156.	2.4	0
1840	Targeting the Tumor Microenvironment in Breast Cancer: Prognostic and Predictive Significance and Therapeutic Opportunities. International Journal of Molecular Sciences, 2023, 24, 16771.	4.1	0

#	Article	IF	CITATIONS
1841	Recent Contributions of Mass Spectrometry-Based "Omics―in the Studies of Breast Cancer. Chemical Research in Toxicology, 2024, 37, 137-180.	3.3	0
1842	The Exploitation of pH-Responsive Eudragit-Coated Mesoporous Silica Nanostructures in the Repurposing of Terbinafine Hydrochloride for Targeted Colon Cancer Inhibition: Design Optimization, In Vitro Characterization, and Cytotoxicity Assessment. Pharmaceutics, 2023, 15, 2677.	4.5	0
1843	Proteomic characterization of epithelial ovarian cancer delineates molecular signatures and therapeutic targets in distinct histological subtypes. Nature Communications, 2023, 14, .	12.8	0
1845	Current and Upcoming Treatment Strategies After CDK4/6 Inhibitors for Patients With ER+/HER2- Advanced Breast Cancer. European Medical Journal Oncology, 0, , 33-43.	0.0	0
1846	Hormone Treatment for Breast Cancer. Korean Journal of Medicine, 2023, 98, 283-288.	0.3	0
1847	The Potent Novel CDK4/6 Inhibitor TQB3616 in Hormone Receptor Positive Breast Cancer: Preclinical Characterization with in vitro and Human Tumor Xenograft Models. Breast Cancer: Targets and Therapy, 0, Volume 15, 899-912.	1.8	1
1848	Advanced Breast Cancer Care: The Current Situation and Global Disparities. Seminars in Oncology Nursing, 2024, 40, 151551.	1.5	0
1850	MDM2-p53 in liposarcoma: The need for targeted therapies with novel mechanisms of action. Cancer Treatment Reviews, 2024, 122, 102668.	7.7	1
1851	Dual functionality of pyrimidine and flavone in targeting genomic variants of EGFR and ER receptors to influence the differential survival rates in breast cancer patients. Integrative Biology (United) Tj ETQq0 0 0 rgBT	Deverlock	2 <b>b</b> 0 Tf 50 42
1852	A novel strategy to bind pyrimidine sulfonamide derivatives with odd even chains: exploration of their design, synthesis and biological activity evaluation. Molecular Diversity, 0, , .	3.9	0
1853	CDK2 inhibition disorders centrosome stoichiometry and alters cellular outcomes in aneuploid cancer cells. Cancer Biology and Therapy, 2023, 24, .	3.4	0
1854	The effectiveness and safety of palbociclib and ribociclib in stage IV HR+/HER-2 negative breast cancer: a nationwide real world comparative retrospective cohort study. Frontiers in Oncology, 0, 13, .	2.8	Ο
1855	The CDK4/6 inhibitor revolution — a game-changing era for breast cancer treatment. Nature Reviews Clinical Oncology, 2024, 21, 89-105.	27.6	4
1856	Patients with HR+/HER2- metastatic breast cancer treated with CDK4/6 inhibitors: a real-world study in Italy. Breast Cancer Management, 2023, 12, .	0.2	0

1857	Firstâ€line CDK4/6 inhibitorâ€based combinations for HR+/HER2– advanced breast cancer: A Bayesian network metaâ€analysis. Journal of Evidence-Based Medicine, 0, , .	1.8	0	
1858	Overall survival in Japanese patients with ER+/HER2â^' advanced breast cancer treated with first-line palbociclib plus letrozole. Breast Cancer, 0, , .	2.9	0	
1859	Estrogen receptor positive breast cancer: contemporary nuances to sequencing therapy. , 2024, 41, .		1	

1860	Recent Progress in CDK4/6 Inhibitors and PROTACs. Molecules, 2023, 28, 8060.	3.8	1

#	Article	IF	CITATIONS
1861	Matching-adjusted indirect comparison of PFS and OS comparing ribociclib plus letrozole <i>versus</i> palbociclib plus letrozole as first-line treatment of HR+/HER2â° advanced breast cancer. Therapeutic Advances in Medical Oncology, 2023, 15, .	3.2	0
1862	Abemaciclib-induced lung damage leading to discontinuation in brain metastases from breast cancer: A case report. World Journal of Clinical Cases, 0, 11, 8425-8430.	0.8	0
1863	Current Management and Future Perspectives of Hormone Receptor–Positive HER2-Negative Advanced Breast Cancer. Seminars in Oncology Nursing, 2024, 40, 151547.	1.5	1
1864	Peripheral blood lymphocytes predict clinical outcomes in hormone receptor-positive HER2-negative advanced breast cancer patients treated with CDK4/6 inhibitors. Therapeutic Advances in Medical Oncology, 2023, 15, .	3.2	0
1865	Aromatase inhibitors: the journey from the state of the art to clinical open questions. Frontiers in Oncology, 0, 13, .	2.8	0
1866	Key Considerations for the Treatment of Advanced Breast Cancer in Older Adults: An Expert Consensus of the Canadian Treatment Landscape. Current Oncology, 2024, 31, 145-167.	2.2	0
1867	Mechanisms of Endocrine Resistance in Hormone Receptor-Positive Breast Cancer. Cancer Treatment and Research, 2023, , 219-235.	0.5	1
1868	A network meta-analysis of efficacy and safety for first-line and second/further-line therapies in postmenopausal women with hormone receptor-positive, HER2-negative, advanced breast cancer. BMC Medicine, 2024, 22, .	5.5	0
1869	Utilization and outcomes of the 21-gene recurrence score in de novo metastatic breast cancer. Expert Review of Molecular Diagnostics, 2024, 24, 99-106.	3.1	0
1870	Hormone, Targeted, and Combinational Therapies for Breast Cancers: From Humans to Dogs. International Journal of Molecular Sciences, 2024, 25, 732.	4.1	0
1871	Upregulated PARP1 confers breast cancer resistance to CDK4/6 inhibitors via YB-1 phosphorylation. Experimental Hematology and Oncology, 2023, 12, .	5.0	0
1873	Relationship between Medication-Related Osteonecrosis of the Jaw and CDK4/6 Inhibitors in Breast Cancer. Current Oncology, 2024, 31, 250-259.	2.2	2
1875	The value of oral selective estrogen receptor degraders in patients with HR-positive, HER2-negative advanced breast cancer after progression on ≥ 1 line of endocrine therapy: systematic review and meta-analysis. BMC Cancer, 2024, 24, .	2.6	1
1876	Case report: ex vivo tumor organoid drug testing identifies therapeutic options for stage IV ovarian carcinoma. Frontiers in Oncology, 0, 13, .	2.8	2
1877	Realâ€world study of palbociclib combined with endocrine therapy for patients with metastatic breast cancer: AÂcomparison of subsequent treatment patterns and HER2 expression analysis. Cancer, 2024, 130, 1476-1487.	4.1	1
1878	The principles of neoplasia and oncology. Surgery, 2024, 42, 125-132.	0.3	0
1879	Integrative score based on CDK6, PD-L1 and TMB predicts response to platinum-based chemotherapy and PD-1/PD-L1 blockade in muscle-invasive bladder cancer. British Journal of Cancer, 2024, 130, 852-860.	6.4	0
1880	Sequential 2.5 mg letrozole/FSH therapy is more effective for promoting pregnancy in infertile women with PCOS: a pragmatic randomized controlled trial. Frontiers in Endocrinology, 0, 14, .	3.5	0

#	Article	IF	CITATIONS
1881	Role of Cyclin-Dependent Kinase 4/6 in Metastatic Breast Cancer: Real-World Data From a Tertiary Care Institute in Eastern India. Cureus, 2024, , .	0.5	0
1882	Which is the best treatment for melanoma brain metastases? A Bayesian network meta-analysis and systematic review. Critical Reviews in Oncology/Hematology, 2024, 194, 104227.	4.4	0
1884	Multi-center retrospective review of vitiligo-like lesions in breast cancer patients treated with cyclin-dependent kinase 4 and 6 inhibitors. Breast Cancer Research and Treatment, 2024, 204, 643-647.	2.5	0
1885	Cyclin-Dependent Kinase 4/6 Inhibitors as Neoadjuvant Therapy of Hormone Receptor-Positive/HER2-Negative Early Breast Cancer: What do we Know so Far?. Clinical Breast Cancer, 2024, 24, e177-e185.	2.4	0
1886	Radiotherapy in the management of lung oligometastases. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2024, 28, 36-48.	1.4	0
1887	Exploring Biomarkers in Breast Cancer: Hallmarks of Diagnosis, Treatment, and Follow-Up in Clinical Practice. Medicina (Lithuania), 2024, 60, 168.	2.0	0
1888	The impact of CDK4/6 inhibitors on the quality of life of working-age women with metastatic breast cancer: a population-based cohort study from Portugal. F1000Research, 0, 13, 75.	1.6	0
1889	Real-world effectiveness of aromatase inhibitors and fulvestrant in HR+/HER2- advanced breast cancer: a snapshot of the last two years before conventional use of CDK 4/6 inhibitors in a Portuguese institution. Journal of Pharmaceutical Policy and Practice, 2024, 17, .	2.4	0
1890	A comparison between the adverse event profiles of patients receiving palbociclib and abemaciclib: analysis of two real-world databases. International Journal of Clinical Pharmacy, 2024, 46, 536-541.	2.1	0
1891	Efficacy of CDK4/6 inhibitors combined with endocrine therapy in HR+/HER2â^' breast cancer: an umbrella review. Journal of Cancer Research and Clinical Oncology, 2024, 150, .	2.5	0
1892	The use of ribociclib in real clinical practice: results of a single-center observational retrospective study. Meditsinskiy Sovet, 2024, , 130-138.	0.5	0
1893	The association between HER2-low status and survival in patients with metastatic breast cancer treated with Cyclin-dependent kinases 4 andÂ6Âinhibitors: a systematic review and meta-analysis. Breast Cancer Research and Treatment, 2024, 204, 443-452.	2.5	1
1894	Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer. Journal of Clinical Oncology, 2024, 42, 994-1000.	1.6	0
1895	Therapeutic Effects of CDK4/6 Inhibitors in Gastric and Colonic Metastases From Breast Cancer: A Case Report. Cureus, 2024, , .	0.5	0
1896	Successful management of bilateral orbital metastases from invasive lobular breast cancer with abemaciclib and letrozole: a case report and literature review. Frontiers in Oncology, 0, 14, .	2.8	0
1897	Seize the engine: Emerging cell cycle targets in breast cancer. Clinical and Translational Medicine, 2024, 14, .	4.0	0
1898	Revolutionizing cancer care strategies: immunotherapy, gene therapy, and molecular targeted therapy. Molecular Biology Reports, 2024, 51, .	2.3	1
1899	A conceptual framework for cautious escalation of anticancer treatment: How to optimize overall benefit and obviate the need for de-escalation trials. Cancer Treatment Reviews, 2024, 124, 102693.	7.7	0

#	Article	IF	CITATIONS
1900	Therapies for the Treatment of Advanced/Metastatic Estrogen Receptor-Positive Breast Cancer: Current Situation and Future Directions. Cancers, 2024, 16, 552.	3.7	0
1901	International multidisciplinary consensus on the integration of radiotherapy with new systemic treatments for breast cancer: European Society for Radiotherapy and Oncology (ESTRO)-endorsed recommendations. Lancet Oncology, The, 2024, 25, e73-e83.	10.7	1
1902	Real-world effectiveness of palbociclib in HR+/HER2- metastatic breast cancer: a literature review. Future Science OA, 2024, 10, .	1.9	0
1904	UGT1A1 Testing in Breast Cancer: should it become routine practice in patients treated with antibody-drug conjugates?. Critical Reviews in Oncology/Hematology, 2024, 196, 104265.	4.4	0
1905	Dispersive liquid-liquid microextraction followed by sweeping micellar electrokinetic chromatography-tandem mass spectrometry for determination of six breast cancer drugs in human plasma. Journal of Chromatography A, 2024, 1718, 464698.	3.7	0
1906	The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study. International Journal of Clinical Oncology, 2024, 29, 258-265.	2.2	0
1907	Cell cycle plasticity underlies fractional resistance to palbociclib in ER+/HER2â^² breast tumor cells. Proceedings of the National Academy of Sciences of the United States of America, 2024, 121, .	7.1	0
1908	Comparative overall survival of CDK4/6 inhibitors in combination with endocrine therapy in advanced breast cancer. Scientific Reports, 2024, 14, .	3.3	0
1909	Early Detection of Disease Progression in Metastatic Cancers: Could CTCs Improve RECIST Criteria?. Biomedicines, 2024, 12, 388.	3.2	0
1910	Recommendations for cyclin‑dependent kinase 4/6 inhibitor treatments in the context of co‑morbidity and drug interactions (Review). Oncology Letters, 2024, 27, .	1.8	0
1911	Improving Dissolution Rate and Solubility of Palbociclib Salts/Cocrystal for Anticancer Efficacy. Journal of Molecular Structure, 2024, 1305, 137756.	3.6	0
1912	CDK4/6 inhibitors in lung cancer: current practice and future directions. European Respiratory Review, 2024, 33, 230145.	7.1	0
1913	Best of the year: Advanced breast cancer in 2023. Breast, 2024, 74, 103677.	2.2	0
1914	Therapeutic Monitoring of Palbociclib, Ribociclib, Abemaciclib, M2, M20, and Letrozole in Human Plasma: A Novel LC-MS/MS Method. Therapeutic Drug Monitoring, 0, , .	2.0	0
1915	Cerebral venous sinus thrombosis in a patient treated with ribociclib for metastatic breast cancer. Case reports and literature review. SAGE Open Medical Case Reports, 2024, 12, .	0.3	0
1916	Identifying prognostic biomarkers for palbociclib add-on therapy in fulvestrant-resistant breast cancer using cell-free DNA sequencing. ESMO Open, 2024, 9, 102385.	4.5	0
1917	HÃ <b>m</b> atologische Neoplasien und solide Tumore. , 2023, , 99-174.		0
1918	Ribociclib + adjuvant hormone therapy in early breast cancer: prevention of recurrence. New opportunities. A review. Journal of Modern Oncology, 2024, 25, 432-439.	0.3	0

#	Article	IF	CITATIONS
1919	Digging in real-word electronic database for assessing CDK 4/6 inhibitors adherence in breast cancer patients from Romania. Frontiers in Pharmacology, 0, 15, .	3.5	0
1920	Recent progress of CDK4/6 inhibitors' current practice in breast cancer. Cancer Gene Therapy, 0, , .	4.6	0
1921	DNA-PKcs suppresses illegitimate chromosome rearrangements. Nucleic Acids Research, 0, , .	14.5	0
1922	Fulvestrant and everolimus efficacy after CDK4/6 inhibitor: a prospective study with circulating tumor DNA analysis. Oncogene, 2024, 43, 1214-1222.	5.9	0
1923	MYC induces CDK4/6 inhibitors resistance by promoting pRB1 degradation. Nature Communications, 2024, 15, .	12.8	0
1924	Tata Memorial Centre Evidence Based Management of Breast cancer. Indian Journal of Cancer, 2024, 61, S52-S79.	0.2	0
1925	Real-world experience with CDK4-6 inhibition in the old and oldest old with a diagnosis of breast cancer. Seminars in Oncology, 2024, , .	2.2	0
1926	Cardiovascular complications of ribociclib in breast cancer patients. Critical Reviews in Oncology/Hematology, 2024, 196, 104296.	4.4	0
1927	Production of letrozole-loaded alginate oxide-gelatin microgels using microfluidic systems for drug delivery applications. International Journal of Biological Macromolecules, 2024, 263, 129685.	7.5	0
1928	Tumor-agnostic baskets to N-of-1 platform trials and real-world data: Transforming precision oncology clinical trial design. Cancer Treatment Reviews, 2024, 125, 102703.	7.7	0
1929	Efficacy and safety of everolimus plus exemestane in patients with hormone receptorâ€positive, <scp>HER</scp> â€2â€negative advanced breast cancer: Results from the openâ€label, multicentre, nonâ€interventional <scp>BRAWO</scp> study. International Journal of Cancer, 2024, 155, 128-138.	5.1	0
1930	Treatment patterns and clinical outcomes of chidamide combined with endocrine therapy in hormone receptorâ€positive, <scp>HER2</scp> â€negative metastatic breast cancer: A realâ€world multicenter study. Cancer Medicine, 2024, 13, .	2.8	0
1931	Gender minorities in breast cancer – Clinical trials enrollment disparities: Focus on male, transgender and gender diverse patients. Breast, 2024, 75, 103713.	2.2	0
1932	A real-world pharmacovigilance study of QT interval prolongation and Torsades de Pointes associated with CDK4/6 inhibitors in breast cancer patients: findings from the FDA adverse event reporting system. Expert Opinion on Drug Safety, 0, , 1-8.	2.4	0
1933	Adjuvant chemotherapy and survival outcomes in older women with HR+/HER2â^' breast cancer: a propensity score-matched retrospective cohort study using the SEER database. BMJ Open, 2024, 14, e078782.	1.9	0
1934	Efficacy of first-line CDK 4-6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia on efficacy: a Turkish Oncology Group (TOC) study. Journal of Chemotherapy, 0, , 1-7.	1.5	0
1937	GINS2 regulates temozolomide chemosensitivity via the EGR1/ECT2 axis in gliomas. Cell Death and Disease, 2024, 15, .	6.3	0
1938	Assessing the clinical benefit of systemic anti-cancer treatments in the Netherlands: The impact of different thresholds for effectiveness. European Journal of Cancer, 2024, 202, 114002.	2.8	0

#	Article	IF	CITATIONS
1939	A Representative Clinical Course of Progression, with Molecular Insights, of Hormone Receptor-Positive, HER2-Negative Bone Metastatic Breast Cancer. International Journal of Molecular Sciences, 2024, 25, 3407.	4.1	0
1940	PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor–Negative Metastatic Breast Cancer. Journal of Clinical Oncology, 0	1.6	0
1941	Elderly patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors in a multicentre cohort. Clinical and Translational Oncology, 0, , .	2.4	0
1942	Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study. Lancet Oncology, The, 2024, 25, 474-487.	10.7	0
1943	Precise nano-system-based drug delivery and synergistic therapy against androgen receptor-positive triple-negative breast cancer. Acta Pharmaceutica Sinica B, 2024, , .	12.0	0